WorldWideScience

Sample records for 125i permanent implant

  1. Three-dimensional verification of 125I seed stability after permanent implantation in the parotid gland and periparotid region

    To evaluate seed stability after permanent implantation in the parotid gland and periparotid region via a three-dimensional reconstruction of CT data. Fifteen patients treated from June 2008 to June 2012 at Peking University School and Hospital of Stomatology for parotid gland tumors with postoperative adjunctive 125I interstitial brachytherapy were retrospectively reviewed in this study. Serial CT data were obtained during follow-up. Mimics and Geomagic Studio software were used for seed reconstruction and stability analysis, respectively. Seed loss and/or migration outside of the treated area were absent in all patients during follow-up (23–71 months). Total seed cluster volume was maximized on day 1 post-implantation due to edema and decreased significantly by an average of 13.5 % (SD = 9.80 %; 95 % CI, 6.82–17.68 %) during the first two months and an average of 4.5 % (SD = 3.60 %; 95 % CI, 2.29–6.29 %) during the next four months. Volume stabilized over the subsequent six months. 125I seed number and location were stable with a general volumetric shrinkage tendency in the parotid gland and periparotid region. Three-dimensional seed reconstruction of CT images is feasible for visualization and verification of implanted seeds in parotid brachytherapy

  2. Nursing care for elderly lung cancer patients treated with CT-guided permanent interstitial co-implantation of 125I seeds and slow-released fluorouracil

    Objective: To investigate the specific measures and effect of the nursing care for elderly lung cancer patients who were receiving the treatment of CT-guided permanent interstitial co-implantation of 125I seeds and slow-released fluorouracil. Methods: Active care, including adequate preoperative preparation, proper support during operation and postoperative nursing,was carried out for fifty-three elderly patients with lung cancer during their treatment course of CT-guided permanent interstitial brachytherapy with co-implantation of 125I seeds and slow-released fluorouracil. Results: In order to ensure accurate puncture and the smooth particle implantation, the possible conditions which might happen after the procedure were informed to the patients before the surgery and useful advice was given to patients to guide their daily activities. All 53 patients showed no obvious fear before surgery and made good cooperation during the procedure, moreover, they well responded to the therapy and recovered pretty soon. Conclusion: CT-guided permanent interstitial co-implantation of 125I seeds and slow-released fluorouracil is a safe, minimally-invasive and newly-developed technique with reliable effect, which is especially suitable for aged patients. Active and adequate nursing care is essential during the whole therapeutic course. (authors)

  3. Comparison of Dosimetric and Biologic Effective Dose Parameters for Prostate and Urethra Using 131Cs and 125I for Prostate Permanent Implant Brachytherapy

    Purpose: To compare the urethral and prostate absolute and biologic effective doses (BEDs) for 131Cs and 125I prostate permanent implant brachytherapy (PPI). Methods and Materials: Eight previously implanted manually planned 125I PPI patients were replanned manually with 131Cs, and re-planned using Inverse Planning Simulated Annealing. 131Cs activity and the prescribed dose (115 Gy) were determined from that recommended by IsoRay. The BED was calculated for the prostate and urethra using an α/β ratio of 2 and was also calculated for the prostate using an α/β ratio of 6 and a urethral α/β ratio of 2. The primary endpoints of this study were the prostate D90 BED (pD90BED) and urethral D30 BED normalized to the maximal potential prostate D90 BED (nuD30BED). Results: The manual plan comparison (α/β = 2) yielded no significant difference in the prostate D90 BED (median, 192 Gy2 for both isotopes). No significant difference was observed for the nuD30BED (median, 199 Gy2 and 202 Gy2 for 125I and 131Cs, respectively). For the inverse planning simulated annealing plan comparisons (α/β 2), the prostate D90 BED was significantly lower with 131Cs than with 125I (median, 177 Gy2 vs. 187 Gy2, respectively; p = 0.01). However, the nuD30BED was significantly greater with 131Cs than with 125I (median, 192 Gy2 vs. 189 Gy2, respectively; p = 0.01). Both the manual and the inverse planning simulated annealing plans resulted in a significantly lower prostate D90 BED (p = 0.01) and significantly greater nuD30BED for 131Cs (p = 0.01), compared with 125I, when the prostate α/β ratio was 6 and the urethral α/β ratio was 2. Conclusion: This report highlights the controversy in comparing the dose to both the prostate and the organs at risk with different radionuclides

  4. Edema-induced increase in tumour cell survival for 125I and 103Pd prostate permanent seed implants - a bio-mathematical model

    Yue, Ning; Chen, Zhe; Nath, Ravinder

    2002-04-01

    Edema caused by the surgical procedure of prostate seed implantation expands the source-to-point distances within the prostate and hence decreases the dose coverage. The decrease of dose coverage results in an increase in tumour cell survival. To investigate the effects of edema on tumour cell survival, a bio-mathematical model of edema and the corresponding cell killing by continuous low dose rate irradiation (CLDRI) was developed so that tumour cell surviving fractions can be estimated in an edematous prostate for both 125I and 103Pd seed implants. The dynamic nature of edema and its resolution were modelled with an exponential function V(T) = Vp (1 + M exp(-0.693T/Te)) where Vp is the prostate volume before implantation, M is the edema magnitude and Te is edema half-life (EHL). The dose rate of a radioactive seed was calculated according to AAPM TG43, i.e. Λg(r) αBED), where α is the linear coefficient of the survival curve. The tumour cell survival was calculated for both 125I and 103Pd seed implants and for different tumour potential doubling time (TPDT) (from 5 days to 30 days) and for edemas of different magnitudes (from 0% to 95%) and edema half-lives (from 4 days to 30 days). Tumour cell survival increased with the increase of edema magnitude and EHL. For a typical edema of a half-life of 10 days and a magnitude of 50%, the edema increased tumour cell survival by about 1 and 2 orders of magnitude for 125I and 103Pd seed implants respectively. At the extreme (95% edema magnitude and an edema half-life of 30 days), the increase was more than 3 and 5 orders of magnitude for 125I and 103Pd seed implants respectively. The absolute increases were almost independent of TPDT and the prostate edema did not significantly change the effective treatment time. Tumour cell survival for prostate undergoing CLDRI using 125I or 103Pd seeds may be increased substantially due to the presence of edema caused by surgical trauma. This effect appears to be more pronounced for

  5. Edema-induced increase in tumour cell survival for 125I and 103Pd prostate permanent seed implants - a bio-mathematical model

    Edema caused by the surgical procedure of prostate seed implantation expands the source-to-point distances within the prostate and hence decreases the dose coverage. The decrease of dose coverage results in an increase in tumour cell survival. To investigate the effects of edema on tumour cell survival, a bio-mathematical model of edema and the corresponding cell killing by continuous low dose rate irradiation (CLDRI) was developed so that tumour cell surviving fractions can be estimated in an edematous prostate for both 125I and 103Pd seed implants. The dynamic nature of edema and its resolution were modelled with an exponential function V(T)=Vp (1+M exp(-0.693T/Te)) where Vp is the prostate volume before implantation, M is the edema magnitude and Te is edema half-life (EHL). The dose rate of a radioactive seed was calculated according to AAPM TG43, i.e. D radical SkΔg(r) φ-baran/r2, where r is the distance between a seed and a given point. The distance r is now a function of time because of edema. The g(r) was approximated as 1/r0.4 and 1/r0.8 for 125I and 103Pd, respectively. By expanding the mathematical expression of the resultant dose rate in a Taylor series of exponential functions of time, the dose rate was made equivalent to that produced from multiple fictitious radionuclides of different decay constants and strengths. The biologically effective dose (BED) for an edematous prostate implant was then calculated using a generalized Dale equation. The cell surviving fraction was computed as exp(-αBED), where α is the linear coefficient of the survival curve. The tumour cell survival was calculated for both 125I and 103Pd seed implants and for different tumour potential doubling time (TPDT) (from 5 days to 30 days) and for edemas of different magnitudes (from 0% to 95%) and edema half-lives (from 4 days to 30 days). Tumour cell survival increased with the increase of edema magnitude and EHL. For a typical edema of a half-life of 10 days and a magnitude of

  6. Edema-induced increase in tumour cell survival for {sup 125}I and {sup 103}Pd prostate permanent seed implants - a bio-mathematical model

    Yue Ning; Chen Zhe; Nath, Ravinder [Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT (United States)

    2002-04-01

    Edema caused by the surgical procedure of prostate seed implantation expands the source-to-point distances within the prostate and hence decreases the dose coverage. The decrease of dose coverage results in an increase in tumour cell survival. To investigate the effects of edema on tumour cell survival, a bio-mathematical model of edema and the corresponding cell killing by continuous low dose rate irradiation (CLDRI) was developed so that tumour cell surviving fractions can be estimated in an edematous prostate for both {sup 125}I and {sup 103}Pd seed implants. The dynamic nature of edema and its resolution were modelled with an exponential function V(T)=V{sub p} (1+M exp(-0.693T/T{sub e})) where V{sub p} is the prostate volume before implantation, M is the edema magnitude and T{sub e} is edema half-life (EHL). The dose rate of a radioactive seed was calculated according to AAPM TG43, i.e. D radical S{sub k}{delta}g(r) {phi}-bar{sub an}/r{sup 2}, where r is the distance between a seed and a given point. The distance r is now a function of time because of edema. The g(r) was approximated as 1/r{sup 0.4} and 1/r{sup 0.8} for {sup 125}I and {sup 103}Pd, respectively. By expanding the mathematical expression of the resultant dose rate in a Taylor series of exponential functions of time, the dose rate was made equivalent to that produced from multiple fictitious radionuclides of different decay constants and strengths. The biologically effective dose (BED) for an edematous prostate implant was then calculated using a generalized Dale equation. The cell surviving fraction was computed as exp(-{alpha}BED), where {alpha} is the linear coefficient of the survival curve. The tumour cell survival was calculated for both {sup 125}I and {sup 103}Pd seed implants and for different tumour potential doubling time (TPDT) (from 5 days to 30 days) and for edemas of different magnitudes (from 0% to 95%) and edema half-lives (from 4 days to 30 days). Tumour cell survival increased

  7. Implant quality and acute urinary toxicity with 125I permanent seed implantation for clinically localized prostate cancer. Results of the first 30 patients treated at PMCC

    It is widely recognized that a steep learning curve exists for departments initiating a prostate low-dose radiation (LDR) implant service. Appropriate team credentialing, willingness to accept mentoring and attention toward ongoing QA initiatives are required to ensure that both clinical and dosimetric endpoints consistently achieve standards deemed appropriate. The department of urological services began a prostate seed service in 4/2002. All participating staff were suitably trained in Seattle, Washington with unit protocols based on standard trans-rectal sonographic pre-planning, modified peripheral loading, prescription dose 145Gy and 4 week CT based post implant dosimetry. Patient eligibility paralleled federal medicare guidelines with men presenting with favorable risk disease, gland volumes 15ml/sec) considered potential candidates. a) Presenting Demographics: (n=30) Median age 62 (41-73), T stage 1c:2a:2b:2c = 18:10:1:1, Median PSA 6.3ng/ ml (5.1ng/ml - 11.1ng/ml), Median IPSS 5 (0-12), Mean Qmax 18ml/s (10ml/s -35ml/s).; b) Acute toxicity: No significant peri-procedural complications. One patient developed urinary retention day 3 and was successfully trialed day 10. All patients experienced some degree of sub-acute urinary irritation although three patients followed for at least 12 months have returned to their baseline level of functioning. c) Post implant Dosimetry: Median D90 139Gy (104Gy - 190Gy). 3 Patients received a D90 < 90% with one at 104Gy receiving additional 'top-up' external beam radiation (20Gy). A definable improvement in implant quality was observed over the 12 month study interval. Although acute toxicity was considered acceptable, patients do experience a sub-acute period of low grade albeit persistent urinary irritation and need to be cautioned appropriately. A high level of implant quality was achieved in the majority of patients. Despite 5 years HDR brachytherapy experience, considerable refinement in technique and approach was

  8. Customized planning for radioactive 125I seed implantation

    Objective: To customize the optimal plans for radioactive 125I seeds volumetric implants in selected regular target volumes. Methods: 125I seeds were symmetrically and uniformly implanted into 3 spherical targets with the diameters of 1, 2 and 3 cm and 7 ellipsoidal targets with the 3 dimensions of 1 cm×1 cm×2 cm, 1 cm×1 cm×3 cm, 1 cm×2 cm×2 cm, 1 cm×2 cm×3 cm, 1 cm ×3 cm ×3 cm, 2 cm×2 cm×3 cm and 2 cm×3 cm×3 cm. The activity and inter-space of seeds were adjusted to obtain the conformal and uniform dose distribution, with the prescribed D90 (the dose delivered to 90% of the targets) greater than 145 Gy. The inter-space of seeds was changed from 1 cm to 0.75 cm, to improve the conformity and uniformity of dose distribution. Plan quality was assessed using homogeneity index (HI), external index (EI) and conformal index (CI). The activity and number of seeds implanted were also recorded and compared. Results: For the spherical target with the diameter of 1 cm, when seeds were implanted with the inter-space of 1 cm and 0.75 cm, the HI were 40.0% and 55.9%, the EI were 98.3% and 95.1%, the CI were 0.44 and 0.44, respectively. For the spherical target with the diameter of 3 cm and the target with the 3 dimensions of 1 cm × 2 cm × 2 cm, the implant with the inter-space of 1 cm provided better indices of HI, EI and CI than those with the inter-space of 0.75 cm. For the other targets, the implants with the inter-space of 0.75 cm provided better indices of EI and CI than those with the inter-space of 1 cm, although they displayed a little worse homogeneity in terms of HI. The activity per seed was 17.0-27.8 MBq and 30.0-58.8 MBq in the implants with the inter-spaces of 0.75 cm and 1 cm, respectively. 2-10 more seeds were needed in the implants with the inter-space of 0.75 cm. Conclusions: For the studied targets except the spherical targets with the diameter of 1 cm and 3 cm and the ellipsoidal target with the dimension of 1 cm × 2 cm × 2 cm, 125I seeds

  9. Radiation protective nursing intervene of 125I seed implantation in non-small cell lung cancer

    Lung cancer is the most common primary malignant tumor. Because most sufferers have already been in later stage in their first diagnosis, the lump body infringing upon the important organs often influences the excision of tumor. 125I seeds permanent implantation is a new method for tumor brachytherapy, which contributes to kill the tumor completely, ensures the normal physiological functions of organs,reduces tissue injuries and treatment of complications, and raises the survival rate of sufferers. The rapid promotion of this technique is also followed by radiation risks in the treatment. Currently, the researches of 125I seeds implantation is limited to the aspects of treatment means and effects, with no detailed study in intraoperative usage, disinfection and protection. Although a satisfactory curative effect is the key in the treatment,the studies in protection principles, means and technological upgradation are also too important to be ignored. (authors)

  10. Clinical application of transperineal 125I-seed implantation guided by ultrasonography in prostate cancer

    Objective: To establish an optimal technological protocol, and to observe the short-term efficacy and morbidity of transperineal 125I-seed implantation guided by transrectal ultrasonography in prostate cancer. Method: Thirty-two patients were treated with transperineal 125I-seed brachytherapy guided by transrectal ultrasound. Among them 6 patients were treated with the seed implantation plus preor post-external beam radiotherapy (EBRT). Biochemical failure was defined as consecutive elevations of PSA level for three times during follow-up period and the biochemical progression-free was defined as biochemical control. Results: The pre- and post-implantation median serum PSA values of 14 patients were (52.14 ± 54.61) ng/ml and (4.26 ± 7.11) ng/ml, respectively (t=3.253, P=0.003). The biochemical control rate was 100%. The pre- and post-treatment median PSA values of 12 recurrent prostate cancer patients were (15.14 ± 20.80) ng/ml and (18.94 ± 35.25) ng/ml, respectively (t=-0.307, P=0.764). Their biochemical control rate was 75%. The pre- and post-implantation median PSA values of 5 patients with bone metastases were (120.03 ± 145.96) ng/ml and (75.53 ± 84.84) ng/ml, respectively (t=0.527, P=0.621). In 34.62% patients treated only with 125I-seed implication urinary complications were not experience and the incidences of Grade I, II, III, IV and V urinary side effects were 38.46%, 11.54%, 11.54%, 0 and 3.85%, respectively. The incidences of Grade I, II, III and IV urinary morbidity were 16.67%, 0, 0 and 16.67%, respectively for patients treated with seed implantation plus EBRT. Grade 1 rectal toxicity was noted in 3.12% patients. In 3.12% patients, one seed migration occurred. Conclusion: Transperineal permanent brachytherapy is safe, convenient, minimally invasive, with low urinary and rectal side effects. (authors)

  11. CT-guided radioactive 125I seed implantation treatment of multiple pulmonary metastases of hepatocellular carcinoma

    Aim: To investigate the clinical value of computed tomography (CT)-guided radioactive 125I seed implantation for the treatment of multiple pulmonary metastases of hepatocellular carcinoma (HCC). Materials and methods: From March 2007 to August 2010, 27 HCC patients with pulmonary metastases who had received computed tomography (CT)-guided radioactive 125I seed implantation were enrolled in the study. All patients had ≥2 metastatic lesions (mean diameter 2 ± 0.6 cm). Under CT-guidance, 125I seeds were implanted into the pulmonary metastases using the plane implantation technique. Results: Among 27 cases, complete response, partial response, stable disease, and progressive disease were observed in four, 15, six, and two cases, respectively, during 6–48 months (mean 20.1 ± 2.2 months) of follow-up CT. The response rate was 92.6%. The mean follow-up time after 125I implantation was 20.1 months (range 6–48 months). The survival rates at 1 and 2 years were 67% and 30.8%, respectively, with a median survival of 13.5 months. Side effects during the procedure included minor pulmonary effusions and pneumothorax. Pulmonary haemorrhage was observed in 18 cases and haemoptysis occurred in five patients. Radial shadows were observed in three cases on follow-up CT images, and seed migration in two cases on follow-up spiral CT images. Conclusion: CT-guided radioactive 125I seed implantation may be a safe and effective treatment option for HCC patients with multiple pulmonary metastases. - Highlights: • HCC patients with pulmonary metastases received CT-guided radioactive 125I seed implantation. • CT-guided radioactive 125I seed implantation may be a safe and effective treatment option. • Prospective studies are needed to confirm its value

  12. Efficacy of CT guided radioactive 125I seed implantation in the treatment of lung cancer

    Objective: To investigate the feasibility, efficacy and complications of CT guided radioactive 125I seed implantation in the treatment of lung cancer. Methods: According to the different treatment methods, 65 patients with lung cancer were divided into two groups, 37 cases in the implantation alone group received CT guided 125I seeds interstitial implantation, the other 28 cases in the combination treatment group received interstitial 125I seeds implantation combined with chemotherapy. All the patients were examined by posologic validation, and were followed up termly. Results: The total effective rate of 65 patients was 80.0%, 1-year survival rate was 90.8%. The effective rates of implantation alone group and combination treatment group were 67.6% and 96.4% respectively. There was a significant difference between the two groups (χ2=8.298, P<0.01). Before treatment, all the patients' mean diameter of the tumor was 5.48 cm; while it was 3.77 cm after treatment (t=7.764, P<0.01). Complications included pneumothorax (36 cases), bloody sputum (7 cases), fever (4 cases) which improved after treatment in 65 patients,but without radiation pneumonia. Conclusion: 125I seed implantation is a highly effective treatment without severe complications in the treatment of lung cancer. (authors)

  13. CT-Guided Radioactive 125I Seed Implantation Therapy of Symptomatic Retroperitoneal Lymph Node Metastases

    PurposeThis study explored the clinical efficacy of CT-guided radioactive 125I seed implantation in treating patients with symptomatic retroperitoneal lymph node metastases.MethodsTwenty-five patients with pathologically confirmed malignant tumors received CT-guided radioactive 125I seed implantation to treat metastatic lymph nodes. The diameter of the metastatic lymph nodes ranged from 1.5 to 4.5 cm. Treatment planning system (TPS) was used to reconstruct the three-dimensional image of the tumor and then calculate the corresponding quantity and distribution of 125I seeds.ResultsFollow-up period for this group of patients was 2–30 months, and median time was 16 months. Symptoms of refractory pain were significantly resolved postimplantation (P 125I seed implantation, which showed good palliative pain relief with acceptable short-term effects, has proved in our study to be a new, safe, effective, and relatively uncomplicated treatment option for symptomatic retroperitoneal metastatic lymph nodes

  14. The clinic application of CT-guided interstitial 125I seeds implantation in curing lung cancer

    Objective: To introduce the procedures and evaluate the clinic value of CT-guided interstitial 125I seeds implantation in treating lung cancer. Methods: Thirty-one cases patients with lung cancer underwent CT-guided interstitial 125I seeds implantation. All patients were scanned on multi-spiral CT (Philips, MX 8000) with optical navigating system (pinpoint), and treatment plan system, needle, and 125I seeds (Chinese Academy of Science) were used. First of all, according to the size of tumor, TPS calculated the optimal quantity of seeds. Then, under the guidance of CT, 125I seeds were percutaneously implanted into the tumors for interstitial radiotherapy. CT follow-up examinations were performed 1, 2, and 6 months after the therapy, respectively. According to the size of tumor, curative effects were graded as 4 grades: grade I: obvious relief (OR) (the size of tumor reduced up to 50%), grade II: relief (PR) (the size of tumor reduced by 25%-50%), grade III: slight relief (SD) (the size of tumor reduced by 1%-25%), and grade IV: no effect (PD) (the size of tumor did not reduce or increase, and clinic symptoms showed no relief). Results: At 1 month, 9 cases were classified as grade I, 6 as grade II, 13 as grade III, and 3 as grade IV, respectively. At 2 months, 17 cases were grade I, 8 grade II, 3 grade III, and 3 grade IV, respectively. At 6 months, 23 cases were grade I, 3 grade II, 2 grade III, and 3 grade IV, respectively. Conclusion: CT-guided interstitial 125I seeds implanted was a safe, reliable, and effective curative method for lung cancer. (authors)

  15. Clinical efficacy of CT-guided 125I seed implantation therapy for advanced pancreatic cancer

    Objective: To discuss the clinical efficacy of CT-guided radioactive 125I seed implantation treatment for unresectable pancreatic cancer. Methods: Forty patients with inoperable pancreatic cancer were enrolled in this study, including 25 males and 15 females with an median age of 69 years (38-89 years). Treatment planning system (TPS) was used to reconstruct 3-dimensional images of pancreatic tumor and to define the quantity and distribution of 125I seeds. The radioactivity of 125I seeds was 0.5 - 0.8 mCi / seed. The seeds were implanted into pancreatic tumor under CT guidance at intervals of 1 cm and were kept away from vessels, pancreatic duct and other adjacent important organs. The tumor matched peripheral dose (MPD) was 60-140 Gy. The median amount of implanted 125I seeds was 36 (18-68) in number. CT scan was performed immediately after the procedure to check the quality of the seeds. In addition, 10 patients received concurrent chemotherapy with arterial infusion of gemcitabin and 5-fluororacil (5-Fu) for 3 to 4 therapeutic courses. Results: The median diameter of the tumors was 4.9 cm. The follow-up period was 2 to 28 months. After the treatment the refractory pain was significantly relieved (P 125I seed implantation is a safe, effective and minimally-invasive brachytherapy for unresectable pancreatic cancer with reliable short-term efficacy. It has an excellent anti-pain effect. The curative results can be further improved when chemotherapy is employed together. However, its long-term efficacy needs to be observed. (authors)

  16. CT-guided 125I Radioactive Seed Implantation on Regional Lymph Node Metastasis after Gastrectomy

    Liangrong Shi

    2013-09-01

    Full Text Available Objective: To evaluate the safety and short-term effect of CT-guided 125I radioactive seed implantation on regional lymph node metastasis after gastrectomy. Methods: Twenty-three patients with regional lymph node metastasis after gastrectomy received CT-guided 125I radioactive seed implantation from June, 2007 to July, 2011 in our hospital. The overall activity and amount of radioactive seeds were calculated by simulating source distribution of radioactive seed implantation plan system before operation. 125I seeds were implanted under the guidance of CT. Effective rate was evaluated according to RECIST criterion, 1, 2 and 3 years of survival rates were calculated by life table method, the effect of relative factors on survival was tested by univariate COX model, and the survival differences between subgroups were compared to draw survival curve by log-rank method. Additionally, systemic therapies were given to 20 patients based on fluorouracil drugs. Results: No severe complications was observed in all study subjects with 14 complete remission (60.9 % , 5 particle remission (21.7 % and 4 progressive diseases (17.4 % , while 1, 2 and 3 years of survival rates as well as median survival time being (87±7 %,(47±11 % , (13±9 % and (22.1±5.1 months, respectively. Univariate COX analysis showed that the maximum diameter of tumor could badly influence the prognosis (χ2 = 9.752, P = 0.002, and the subgroups analysis relieved the significant difference (χ2 = 5.828, P = 0.016, log-rank test with 3 cm being the cut-off value. Conclusion: CT-guided 125I radioactive seed implantation has high local control rate with small trauma and slight complications.

  17. Permanent 125I-seed prostate brachytherapy: early prostate specific antigen value as a predictor of PSA bounce occurrence

    Mazeron Renaud

    2012-03-01

    Full Text Available Abstract Purpose To evaluate predictive factors for PSA bounce after 125I permanent seed prostate brachytherapy and identify criteria that distinguish between benign bounces and biochemical relapses. Materials and methods Men treated with exclusive permanent 125I seed brachytherapy from November 1999, with at least a 36 months follow-up were included. Bounce was defined as an increase ≥ 0.2 ng/ml above the nadir, followed by a spontaneous return to the nadir. Biochemical failure (BF was defined using the criteria of the Phoenix conference: nadir +2 ng/ml. Results 198 men were included. After a median follow-up of 63.9 months, 21 patients experienced a BF, and 35.9% had at least one bounce which occurred after a median period of 17 months after implantation (4-50. Bounce amplitude was 0.6 ng/ml (0.2-5.1, and duration was 13.6 months (4.0-44.9. In 12.5%, bounce magnitude exceeded the threshold defining BF. Age at the time of treatment and high PSA level assessed at 6 weeks were significantly correlated with bounce but not with BF. Bounce patients had a higher BF free survival than the others (100% versus 92%, p = 0,007. In case of PSA increase, PSA doubling time and velocity were not significantly different between bounce and BF patients. Bounces occurred significantly earlier than relapses and than nadir + 0.2 ng/ml in BF patients (17 vs 27.8 months, p Conclusion High PSA value assessed 6 weeks after brachytherapy and young age were significantly associated to a higher risk of bounces but not to BF. Long delays between brachytherapy and PSA increase are more indicative of BF.

  18. Permanent 125I-seed prostate brachytherapy: early prostate specific antigen value as a predictor of PSA bounce occurrence

    To evaluate predictive factors for PSA bounce after 125I permanent seed prostate brachytherapy and identify criteria that distinguish between benign bounces and biochemical relapses. Men treated with exclusive permanent 125I seed brachytherapy from November 1999, with at least a 36 months follow-up were included. Bounce was defined as an increase ≥ 0.2 ng/ml above the nadir, followed by a spontaneous return to the nadir. Biochemical failure (BF) was defined using the criteria of the Phoenix conference: nadir +2 ng/ml. 198 men were included. After a median follow-up of 63.9 months, 21 patients experienced a BF, and 35.9% had at least one bounce which occurred after a median period of 17 months after implantation (4-50). Bounce amplitude was 0.6 ng/ml (0.2-5.1), and duration was 13.6 months (4.0-44.9). In 12.5%, bounce magnitude exceeded the threshold defining BF. Age at the time of treatment and high PSA level assessed at 6 weeks were significantly correlated with bounce but not with BF. Bounce patients had a higher BF free survival than the others (100% versus 92%, p = 0,007). In case of PSA increase, PSA doubling time and velocity were not significantly different between bounce and BF patients. Bounces occurred significantly earlier than relapses and than nadir + 0.2 ng/ml in BF patients (17 vs 27.8 months, p < 0.0001). High PSA value assessed 6 weeks after brachytherapy and young age were significantly associated to a higher risk of bounces but not to BF. Long delays between brachytherapy and PSA increase are more indicative of BF

  19. CT guided radioactive seed 125I implantation in treating hilar hepatic tumor and metastatic lymph nodes

    Objective: To investigate the clinical value of CT guided radioactive seed 125I implantation in treating hilar hepatic tumor and metastatic lymph nodes. Methods: 32 patients with pancreatic cancer accepted CT guided radioactive seeds 125I implantation were enrolled in this study. The average tumor dimension was 4.2 cm. In this series, there were 8 cases of hepatocellular carcinoma, 12 cases of hilar cholangio carcinoma, 6 cases of hepatic metastasis and 6 of hepatic hilar tumor and metastatic lymph nodes. Among these patients, 14 cases had cholangiectasis and 22 cases had cirrhosis. Under CT guidance, 125I seeds of 0.6-0.9 mCi were implanted into the pancreatic cancer at a distance of 1.0-1.5 cm according to TPS. Results: Two cases died on account of metastasis and three died through liver function failure. Among CT followed-up of 32 patients in 2 months, 2 obtained CR, 20 obtained PR, 5 NC and 5 PD. The responsive rate was 68.8%. The side effects occurred during the procedure including pneumothorax in 1 case with lung compression less than 30%; 7 seeds migration in liver and 3 seeds in lung. WBC decreased slightly in 1 cases during 2 months follow up. No massive bleeding, biliary fistula, intestinal fistula, intestinal hemorrhage, acute pancreatitis, enterorrhagia and intra-abdominal abscess were encountered. Conclusions: CT guided radioactive seed 125I implantation procedure is a safe and effective method in treating hilar hepatic tumor and metastatic lymph nodes with good clinical effects of minimal damage and few complications. (authors)

  20. 125I seed implant brachytherapy for the treatment of parotid gland cancers in children and adolescents

    Background and purpose: There is a lack of optimal treatment strategies for managing salivary gland cancers in children and adolescents. This study is aimed at assessing the effect of 125I seed implantation for the treatment of parotid cancers in children and adolescents. Patients and methods: A total of 12 patients younger than 16 years with parotid gland malignant tumors underwent 125I seed implant brachytherapy between October 2003 and November 2008. All patients were assessed after treatment and at the local tumor control appointments. Facial nerve function, maxillofacial development, and radioactive side-effects were assessed. Results: The follow-up period ranged from 41-104 months. One patient with T4b died of pulmonary metastasis. The other patients were alive during the follow-up period. There were no serious radiation-related complications. The treatment did not affect facial nerve function and dentofacial growth in any of the children. Conclusion: For parotid gland cancers in children, 125I seed implant brachytherapy may be an acceptable treatment without serious complications and with satisfactory short-term effects. (orig.)

  1. Clinical effect observation of 125I seed implantation combined with endocrinal therapy for prostate cancer

    Objective: To retrospectively study the efficacy and side-effect of 125I seed implantation combined with endocrinal therapy in stage T3N0M0 prostate cancer. Methods: The study included 22 patients with clinical stage T3N0M0 prostate cancer who were treated with transperineal 125I seed implantation guided by transrectal ultrasound, real time TPS and endocrinal therapy. The minimum peripheral doses (MPD) were 140-160 Gy. The median number of seeds was 74(26-90). The activity of each seed was 1.55 × 107 (1.30 × 107-1.85 × 107) Bq. 11 patients were treated with orchidectomy, and 11 patients were treated with androgen deprivation therapy. Results: All 22 patients completed the seed implantation successfully. The 5-year biochemical progression-free survival was 70.6%, and 5-year overall survival was 81.8%. 2 patients were found biochemical failure in 12 months after seed implantation, and another 1 patient failed in 90 months. Endocrinal therapy was followed thereafter. After the seed implantation, the urinary complications of grade 1 and 2 were 54.5% and 9.1% respectively, and the rectum side-effect of grade 1 and 2 were 22.7% and 9.1%.1 patient suffered rectal complication of grade 4. Conclusions: Good effect and tolerance are observed in prostate cancer patients of stage T3N0M0 receiving 125I seed implantation plus endocrinal therapy.The treatment can be considered for those who refuse to receive external beam radiotherapy. (authors)

  2. Pathological impairments induced by interstitial implantation of 125I Seeds in spinal canal of banna mini-pigs

    Yang Zuozhang

    2012-03-01

    Full Text Available Abstract Background Use a banna mini-pig to set up 125I implantation model, and investigate the consequence of radiation-related impairments. Methods In present study, 125I seeds were implanted into spinal canal of T13 level of spine in banna mini-pigs. After operation, the pigs were raised up to 8 months, behavior changes were recorded within this period. After 8 months, spinal cords were collected for pathological analysis. Results In this study, a 125I brachytherapy animal model had been successfully established, in the model group, the banna pigs' Tarlov scale decreased from 5 to 2.57 ± 0.36, significant cellular impairments were noted by pathological analysis. Conclusions Without any protection and operation improvement, 125I implantation can cause serious histological impairments and moving difficulty for banna mini-pigs; this present research provides an alternative tool to study spinal 125I brachytherapy.

  3. Linear 125I seeds strand implantation combined with biliary stenting for the treatment of malignant biliary obstruction

    Objective: To evaluate the therapeutic efficacy of linear 125I seeds strand implantation combined with biliary stenting in treating malignant biliary obstruction. Methods: Linear 125I seeds strand implantation combined with biliary stenting was carried out in 28 patients with malignant biliary obstruction. The technical success rate, the clinical efficacy, the postoperative complications and the survival rate were analyzed. Results: Both biliary stenting and 125I seeds strand implantation were successfully accomplished in all patients. No serious complications occurred. After the procedure the biliary obstruction symptoms were markedly improved and the bilirubin level was significantly reduced (P125I seeds strand implantation together with biliary stenting is safe and effective although its long-term efficacy needs to be further studied. (authors)

  4. CT-guided 125I radioactive seed implantation for locally recurrent rectal cancer

    Objective: To evaluate the efficacy and adverse reactions of CT-guided 125I radioactive seed implantation in treatment of locally recurrent rectal cancer (LRRC). Methods: Thirty patients with LRRC who refused operation or were unable to endure pelvic radiotherapy received 125I seed implantation under CT guidance. Three-dimensional treatment planning system was used to calculate the number, activity, and dose of the seeds needed. The activity of seeds ranged from 14.8 to 29.6 MBq with a median of 25.9 MBq, the seed numbers ranged from 33 to 137 with a median of 74.5, the prescription doses ranged from 120-160 Gy,and the actual verification dose D90 ranged from 75.91 to 159.32 Gy with a median of 119.77 Gy. Dosimetric verification by CT scanning was conducted immediately after the treatment. Follow-up was conducted for 15.2 months(4.2-35.0 months). Results: The follow-up rate was 93.3%. The pain relief rate was 95.2%. The overall response rate was 50.0%, including a complete response rate of 13.3% and a partial response rate of 36.7%. The 1- and 2-year local control rates were 30.0% and 8.0% respectively. The median local control survival time was 7.8 month. The 1- and 2-year survival rates were 66.5% and 32.9% respectively. The median overall survival time was 21.5 months. Complications, mainly adverse effects of skin and urinary system (frequent urination, urgent urination, and dysuria) occurred in 6 patients with a rate of 20.0%. Conclusions: Minimally invasive and with satisfying efficacy and tolerable complications, CT-guided 125I radioactive seed implantation is a favorable option for treatment of LRRC, especially for the patients who have undergone previous pelvic radiation. (authors)

  5. The effectiveness and safety of 125I seed implantation for treatment of gastric cancer

    Objective: To explore the effectiveness of 125I seed implantation for gastric cancer and to determine whether the therapy could increase the survival rate. Methods: Seventy-six gastric cancer patients in stage Ⅱ or Ⅲ were involved and randomly divided into treatment group (n=42) and control group (n=34) by simple random sampling method. The patients in the control group underwent D2 or D3 surgery and the patients in treatment group underwent D2 or D3 surgery plus interstitial implantation of 125I seeds. All patients signed the informed consents. Treatment results were evaluated as CR, PR, NC and PD. CR and PR were considered as effective and the effective rate was calculated. All patients were followed up and the three-or five-year survival rate was calculated, the complications were examined. χ2 test was used to compare the significant difference between the two groups. Results: The total effective rate in control group was 50.00% (17/34), lower than that of treatment group (73.81%, 31/42; χ2=4.578, P<0.05). In the treatment group, the three-year and five-year survival rates were 61.90% (26/42) and 42.86% (18/42) respectively, and the corresponding rates in the control group were 11.76%(4/34) and 0(0/34) respectively (χ2=19.771, 19.094, both P<0.001). Both of the two groups had few severe side effects. Conclusion: Radical surgery plus 125I seed implantation is effective and safe for the treatment of stage Ⅱ or Ⅲ gastric cancer and can further improve long-term survival. (authors)

  6. Optimum timing for image-based dose evaluation of 125I and 103Pd prostate seed implants

    timing for conventional postimplant dose evaluation was identified as the time at which a minimum difference between the conventional DVH and the dynamic model DVH was achieved. The analysis was done on 29 prostate seed implant patients for both 125I and 103Pd. The edema magnitude was assumed to be 30%, 40%, 50%, 75%, and 100% of original prostate volume, and the half-life of edema was assumed to be 4, 7, 10, 15, 20, and 25 days. In this study, the original volume of prostate varied from 17 cm3 to 91 cm3, and number of seeds in the implants varied from 57 to 119. Results: The optimum timing was mainly dependent on the half-lives of edema and radionuclides, and varied slightly with edema magnitude, prostate volume, and number of seeds. It can be expressed as a function of edema half-life in the form of C0+ C1exp(-C2Te). However, if the dose evaluation was performed based on the image scans taken too early or too late, the error became larger, as the edema magnitude was larger. By averaging all 29 patients and various edemas, it was found that for 125I seed implants, if the postimplant dose evaluation is performed based on image scans taken between 5 and 9 weeks, the average error will be less than 5%, with a maximum possible error less than 10% in 80% coverage dose; for 103Pd seed implants, if the postimplant dose evaluation is performed based on image scans taken between 2 and 4 weeks, the average error will be less than 5%, with a maximum error less than 15% in 80% coverage dose. Because of edema, a conventional preimplant plan also overestimates dose coverage of prostate. On the average, a standard preimplant planning overestimates dose coverage by about 6% for 125I implants and 14% for 103Pd implants in our study. Conclusion: Based on the dynamic model, the optimum timing of image scans for postimplant dose evaluation of prostate seed implantation is 7 weeks postimplantation for 125I implants and about 3 weeks for 103Pd implants. The time-window for reasonable

  7. The clinical application of TACE together with RFA and 125I seed implantation in treating hepatocellular carcinoma

    Objective: to assess the clinical value of the combined treatment of transcatheter arterial chemoembolization (TACE), CT-guided radiofrequency ablation (RFA) and radioactive 125I seed implantation for hepatocellular carcinoma (HCC). Methods: During the period from March 2008 to Dec. 2010, 15 patients with HCC were admitted to the hospital. A total of 25 hepatic lesions were detected with the size of 1-8 cm. TACE was carried out first, which was followed by CT-guided RFA and radioactive 125I seed implantation. With the help of treat plan system (TPS), the radioactive 125I seed implantation was conducted to make additional management for the same lesion when RFA was finished, or the radioactive 125I seeds were directly implanted into the areas where RFA could not reach. The radioactive dose was 60-100 Gy. All the patients were followed up and were kept under observation for the signs of related complications. The therapeutic results were evaluated. Results: The combined treatment was successfully accomplished in all patients. All patients were followed up for 3-28 months (mean of 10.6 months). The complete necrosis rate of the tumor was 96%. No serious complications occurred except the immigration of 125I seeds in 1 case. Conclusion: The combined treatment of TACE and CT-guided RFA together with 125I seed implantation is a safe, reliable and effective therapy for HCC with excellent short-term result. (authors)

  8. Radiochemotherapy with interstitial implantation of 125I seeds and 5-FU slow-release seeds for recurrent thyroid cancer

    Objective: To investigate the combined treatment technological feasibility, efficacy with interstitial implantation of 125I seeds and 5-FU slow-release seeds for recurrent thyroid cancer. Methods: From March 2002 to December 2003, 9 cases of recurrent thyroid cancer were treated with radiochemotherapy. They were all patients with recurrent thyroid cancer after operation and radiation. The authors implanted alternately 125I seeds and 5-FU slow-release seeds by guiding of treatment planning system. The MPD of 125I seed implantation were 60-90 Gy. The mean 8 granules of 125I seeds and 5-FU 200 mg were used in every patient. Results: Fully operating procedure was accomplished for all the patients. No operating complication occurred. No displacement of 125I seeds was found by cervical X-ray. CT scan showed that the reduced size of tumor changed in different degree. The CR was 11.11%(1/9). The PR was 66.66%(6/9). The NC was 22.22% (2/9). Following up 8-26 months, all patients survived. Conclusion: Using radiochemotherapy with interstitial implantation of 125I seeds and 5-Fu slow-release seeds is safe, minimally invasive and effective for treatment of recurrent thyroid cancer

  9. Radiation safety and protection of close contacts from radiators after implantation of radioactive 125I seeds

    Objective: To study the effective dose and precaution time of the irradiation of the close contact from the radiators who underwent implantation of radioactive 125I seeds so as to guide scientifically people how to avoid radiation damage. Methods: Twenty patients with different types of cancer underwent implantation of radioactive 125I seeds with the median value of implantation depth of 2.16 cm. Within 24 h after the operations the dose rates 30 cm and 100 cm from the skin were measured with pocket-size radiometer so as to imitate the situations of the close contacts. The effective doses and precaution times of different persons were calculated according to relevant formula. Results: The dose rate a person received at the same time points (1, 54, 78, and 109 d, respectively) decreased along with the increase of the distance from the skin (t=5.962, 5.961, 5.961, 5.962, P<0.05), and the dose rate a person received at the same distance from the skin decreased along with the extension of time (30 cm: t=6.236, 6.236, 6.235, P<0.05; 100 cm: t=7.310, 7.315, 7.314, P<0.05). At different time points, the dose rates at 30 cm distance point were all significant higher than those at the 100 cm point (P <0.05). The adult living together, minors and pregnant women sharing the room, colleagues,adults who slept together with the patients began to reach the 50% dose constraint values 0, 54, 78 and 109 days after the operation. Conclusions: After their precaution time, it's safe to contact with the patients for the groups; otherwise, it's necessary to take some protect works within the precaution time. (authors)

  10. Clinical application of CT-guided 125I seed interstitial implantation for local recurrent rectal carcinoma

    The present study aimed to explore the safety profile and clinical efficacy of CT-guided radioactive seed implantation in treating local recurrent rectal carcinoma. CT-guided 125I seed implantation was carried out in 20 patients with locally recurrent rectal carcinoma. 14 of the 20 patient had prior adjuvant external-beam radiation therapy (EBRT). The treatment planning system (TPS) was used preoperatively to reconstruct three dimensional images of the tumor and to calculate the estimated seed number and distribution. The median matched peripheral dose (MPD) was 120 Gy (range, 100-160 Gy). Of the 20 patients, 12 were male, 8 were female, and ages ranged from 38 to 78, with a median age of 62. Duration of follow-up was 3-34 months. The response rate of pain relief was 85% (17/20). Repeat CT scan 2 months following the procedure revealed complete response (CR) of the tumor in 2 patients, partial response (PR) in 13 patients, stable disease (SD) in 3 patients, and progressive disease (PD) in 2 patients. 75% of patients had either CR or PR. Median survival time was 18.8 months (95% CI: 3.5-22.4 months). 1 and 2 year survival rates were 75% and 25%, respectively. 4 patients died of recurrent tumor; 4 patients died of distant metastases; 9 patients died of recurrent tumor and distant metastases. 3 patients survived after 2 year follow up. Two patients were found to have mild hematochezia, which was reversible with symptomatic management. CT-guided 125I seed implantation appeared to be a safe, useful and less complicated interventional treatment option for local recurrent rectal carcinoma

  11. Treatment of Central Type Lung Cancer by CT Guided Percutaneous Implants of 125I Radioisotopes

    Xiaokun Hu; Mingyou Wang; Zhiguo Yang; Chundong Qiu; Dongfang Lü; Xiaodong Li; Taiyang Zuo

    2005-01-01

    OBJECTIVE To discuss the method, safety and effectiveness of the treatment for central-type carcinoma of the lungs by CT guided percutaneous implants of 125I radioisotopes in tissues.METHODS Twenty-two cases of central-type lung cancer located by plain and /or enhanced CT scans were retrospectively analyzed, among which 18cases were verified pathologically using a CT guided percutaneous puncture and biopsy before treatment. The CT guided treatment was conducted immediately after the pathological results were obtained. The number of the radioisotopes used was seven to 16. The intensities of radioactivity for 125I radioisotopes were 22, 26, 30 and 33 MBq per particle.The total intensity of radioactivity was 181 to 355 MBq. The puncture point was only one. The frequency for adjustment of needling direction was two to five times. The punctures were conducted through the anterior chest wall in eight cases, through the lateral chest wall in eight cases and thruogh the posterior chest wall in six cases. Six of the 22 cases were given intravenous chemotherapy.RESULTS Of the 22 cases, 20 were followed-up for more than one month, 16over two months, ten over three months and three cases for six months. In the 20 cases which were followed-up for one month, the diameters of the tumors were reduced by 50% or more in 18 cases, showed no change in two cases with none showing enlargement. In the 16 cases followed-up for more than two months, the diameters of tumors were reduced by 50% or more in 15cases, one case showed no change and none enlarged. In the ten cases with three months of follow-up, the tumor diameters were diminished by 50%or more in eight cases, showed no change in one case and enlarged in one case. In the three cases followed-up for six months, the diameters of tumors were reduced by 50% or more in all the cases. Of the 22 cases, atelectasis occurred in 12 before therapy. The lungs expanded again in nine cases in the follow-up after treatment. Symptoms after

  12. CT-guided 125I seed implantation for locoregional lymph node metastases in patients with recurrent gastric cancer

    Objective: To evaluate the safety and short term effect of 125I seed implantation for locoregional lymph node metastases in patients with recurrent gastric cancer. Methods: The data of 23 gastric cancer patients with locoregional lymph node metastases treated by CT-guided 125I seed implantation were retrospectively studied. Patient characteristics and survival data were collected and analyzed. The procedure for seed implantation was performed under CT guidance according to preoperative treatment planning. Evaluation of short-term effect was carried out two months after the 125I seed implantation using response evaluation criteria in solid tumors (RECIST). The 1-, 2-and 3-year survival rates were plotted using the life table method.The potential predictors of survival were tested using univariate Cox models. Log-rank method was used to test the difference of survival in subgroups with tumor size >3 cm and <3 cm. Twenty patients underwent fluoropyrimidine-based chemotherapy after 125I seed implantation. Results: None of the 23 patients had serious complications. Two months after 125I seed implantation, the CR, PR and PD rates were 60.9% (14/23), 21.7% (5/23) and 17.4% (4/23), respectively. The median survival time was (22.1±5.1) months,and the 1-, 2-, 3-year survival rates were (87±7)%, (47± 11)% and (13 ±9)%, respectively. The tumor size (longest diameter) was the most significant factor for prognosis (χ2=9.752, P=0.002). Patients with tumor <3 cm in diameter had longer survival time than those with tumor >3 cm ((30.0±5.1) vs (17.0±5.0) months; χ2=5.828, P=0.016). Conclusion: CT-guided brachytherapy using 125I seed implantation is a safe and effective method for palliative treatment of locoregional lymph node metastases for recurrent gastric cancer. (authors)

  13. Nursing care for patients with local recurrent rectal cancer after CT-guided 125I seed implantation therapy

    Objective: To discuss the nursing care strategy for patients with local recurrent rectal cancer who has been treated with CT-guided 125I seed implantation therapy. Methods: Twenty patients with local recurrent rectal cancer received a series of nursing interventions, including comfort care and pain care. The clinical results were observed and analyzed. Results: The therapy was smoothly accomplished in all patients. The pain was remarkably relived and the anxiety was alleviated. No displacement of implanted 125I seed occurred. Conclusion: For patients with local recurrent rectal cancer occurred after CT-guided 125I seed implantation therapy, careful nursing can effectively relieve the pain and anxiety feeling,and the living quality can also be markedly improved. (authors)

  14. 125I implantation combined with chemotherapy for treatment of local recurrent stage Ⅲ non-small cell lung cancer

    Objective: To investigate the associated effect of 125I implantation plus chemotherapy in local recurrent stage Ⅲ NSCLC patients. Methods: From January 2006 to January 2009, 34 patients documented with local recurrent stage Ⅲ NSCLC were divided into two groups by random number table. The treatment group was treated with 125I permanent implantation combined with DP regimen (docetaxel 60 mg/m2 + cisplatinum 75 mg/m2), while the control group received only DP chemotherapy. According to the TPS, the treatment group received CT-guided percutaneous implantation of 125I seeds with a particle activity of 2.22 ×107-2.59 × 107 Bq. The prescribed dose was in the range of 90-110 Gy and the postoperatively matched peripheral dose (mPD) and D90 were verified by TPS. The control group received a DP chemotherapy regime for 4 cycles after the procedure. This study was approved by the ethics committee,and all patients signed informed consents. The follow up time was up to disease progression. Kaplan-Meier survival analysis was used to describe the local lesion control (LLC) time and progression free survival (PFS). Log-rank test was used in the comparison of the survival rates between the two groups. Fisher's exact test was used to analyze the differences of CR rate and recent efficiency between two groups. Results: In the treatment group, postoperative mPD was 93.9-130.4 (M 116.7) Gy, and D90 was 103.6-148.2 (M 130.6) Gy. The LLC time was 4.7 to 24.0 months with a median of 11.6 (95% CI: 8.7-14.6) months. In two cases, there was no recurrence during the follow-up time of 24 months.PFS was 4.7 to 24.0 months with a median of 10.5 (95% CI: 7.4-13.6) months. The recent effective rate of the treatment group was 64.7% (11/17).CR, PR, SD and PD were 41.2% (7/17), 23.5% (4/17), 23.5% (4/17) and 11.8% (2/17), respectively. In the control group, the LLC time was 4.5 to 11.4 months with a median of 7.5 (95 % CI: 6.7-8.3) months, and the median of PFS was 6.5 (4.5-10.5) (95% CI: 5

  15. Characterization of some dosimetric parameters of 125I seeds used for prostate implants using Monte Carlo simulations

    In the prostate cancer treatment, there is an increasing interest in the permanent radioactive seeds implant technique, where 125I seeds are inserted into the patient's prostate, allowing the delivery of high doses and preserving nearby organs at risk. For the calculation of dose distributions, treatment planning systems (TPS) makes use of the calculation proposed by the protocol TG-43. According to the document, data of dose distribution should be made more precise, either experimentally or by computational simulations, to be used in the TPS. Several authors used Monte Carlo simulations to generate the parameters of brachytherapy sources (seeds) that are recommended by TG-43 protocol, which are used for dose calculations in the TPS. For a single seed, there are variations in the geometry chosen to calculate the dosimetric parameters recommended and in the medium where the dose distributions are calculated (liquid water or solid water) and also in the Monte Carlo code used. The TPS consider the sources as point entities and do not consider the attenuation effects among the seeds. In this work, computational simulations of the geometry of one of the most used seeds in permanent prostate implants, the Amersham model 6711, were performed through the Monte Carlo method using the MCNP5 code. The dosimetric parameters radial dose function g(r) and anisotropy function F(r,θ) were simulated and the results show good agreement with other works. This model can be used in the future to study the impact of the approaches and other problems in the implant procedure. (author)

  16. Implantation of 125I seeds for the treatment of non-small cell lung cancer: evaluation of short-term effect

    Objective: To assess the short-term effect, feasibility and safety of 125I seeds implantation in treating non-small cell lung cancer. Methods: During the period from June 2010 to December 2012 a total of 353 patients with lung cancer were admitted to authors' hospital, of whom 56 met the study standards. The 56 cases were divided into study group (n=24) and control group (n=32). Bronchial artery chemotherapy with subsequent 125I seeds implantation was carried out in the patients of study group, while only bronchial artery chemotherapy was performed in the patients of control group. The median survival time was compared between the two groups. Results: The median survival time of the study group and the control group was (22.8±1.9) months and (14.2±1.3) months respectively. The median survival time of the study group was significantly higher than that of the control group (P=0.006). Conclusion: Compared with simple bronchial artery chemotherapy, permanent implantation of 125I seeds combined with bronchial artery chemotherapy can significantly improve the quality of life and prolong the survival time as well. Therefore, this technique is an effective therapy for advanced lung cancer and should be recommended in clinical practice. (authors)

  17. Effects of TPS calculation grid on dose calculation accuracy for 125I seed implantation

    Objective: To study the influence of TPS calculation grid on the dose calculation accuracy for 125I seed implantation. Methods: Ten verification plans were selected randomly. Calculating grids were modulated into four groups: 128 × 128, 96 × 96, 64 × 64 and 32 × 32. Under the conditions of same seeds number, location, activity and target volume, the doses resulting from every plan were calculated using TPS to obtain D90, V90, V100 and V150. Data were grouped into A, B, C and D by means of the calculating grid of 128 × 128, 96 × 96, 64 × 64 and 32 × 32. The percentage errors of four groups were calculated. Results: The arithmetic mean D90 of group A, B, C and D were (7 178.8 ± 2 237.7), (7 072.7 ±2 240.8), (6 889.1 ±2 305.5) and (6 351.0 ±2 515.7) cGy, respectively. The arithmetic mean of percentage errors of the four groups were (0.74 ± 0.6)%, (-0.89 ± 2.2)%, (-3.85 ± 4.7)% and (-10.46 ±4.8)% (F=8.95, P <0.05). The V90 of group A, B, C and D were (93.12 ± 0.32)%, (92.75 ±0.29)%, (91.87±1.28)% and (88.06 ±5.06)% (F=7.85, P<0.05). The V100 of group A, B, C and D were (90.21 ±0.14)%, (89.67 ±0.64)%, (88.68 ± 1.80)% and (84.10±6.56)% (F=6.64, P<0.05). The V150 of group A, B, C and D were (73.48 ±3.49)%,(72.66±3.96)%,(71.33±4.83)% and (65.41 ±9.49)% (F=3.90, P<0.05). Conclusions: The dose calculating accuracy of 125I seeds implantation is influenced significantly by TPS calculating grid. The calculating grid of 128 × 128 should be used as long as the calculating speed is not reduced. (authors)

  18. Safety evaluation in vicinity during and after 125I seeds implantation in head and neck region

    Objective: To measure the radiation dose during and after 125I seeds implantation in head and neck region, and to evaluate the radiation safety in the vicinity. Methods: Forty patients who had 125I seeds implanted in head and neck region were divided into two groups as facial and neck group as well as intra-oral group. The radiation doses were measured at the distance of 30 cm in three different directions during operation and at the distances of 30, 50, and 100 cm after operation when the patients opened and closed their mouth, respectively. Results: The radiation dose rate on the treatment side [(2.60±0.37) μSv] was higher than that on the other two sides [(0.28±0.05) and (0.15±0.03 μSv)] during the operation, with the statistical difference (t=25.62, 29.51, P0.05). On the treated side at all the distances of 30, 50, and 100 cm, the radiation dose rates were higher in the facial and neck group [(66.28±3.31), (35.06±3.05) and (1.72±0.17) μSv/h] than those in the intra-oral group [(52.46±3.54), (20.78±2.01) and (1.55±0.13) μSv/h], with the statistical difference (t=12.74, 15.51, 3.69, P<0.05). At the distance of 100 cm, the radiation dose rates were (1.72±0.17) μSv/h in facial and neck group, (1.55±0.13) μSv/h when which was safe for the public. Conclusions: Radiation exposure to the medical workers and the public from the patients is very low. It is easy to achieve the radiation safety by reducing the exposure time, increasing the distance and changing the exposure direction. (authors)

  19. Radiation protective nursing intervene of 125I seed implantation in non-small cell lung carcinoma guided by CT

    Objective: To research radiation protective nursing intervene and important notice of 125I seeds minimally invasive implantation in non-small cell lung carcinoma (NSCLC) by CT. Methods: Under the system of therapy planning system (TPS) and posologic validation, 125I seeds were implanted in 89 cases of NSCLC patients. The consistent radiation protective nursing intervene was used in perioperative period management. The operative successful rate, therapeutic effect and complication rate, therapeutic effect and complication rate was observed. Results: The scientific radiation protective nursing intervene can ensure that the radioactive dose distribution of 125I seed implantation brachytherapy is consistent with the principles of effective and minimally invasive. The operative successful rate was 100%. The local control rate and 1 year survival rate respectively was 97.4% and 92.2%. But the early and later incidence rate of radioactive damaging effect was 14.6% and 1.1% respectively. Leakage of radioactive contamination has not occurred. Conclusion: The consistent TPS and posologic validation 125I seeds implantation integrated scientific radiation protective nursing intervene. It is very important to improve the therapeutic effect of NSCLC and reduce the incidence of complications. (authors)

  20. CT-guided percutaneous interstitial implantation of 125I seeds into the pancreas: an experimental study in pigs

    Objective: To investigate the feasibility and safety of percutaneous interstitial implantation of 125I seeds into the pancreas of pig under CT-guidance. Methods: Twelve healthy pigs were equally divided into 6 groups. 125I seed implantation into the pancreatic tail under CT-guidance was performed in pigs of study groups (group A - E), while ghost seeds that contained no radioactive materials were used in the control group (group F). Imaging examination and laboratory tests, including serum amylase, hepatic and renal functions, were conducted before and 1, 7, 15, 21, 30, 60 days after the procedure. Every two pigs (group A - E) were sacrificed each time at 15, 30, 45, 60, and 75 days after treatment, and specimens of pancreas, duodenum, liver, kidney, etc. were collected and sent for pathologic examination. Results: The 125I seeds were successfully implanted in all pigs. During the follow-up period, no severe complications occurred. Imaging and pathologic studies demonstrated that in study groups necrosis of pancreatic tissue appeared around the implanted 125I seeds in 15 days, the necrosis area increased significantly in 45 and 60 days, and in 75 days the necrosis size remained quite the same as seen in 60 days. No necrosis was found in the control group (group F) 60 days after treatment. No serious complications, such as effusions, hemorrhage or necrosis of the adjacent duodenum, stomach, liver or kidney, occurred 75 days after the treatment. Conclusion: Percutaneous interstitial implantation of 125I seeds into the pig's pancreas under CT-guidance is safe and feasible. (authors)

  1. Development of measurement method using TLD for workers occupation personally exposed to 125I seed source in the implant

    Objective: To explore the method for measuring and calculating both absorbed dose and effective dose received in organ and tissues of occupational workers by using TLDs for the implantation of 125I seed sources. Methods The experiments with 60Co γ-rays were carried out for the stability. A group of TLD chips was exposed to 125I seed sources to establish standard dose curve for air kerma. During the 125I seed implantation, the TLD chips were pasted to 13 locations like thyroid inside and outside the lead aprons worn by occupational workers to measure average absorbed dose and calculate the absorbed doses and effective to organs and tissues. Results: For 3 cases of prostate cancers with implantation of 125I seeds, the worker's organs and tissues received the absorbed dose 0.02 -3.80 μ Gy and effective dose 0.06- 1.81 μSv outside lead aprons and the highest absorbed dose 2.35 μ Gy and effective 0.02 μSv inside lead aprons, respectively, with more than 65.9% of rays shielded. For 3 cases of brain cancers with implantation of 125I seeds, the workers received the absorbed dose 0.23 - 11.31 μGy and effective dose 0.88-4.07 μSv outside lead aprons and the highest absorbed dose 2.22 μ Gy and effective dose 0.09 μSv inside lead aprons, respectively, with more than 54.5% of rays shielded. For 3 cases of lung cancers with implantation of 125I seeds, the workers received the absorbed dose 0.03 - 14.78 μGy and effective dose 0.35 -7.59 μSv outside lead aprons and the highest absorbed dose 4.09 μGy and effective 0.22 μSv inside lead aprons, respectively, with more than 58.4% of rays shielded. For 2 cases of mediastinum cancers with implantation of 125Iseeds, the workers received the absorbed dose 0.06 - 74.91 μGy and effective dose 0.83-17.96 μSv outside lead aprons and the highest absorbed dose 10.29 μGy and effective 0.5 μSv inside lead aprons, respectively, with more than 85% of rays shielded. For one case of ovary cancer with implantation of 125I seeds

  2. Comparison of methods for calculating rectal dose after 125I prostate brachytherapy implants

    Purpose: To compare several different methods of calculating the rectal dose and examine how accurately they represent rectal dose surface area measurements and, also, their practicality for routine use. Methods and Materials: This study comprised 55 patients, randomly selected from 295 prostate brachytherapy patients implanted at the Vancouver Cancer Center between 1998 and 2000. All implants used a nonuniform loading of 0.33 mCi (NIST-99) 125I seeds and a prescribed dose of 144 Gy. Pelvic CT scans were obtained for each patient ∼30 days after implantation. For the purposes of calculating the rectal dose, several structures were contoured on the CT images: (1) a 1-mm-thick anterior rectal wall, (2) the anterior half rectum, and (3) the whole rectum. Point doses were also obtained along the anterior rectal surface. The thin wall contour provided a surrogate for a dose-surface histogram (DSH) and was our reference standard rectal dose measurement. Alternate rectal dose measurements (volume, surface area, and length of rectum receiving a dose of interest [DOI] of ≥144 Gy and 216 Gy, as well as point dose measures) were calculated using several methods (VariSeed software) and compared with the surrogate DSH measure (SADOI). Results: The best correlation with SA144Gy was the dose volumes (whole or anterior half rectum) (R = 0.949). The length of rectum receiving ≥144 Gy also correlated well with SA144Gy (R ≥0.898). Point dose measures, such as the average and maximal anterior dose, correlated poorly with SA144Gy (R ≤0.649). The 216-Gy measurements supported these results. In addition, dose-volume measurements were the most practical (∼6 min/patient), with our surrogate DSH the least practical (∼20 min/patient). Conclusion: Dose-volume measurements for the whole or anterior half rectum, because they were the most practical measures and best represented the DSH measurements, should be considered a standard method of reporting the rectal dose when

  3. {sup 125}I seed implant brachytherapy for the treatment of parotid gland cancers in children and adolescents

    Zheng, L.; Zhang, J.; Song, T.; Zhang, J.; Yu, G.; Zhang, Y. [Peking University School and Hospital of Stomatology, Beijing (China). Dept. of Oral and Maxillofacial Surgery

    2013-05-15

    Background and purpose: There is a lack of optimal treatment strategies for managing salivary gland cancers in children and adolescents. This study is aimed at assessing the effect of {sup 125}I seed implantation for the treatment of parotid cancers in children and adolescents. Patients and methods: A total of 12 patients younger than 16 years with parotid gland malignant tumors underwent {sup 125}I seed implant brachytherapy between October 2003 and November 2008. All patients were assessed after treatment and at the local tumor control appointments. Facial nerve function, maxillofacial development, and radioactive side-effects were assessed. Results: The follow-up period ranged from 41-104 months. One patient with T4b died of pulmonary metastasis. The other patients were alive during the follow-up period. There were no serious radiation-related complications. The treatment did not affect facial nerve function and dentofacial growth in any of the children. Conclusion: For parotid gland cancers in children, {sup 125}I seed implant brachytherapy may be an acceptable treatment without serious complications and with satisfactory short-term effects. (orig.)

  4. Treatment of Metastatic Spinal Tumors by Percutaneous Vertebroplasty versus Percutaneous Vertebroplasty Combined with Interstitial Implantation of 125I Seeds

    Zuozhang Yang; Lin Xie; Yunchao Huang; Hongpu Sun; Pengjie Liu; Zhongxiong Wu (Dept. of Orthopedics, Tumor Hospital of Yunnan Province, Third Affiliated Hospital of Kunming Medical College, Kunming, Yunnan (China)). e-mail. yangzuozhang@163.com; Dakuan Yang (Second Affiliated Hospital of Kunming Medical College, Kunming Yunnan (China)); Yuqing Sun (Dept. of Orthopedic Oncology, Beijing Jishuitan Hospital, Beijing (China))

    2009-12-15

    Background: As the most frequent bone metastasis, spinal metastases cause severe pain and damage to vertebral bodies such as spinal osteolytic destruction and compression fractures. To avoid the trauma and complications of open surgery, a minimally invasive procedure, percutaneous vertebroplasty (PVP), has recently been developed to treat metastatic spinal tumors. Purpose: To analyze the treatment outcomes of metastatic spinal tumors by percutaneous vertebroplasty (PVP) alone or PVP combined with interstitial implantation of 125I seeds. Material and Methods: 80 patients with metastatic spinal tumors were randomized to receive PVP alone (40 cases) or PVP combined with 125I seed implantation (40 cases). Digital subtraction angiography (DSA)-guided vertebroplasty was performed under local anesthesia, and acrylic bone cement was injected into the vertebra through a bone trocar to the center of the lesion, with or without simultaneous interstitial implantation of 125I seeds. Results: At 6-month follow-up, PVP combined with 125I seed implantation resulted in zero cases with complete relief (CR), 36 with partial relief (PR), four with no changes (NC), and zero with progression of disease (PD), while PVP alone without seed implantation resulted in 0 CR, 31 PR, 7 NC, and 2 PD. While the combined-treatment group and the single-PVP group showed overall clinical benefit rates without significant difference (100% and 95.0%, respectively), their visual analogue pain scales (VAS; 2.26+-1.05 and 5.41+-0.94, respectively) and Karnofsky performance scores (KPS; 92.5+-7.1 and 87.7+-7.3, respectively) were significantly different after treatment (P = 0.028 and P = 0.009, respectively). Patients in both groups had 1-year follow-up, and the mean time to tumor progression (TTP) was 9.0 and 8.9 months, respectively (not significant). Conclusion: PVP is a minimally invasive procedure with small wounds and minor complications. It is effective in the alleviation of pain in metastatic spinal

  5. Treatment of Metastatic Spinal Tumors by Percutaneous Vertebroplasty versus Percutaneous Vertebroplasty Combined with Interstitial Implantation of 125I Seeds

    Background: As the most frequent bone metastasis, spinal metastases cause severe pain and damage to vertebral bodies such as spinal osteolytic destruction and compression fractures. To avoid the trauma and complications of open surgery, a minimally invasive procedure, percutaneous vertebroplasty (PVP), has recently been developed to treat metastatic spinal tumors. Purpose: To analyze the treatment outcomes of metastatic spinal tumors by percutaneous vertebroplasty (PVP) alone or PVP combined with interstitial implantation of 125I seeds. Material and Methods: 80 patients with metastatic spinal tumors were randomized to receive PVP alone (40 cases) or PVP combined with 125I seed implantation (40 cases). Digital subtraction angiography (DSA)-guided vertebroplasty was performed under local anesthesia, and acrylic bone cement was injected into the vertebra through a bone trocar to the center of the lesion, with or without simultaneous interstitial implantation of 125I seeds. Results: At 6-month follow-up, PVP combined with 125I seed implantation resulted in zero cases with complete relief (CR), 36 with partial relief (PR), four with no changes (NC), and zero with progression of disease (PD), while PVP alone without seed implantation resulted in 0 CR, 31 PR, 7 NC, and 2 PD. While the combined-treatment group and the single-PVP group showed overall clinical benefit rates without significant difference (100% and 95.0%, respectively), their visual analogue pain scales (VAS; 2.26±1.05 and 5.41±0.94, respectively) and Karnofsky performance scores (KPS; 92.5±7.1 and 87.7±7.3, respectively) were significantly different after treatment (P = 0.028 and P = 0.009, respectively). Patients in both groups had 1-year follow-up, and the mean time to tumor progression (TTP) was 9.0 and 8.9 months, respectively (not significant). Conclusion: PVP is a minimally invasive procedure with small wounds and minor complications. It is effective in the alleviation of pain in metastatic spinal

  6. CT-guided radioactive 125I-seed implantation for the treatment of pancreatic carcinoma: a clinical observation of 19 cases

    Objective: To explore the dynamic changes of serum tumor markers after CT-guided radioactive 125I-seed implantation treatment in patients with pancreatic carcinoma and to assess the therapeutic effectiveness of 125I-seed implantation. Methods: CT-guided radioactive 125I-seed implantation was performed in 19 patients with unresectable advanced pancreatic cancer. Treatment planning system was used to reconstruct 3-dimentional images of the tumor, and the quantity and distribution of 125I-seeds to be implanted were thus determined. Under CT guidance 125I-seeds were embedded into pancreatic cancer. Before and after the 125I-seed implantation the levels of serum tumor markers, including CEA, CA19-9 and CA50, were determined by using radioimmunoassay method. The clinical effects were observed and the therapeutic results were statistically analyzed. Results: The pain stared to be relieved 2 to 5 days after implantation. The total effective rate (CR + PR) at one and three months after treatment was 68.42% (13 /19) and 63.16% (12 /19) respectively. One month after 125I-seed implantation, the levels of serum CEA, CA19-9 and CA50 were significantly different to that determined before implantation in all cases (P 125I-seed implantation is a safe and effective interventional treatment for advanced pancreatic cancer with reliable short-term result and remarkable pain-relieving effect. Moreover, this therapy can significantly lower the levels of many serum tumor markers, which play some suggestive roles in evaluating the clinical curativeness. (authors)

  7. The clinical analysis of 125I particles implantation by fibrobronchoscope and percutaneous in the treatment of tracheal stenosis of advanced lung cancer

    Objective: To evaluate the clinical efficacy of 125I particles implantation in the treatment of tracheal stenosis due to advanced lung cancer. Methods: Eighteen cases with end stage lung cancer were collected.125I particles were implanted by inserting the bronchoscope into the pathological bronchial tubes of distal puncture. The number of 125I particles implanted ranged from 4-15. The tumor sizes were compared before and 30 d, 60 d, 180 d after the 125I particles implantation according to the examination of CT, and the clinical symptoms were studied. Results: The symptoms of shortness of breath were relieved after 125I particles implantation. Thirty days follow-up after the therapy showed 15 cases of enlarged bronchial lumen, 13 cases of disappeared obstructive pneumonia symptoms, and no obvious complication occurred during the follow-up. Conclusion: The implantation of 125I radioactive particles has a good effect for the tracheal stenosis in the treatment of advanced lung cancer; the therapy is safe and worth to be spread. (authors)

  8. Percutaneous transcatheter implantation of 125I iodine seeds for the treatment of liver cancer associated with portal vein tumor thrombus: initial experience in 19 cases

    Objective: To evaluate the feasibility and therapeutic efficacy of percutaneous transcatheter implantation of 125I iodine seeds in treating liver cancer associated with portal vein tumor thrombus. Methods: Nineteen patients with primary hepatocellular carcinoma complicated by portal vein tumor thrombus received implantation of 125I iodine seeds via portal vein. The puncturing of portal vein was guided by ultrasound. Under fluoroscopic guidance the 125I iodine seeds were implanted within the portal vein tumor thrombus at 8 mm distance. The number of 125I iodine seeds used in one procedure was 8 to 30 in total. The technical success rate, the postoperative complications, the hepatic and renal functions as well as routine blood test, and the suppression of portal vein tumor thrombus were determined, and the results were analyzed. Results: The implantation of 125I seeds was successfully accomplished in all the patients. No serious procedure-related complications occurred. During the follow-up period lasting for 3-22 months, the portal vein tumor thrombus showed a significant shrinkage in all patients. Conclusion: For the treatment of portal vein tumor thrombus, percutaneous transcatheter implantation of 125I iodine seeds is clinically feasible and effective. (authors)

  9. 125I interstitial implants in the RIF-1 murine flank tumor: an animal model for brachytherapy

    The development of a model for interstitial brachytherapy that uses high-activity, removable 125I sources in the RIF-1 murine flank tumor is reported. Experimental end points are clonogenic cell and tumor regrowth delay assays. For the clonogenic cell assay, interestitial radiation is delivered at total doses of 500-10,000 rad at dose rates of 0.9-2.7 rad/min to cells in annuli of tissue in the tumor. Dose-survival curves are characterized by an initial shoulder followed by a straight (exponential) portion, with D0 similar to that of the curve obtained by external irradiation of the RIF-1 tumor in a self-contained cesium irradiator at similar dose rates. Tumor regrowth curves have been obtained for minimum tumor doses of 500-5000 rad; marked tumor regression has been observed with minimum tumor doses as low as 2000 rad, but results are not as reproducible as the results obtained with the clonogenic cell assay

  10. The clinical application of 125I seeds implantation together with bronchial arterial infusion chemotherapy for the treatment of advanced lung cancer

    Objective: To assess the clinical value of 125I seeds implantation combined with the bronchial arterial infusion chemotherapy in treating advanced lung cancer. Methods: 125I seeds implantation combined with the bronchial arterial infusion chemotherapy was performed in 30 patients with advanced lung cancer. About 3 -70 seeds of 125I (6711 type, 0.7 mCi / seed) were delivered in each patient. In all patients bronchial arterial infusion chemotherapy was carried out at the time of 7 days before the implantation and 30 and 60 days after the implantation. The results and complications were observed. The clinical data were retrospectively analyzed. The therapeutic efficacy was evaluated according to RECIST standards. Results: A total of 40 lesions were detected in all 30 patients and 125I seeds were successfully embedded in all lesions. No procedure-related complications occurred. All patients were followed up for 2 -24 months. The two-year survival rate was 86.6% (26 / 30). Therapeutic evaluation made at four months after the treatment showed that CR, PR, NC and PD was seen in 26, 10, 2 and 2 lesions respectively,with a total effective rate of 90%. Conclusion: 125I seeds implantation combined with the bronchial arterial infusion chemotherapy is a safe and effective therapy for advanced lung cancer with excellent clinical results. (authors)

  11. Anti-tumor effects of 125I radioactive particles implantation on transplantated tumor model of human breast cancer cells in nude mice

    Objective: To study the anti-tumor effects of 125I radioactive particles implantation on transplantated tumor model of human breast cancer cells in nude mice and clarify their anti-tumor mechanisms. Methods 120 nude mice transplantated with human breast cancer cells MCF-7 were randomly divided into 3 groups (n=40): 125I radioactive particles implanted group, non-radioactive particles implanted group and non-particles implanted group. The articles were implanted into mice according to Pairs system principle. The expressions of Fas mRNA and protein and the activaties of caspase-3 and caspase-8 enzyme were detected by RT-PCR and Western blotting. The changes of cell cycle were detected by flow cytometry. Results: Compared with non-radioactive particles implanted group and non-particles implanted group, the size of cancer tissues in 125I radioactive particles implanted group was reduced significantly (P0/G1 phase was significantly increased (P125I radioactive particles into transplantated tumor model of human breast cancer cells can kill tumor cells, inhibit the growth cycle of tumor cells and induce the apoptosis of tumor cells in nude mice. (authors)

  12. Study of percutaneous 125I seeds implantation guided by CT in elderly patients of stage I peripheral non-small cell lung cancer

    Objective: To evaluate the efficacy, feasibility and safety of CT guided percutaneous 125I seeds implantation in elderly patients of stage I peripheral non-small cell lung cancer (NSCLC). Methods: Clinical data of 16 elderly peripheral stage I NSCLC patients (10 squamous carcinoma and 6 adenocarcinoma; 13 stage IA and 3 stage IB) who received radioactive 125I seeds implantation because of refusal or being unsuited to operation or external radiotherapy were retrospectively analyzed. Prescribed dose was 140 - 160 Gy. Under CT guidance, 125I seeds were implanted percutaneously into tumors for interstitial radiotherapy according to treatment plan system. Results: Mean number of 125I seeds each patient received was 21.1. 12 complete response (CR) and 4 partial response (PR) were achieved. Total response rate (CR + PR) was 100%. 100% patients completed 10 to 56 months of follow-up, 15, 13, 8 and 6 patients completed 1-, 2-, 3-and 4-years' follow-up, respectively. The median local progression free time was 14 months. The 1-, 2-, 3-and 4-year overall survival rate were 60%, 54%, 50% and 33%, respectively (median : 14 months). 7 cases died of non-tumor disease and 5 died of metastasis. No severe complications were observed. Conclusions: CT guided 125I seeds implantation is a safe, reliable and effective radical treatment method for elderly stage I peripheral NSCLC patients, who refuse to or are unsuitable to operation or external radiotherapy. (authors)

  13. CT-guide coaxial 125I seeds implantation for the treatment of retroperitoneal lymph node metastasis: analysis of 21 cases

    Objective: To investigate the method, safety and clinical value of CT-guided coaxial percutaneous 125I seed implantation in treating retroperitoneal metastatic lymph nodes. Methods: CT-guided coaxial percutaneous 125II seed implantation, as interstitial brachytherapy, was carried out in 21 patients with retroperitoneal lymph node metastasis. Before operation therapeutic plan system (TPS) was used in all patients to design the distribution of radioactive particles, and after the procedure CT scanning was performed to verify the distribution of radioactive particles. After the treatment, the abdominal pain, abdominal distension, serum tumor marker levels and local reaction of the target lymph nodes were evaluated. Results: The technical success rate was 100%, and after the operation no serious complications such as gastrointestinal perforation, radiation enteritis, vascular injury, bleeding, etc. occurred. Follow-up CT scanning was conducted once every 1-2 months. Six months after the treatment, complete remission (CR) was obtained in 13 cases, partial remission (PR) in 6 cases, stable disease (SD) in 2 cases, and progression disease (PD) in none. The overall response (CR + PR) rate was 90.5%. The abdominal pain and abdominal distension were relieved in different degrees in 16 patients, and the serum tumor marker levels were decreased in different degrees in 14 patients. Conclusion: For the treatment of retroperitoneal lymph node metastasis, CT-guided coaxial percutaneous l25I seed implantation is effective, safe and reliable. This technique provides a new minimally-invasive treatment for retroperitoneal lymph node metastasis. (authors)

  14. Effects of 125I-Labeled Peptide Nuclear Acid Targeting Ki67 on the Growth of Implanted Human Renal Cell Carcinoma in Nude Mice

    JiacunChen; JunnianZheng; SongWu; HaibiaoLai; XiaoqingSun; JunjieLiu

    2004-01-01

    OBJECTIVE To investigate the potential of 125I-labeled anti-sense peptide nucleic acids (125I-AS-PNAs) to inhibit the expression of the Ki-67 gene and growth of implanted human renal carcinoma cells in nude mice.METHODS Anti-sense peptide nucleic acids (AS-PNAs) targeting the Ki67 gene were synthesized and labeled with 125I by the Chloraseptine-T method. Drugs including PNAs and 125I-AS-PNAs capsulated by cationic lipid were directly injected into tumors in nude mice. The Ki67 expression in tumors was detected by an immunohistochemical technique and Western blot. The apoptosis of tumor cells was detected by a TUNEL assay. Tumor volumes were measured every 3 days and tumor suppression rates were calculated at 12 days after treatment. Control groups were treated with AS-PNA, MMPNAs (mismatch PNAs) and 125I-Na.RESULTS The Ki67 expression rate of tumors treated by 125I-AS-PNAs [(15.3±1.8)%] was lower than that treated by AS-PNAs [(23.0±2.4)%] (P<0.01). The Ki67 protein production rate of tumors treated by 125I-AS-PNAs [(43.6±3.5)%] was lower than that treated by AS-PNAs [(59.7±2.3)%] (P<0.01 ). The apoptosis rate of tumors treated by 125I-AS-PNAs [(40.3±2.4)%] was higher than that treated by AS-PNAs [(31.1 ±2.0)%] (P<0.01). The volume of tumors treated by 125I-AS-PNAs [(330.4±57.8) mm3 ]was smallerthan that treated by AS- PNAs [(513.2±64.2 ) mm3] (P<0.01 ).CONCLUSION 125I-AS-PNAs targeted against the Ki67 gene have a greater inhibitory effect on the expression of the Ki67 gene and a larger apoptotic action on human renal carcinoma cells and can more efficiently inhibit tumor growth than AS-PNAs. 125I-AS-PNAs targeting the Ki67 gene may be a promising anti-sense/anti-gene radiotherapy method for treating renal cell carcinoma.

  15. CT-guided percutaneous vertebroplasty combined with 125I-seed implantation for metastatic vertebral carcinoma involving the spinal canal: analysis of 23 cases

    Objective: To evaluate the safety and efficacy of CT-guided percutaneous vertebroplasty (PVP) combined with 125I-seed implantation for the treatment of metastatic vertebral carcinoma involving the spinal canal. Methods: A total of 28 involved vertebrae were detected in 23 patients with metastatic vertebral carcinoma. Each patient had 1-2 diseased vertebrae. The lesions included cervical vertebra (n=4), thoracic vertebra (n=13) and lumbar vertebra (n=11). Destroyed posterior vertebral wall was seen in all involved vertebrae. Thirteen vertebrae found in 12 patients showed involvement of the epidural space. According to treatment planning system (TPS) CT-guided implantation of 125I seeds was carried out first for cervical lesions, which was followed by PVP. For the thoracic and lumbar lesions, unilateral or bilateral puncturing with several particle needles was employed to implant the 125I seeds, then, PVP with bone cement injection was performed. The complications and the clinical efficacy were analyzed. Results: Successful operation was obtained in all patients. The number of implanted 125I seeds ranged from 4 to 30 per vertebra, and the volume of injected bone cement was 1-6 ml per vertebra. After the operation the pain relief rate was 86.9% (n=20). The incidence of bone cement leakage was 17.8% (5/28). One patient had radicular pain caused by neuropore leakage, which was relieved after medication. No serious complications, such as spinal cord injury or radiation myelitis, occurred. Conclusion: CT-guided PVP combined with 125I-seed implantation is effective and safe for the treatment of metastatic vertebral carcinoma involving the spinal canal. This therapy can effectively relieve the pain and control the deterioration of tumor, besides, the incidence of bone cement leakage is very low. (authors)

  16. Intra-operative dosimetry of trans-rectal ultrasound guided 125I prostate implants using C-arm fluoroscopic images

    Ravindran Paul

    2006-01-01

    Full Text Available Permanent implantation of radioactive seeds is a viable and effective therapeutic option widely used today for early-stage prostate cancer. The implant technique has improved considerably during the recent years due to the use of image guidance; however, real-time dose distributions would allow potential cold spots to be assessed and additional seeds added. In this study, we investigate the use of a conventional C-arm fluoroscopy unit for image acquisition and evaluation of dose distribution immediately after the implant. The phantom study indicates that it is possible to obtain seed positions within ±2 mm. A pilot study carried out with three patients indicated that it is possible to obtain seed positions and calculate the dose distribution with C-arm fluoroscopy and about 95% of the seeds were reconstructed within ±2 mm. The results could be further improved with better digital imaging.

  17. Early therapy monitoring of 125I seed interstitial implant in a pancreatic cancer xenograft by 18F-FDG Micro-PET/CT

    Objective: To investigate the application value of early evaluation and monitoring of 125I interstitial implantation in a pancreatic cancer xenograft. Methods: Xenograft models were created by subcutaneous injection of Sw 1990 human pancreatic cancer cell suspensions into the right hind limbs of the immunodeficient BABL/c nude mice. The tumors size were about 8-10 mm after two weeks. The mice were randomly divided into 3 groups,including control group (n=4), empty seed implantation group (n=4) and 125I implantation group (n=4). Before treatment and one week after treatment, 18F-FDG Micro-PET/CT scan was performed and then maximum standardized uptake values (SUVmax), mean standardized uptake values (SUVmean), tumor size and necrosis rate were measured. HE staining and TK1 immunohistochemistry examination were carried out in the paraffin-embedded sample. Results: Before treatment the SUVmax and SUVmean values of three groups did not reach statistical significance. One week after treatment the SUVmax and SUVmean values of three groups were 3.53±1.20 and 0.57±0.26 vs. 3.83±2.13 and 0.59 ±0.24 vs. 0.29±0.23 and 0.016±0.001, respectively, with a significant difference (F=7.62, P=0.01; F=10.34, P=0.005). The SUVmax and SUVmean values of 125I implant group were significantly lower than empty seed implant group and control group and were significantly lower than before treatment. Before treatment, tumor necrosis rate of three groups were not significantly different. Immunohistochemical staining found the TK1 positive staining index of three groups were respectively (64.25±1.71)%, (62.25±2.22)% and (38.25±1.71)% with statistically significant difference (F=233.67, P<0.001). The TK1 positive staining index of 125I implant group was significantly lower than empty seed implant group and control group. The SUVmax values had some positive correlation with TK1 positive staining index (r=0.85, P=0.001). Conclusions: 18F-FDG Micro-PET/CT may be useful as a noninvasive

  18. Dynamic observation on changes of serum tumor markers levels after implantation of 125I radioactive seeds as treatment for several malignancies

    Objective: To study the dynamic changes of serum levels of several tumor markers after implantation of 125I seeds as treatment for breast, prostate and lung malignancies. Methods: Serum CA15-3 (in 48 cases of breast cancer), PSA (in 59 cases of prostate cancer) and CYFRA21-1 (in 59 cases of lung cancer) levels were measured with RIA both before and after implantation of 125I seeds as treatment. Furthermore, dynamic observation on the serum markers levels was carried out every 3 months in ten patients in each category. Results: After treatment, levels of these markers dropped significantly. Dynamic observation revealed that in the 10 cases of breast cancer, the levels of CA15-3 dropped continually. However, in the 10 cases of prostatic cancer, the disease got worse and the PSA levels kept increasing. In the lung cancer group, the CYFRA21-1 levels rose markedly and all patients expired before 9 months. Conclusion: Dynamic observation on changes of serum tumor markers (CA15-3, PSA, CYFRA21-1) levels after 125I seed implantation treatment was of definite prognostic value. (authors)

  19. Clinical efficacy of CT-guided 125I radioactive seeds implantation for stage Ⅲ of non-small cell lung cancer

    Objective: To evaluate the clinical effects of CT-guided 125I radioactive seed implantation in treatment of stage Ⅲ non-small cell lung cancer (NSCLC) and the influential factors of prognosis. Methods: 247 patients of stage Ⅲa/Ⅲb NSCLC underwent CT-guided 125I radioactive seed implantation. The clinical effects and the factors affecting prognosis were analyzed by univariate and multivariate analyses. Results: The 1-, 3-, and 5- year overall survival rates were 82.8%, 23.8%, and 11.5 %, respectively. The median survival time was 24.8 months, and the local control rate was 92.2 %, 63.8%, and 25.7%, respectively. The 5- year overall survival rate was 14.7%, and the median survival time was 29.7 months of the stage Ⅲ, patients. And the 5- year overall survival rate was 11.2%, and the median survival time was 24.0 months at the stage Ⅲb. Univariate analysis showed that age, course of disease, hemoglobin before treatment, clinical stage, maximum diameter of tumor, prescribed dose (PD), post-operational mean dose,post-operational dose covering 100% volume (D100), remedial model were the main prognostic factors; however, multivariate analysis revealed that hemoglobin ≥ 120 g/L before treatment, post-operational dose covering 100% volume (D100) and maximum diameter of tumor were the independent risk factors for predicting the survival. Aerothorax was observed in 37 patients with an incidence rate of 14.9%, and hemothorax was observed in 22 patients with an incidence rate of 9%. Conclusions: 125I radioactive seed implantation therapy is effective in the treatment of stage Ⅲ NSCLC. Hemoglobin level before treatment, post-operational dose covering 100% volume (D100), and maximum diameter of tumor are the main prognostic factors for the NSCLC patients treated with radiotherapy for NSCLC. (authors)

  20. Preparation and deployment of indigenous 125I- seeds for the treatment of prostate cancer: dawn of prostate brachytherapy in India

    'Permanent seed implantation' using 125I- seeds represents an effective treatment modality for prostate cancer. An innovative strategy to prepare and deploy 125I- seeds for treatment of prostate cancer has been evolved. Seeds prepared by chemisorptions of 125I on palladium coated silver wires were characterized and encased in titanium tubes by ND:YAG laser. Several batches of critically evaluated seeds exhibiting release of 125I were supplied to P.D. Hinduja Hospital, Mumbai for treatment of prostate cancer patients. Successful deployment of indigenous seeds in prostate brachytherapy has opened a new window for making prostate brachytherapy affordable to needy cancer patients. (author)

  1. CT-guided iodine-125 seed permanent implantation for recurrent head and neck cancers

    To investigate the feasibility, and safety of 125I seed permanent implantation for recurrent head and neck carcinoma under CT-guidance. A retrospective study on 14 patients with recurrent head and neck cancers undergone 125I seed implantation with different seed activities. The post-plan showed that the actuarial D90 of 125I seeds ranged from 90 to 218 Gy (median, 157.5 Gy). The follow-up was 3 to 60 months (median, 13 months). The median local control was 18 months (95% CI, 6.1-29.9 months), and the 1-, 2-, 3-, and 5- year local controls were 52%, 39%, 39%, and 39%, respectively. The 1-, 2-, 3-, and 5- survival rates were 65%, 39%, 39% and 39%, respectively, with a median survival time of 20 months (95% CI, 8.7-31.3 months). Of all patients, 28.6% (4/14) died of local recurrence, 7.1% (1/14) died of metastases, one patient died of hepatocirrhosis, and 8 patients are still alive to the date of data analysis. CT-guided 125I seed implantation is feasible and safe as a salvage or palliative treatment for patients with recurrent head and neck cancers

  2. Long-term results of ultrasonically guided implantation of 125-I seeds combined with external irradiation in localized prostatic cancer

    Iversen, P; Rasmussen, F; Holm, H H

    1991-01-01

    Transperineal 125-iodine seed implantation guided by transrectal ultrasonography and subsequent external beam irradiation was employed in the treatment of 32 patients with localized prostatic carcinoma (16 poorly differentiated). Follow-up is currently 35-98 months with a median of 65 months. Dis...

  3. Radiation protection after interstitial permanent prostate brachytherapy implants

    Pirraco, R.; Pereira, A.; Cavaco, A. [Instituto Portugues de Oncologia Francisco Gentil - Centro R egional de Oncologia do Porto, SA, Porto (Portugal)

    2006-07-01

    Full text of publication follows: In this study we measure patients radiation exposure dose after interstitial {sup 125}I permanent prostate Brachytherapy implants, and correlate it with dose limits for public, total activity implanted, patient preoperative weight(1), distance between prostate walls and anterior skin surface. Methods and Material: We analyse 20 patients who were implanted with {sup 125}I seeds. The instrument used to measure radiation is a calibrated Berthold Umo LB 123 aco-plated to a LB 1236-H10 detector. Three measurements were taken: at the perineal and anterior pelvic zones on contact with the skin and at 1 m from the patient. The maximum value was taken for all measurements. The dose at a distance of one meter is obtained at anterior pelvic zone, perpendicular to the skin, according to the recommendations of A.A.P.M.(1). The distance between prostate walls was determined using post -operative CT images. Results: The doses at the perineal zone have determined an average of 186 {mu}Sv/h (range: 110 340 {mu}Sv/h) and at surface pelvic zone of 41 {mu}Sv/h (range: 15 103 {mu}Sv/h). The dose at a distance of 1 meter has an average value of 0.4 {mu}Sv/h (range: 0.2 1.0 {mu}Sv/h). The average total activity implanted was 25 mCi (range: 17 38 mCi). The distance between prostate walls and skin pelvic surface of the patients has an average value of 8.9 cm (range: 6.6 -11.5 cm). At a distance of 1 meter from the pelvic zone the dose measured is very low and below dose limits imposed by the European Directive EURATOM 2 and the Portuguese law. For general public to reach annual dose limit (EURATOM - 1 mSv/year) when contacting the pelvic zone, we extrapolate that 4 days (range: 1.6 11.1 days) would be needed, assuming a daily contact period of 6 hours. Conclusion: We established a correlation between the distance of prostate walls to the skin perineal surface and the total dose, but we find no correlation between measured doses, total activity implanted

  4. Methodology of quality control for brachytherapy {sup 125}I seeds

    Moura, Eduardo S.; Zeituni, Carlos A.; Manzoli, Jose E.; Rostelato, Maria Elisa C.M. [Instituto de Pesquisas Energeticas e Nucleares (IPEN/CNEN-SP), Sao Paulo, SP (Brazil)]. E-mail: esmoura@ipen.br

    2007-07-01

    This paper presents the methodology of quality control of {sup 125}I seeds used for brachytherapy. The {sup 125}I seeds are millimeter titanium capsules widely used in permanent implants of prostate cancer, allowing a high dose within the tumour and a low dose on the surrounding tissues, with very low harm to the other tissues. Besides, with this procedure, the patients have a low impotence rate and a small incidence of urinary incontinence. To meet the medical standards, an efficient quality control is necessary, showing values with the minimum uncertainness possible, concerning the seeds dimensions and their respective activities. The medical needles are used to insert the seeds inside the prostate. The needles used in brachytherapy have an internal diameter of 1.0 mm, so it is necessary {sup 125}I seeds with an external maximum diameter of 0.85 mm. For the seeds and the spacer positioning on the planning sheet, the seeds must have a length between 4.5 and 5.0 mm. The activities must not vary more than 5% in each batch of {sup 125}I seeds. For this methodology, we used two ionization chamber detectors and one caliper. In this paper, the methodology using one control batch with 75 seeds manufactured by GE Health care Ltd is presented. (author)

  5. The effect of local control on metastatic dissemination in carcinoma of the prostate: Long-term results in patients treated with 125I implantation

    The study evaluates the effect of the locally recurring tumor on the incidence of metastatic disease in early stage carcinoma of the prostate. The probability of distant metastases was studied in 679 patients with Stage B-C/N0 carcinoma of the prostate treated at MSKCC between 1970 and 1985 (median follow-up of 97 months). Patients were staged with pelvic lymph node dissection and treated with retropubic 125I implantation. The actuarial distant metastases free survival (DMFS) for patients at risk at 15 years after initial therapy was 37%. Cox proportional hazard regression analysis of covariates affecting the metastatic outcome showed that local failure, used in the model as a time dependent variable, was the most significant covariate, although stage, grade, and implant volume were also found to be independent variables. The relative risk of metastatic spread subsequent to local failure was 4-fold increased compared to the risk without evidence of local relapse. The 15-year actuarial DMFS in 351 patients with local control was 77% compared to 24% in 328 patients who developed local relapses (p less than 0.00001). The relation of distant spread to the local outcome was observed regardless of stage, grade, or implant dose. Even stage B1/N0-Grade I patient with local control showed a 15-year actuarial DMFS of 82%, compared to 22% in patients with local relapse (p less than 0.00001). The median local relapse-free survival (LRFS) in the 268 patients with local recurrences who did not receive hormonal therapy before distant metastases were detected was 51 months, compared to a median of 71 months for DMFS in the same patients (p less than 0.001), consistent with the possibility that distant dissemination may develop secondary to local failure

  6. Preparation and deployment of indigenous 125I-seeds for the treatment of prostate cancer. Dawn of prostate brachytherapy in India

    'Permanent seed implantation' using 125I- seeds has emerged as an effective treatment modality for management of prostate cancer. An indigenous technology for the production of 125I brachytherapy sources ('BARC 125I Ocu-Prosta seed') has been developed. In this current work, we describe an overview of our experience on large scale production of 125I brachytherapy sources, their quality assessment, in vivo bio-evaluation and initial experience on their journey from bench to bed-side for the treatment of prostate cancer. (author)

  7. Permanent transvenous pacemaker implantation in forty dogs

    Permanent transvenous cardiac pacemakers were implanted in 40 dogs. Electrocardiographic diagnoses included persistent atrial standstill (3 dogs), sick sinus syndrome (8 dogs), and high-grade second-degree or third-degree atrioventricular (AV) block (29 dogs). Thirteen dogs were alive and well 4 to 42 months after pacemaker implantation (mean, 16.9 months). The mean and median survival times of the 26 dogs that died or were euthanatized during the study were 17.9 months and 13 months, respectively. Most of these dogs succumbed to problems unrelated to the arrhythmia and pacemaker implant. One dog was lost to follow-up. Complications associated with permanent transvenous pacemaker implantation included lead dislodgement, infection, hematoma formation, skeletal muscle stimulation, ventricular arrhythmia, migration of the pulse generator, and skin erosion. Lead dislodgement was the most common complication, occurring in 7 of 9 dogs paced using untined electrode leads and in 6 of 30 dogs paced using tined leads. Lead dislodgement did not occur in the only dog paced using an actively fixed endocardial lead. It was concluded that permanent transvenous cardiac pacing is a feasible, less traumatic alternative to epimyocardial pacing in dogs, but that successful use of this technique requires careful implantation technique and anticipation of the potential complications

  8. Occupational exposure of professionals during interstitial permanent prostate brachytherapy implants

    Full text of publication follows: Introduction: In this study we present dose measurements for professionals exposed during interstitial 125 I permanent prostate brachytherapy implants. Methods and Materials: The implant technique used was intra operative real time using strand and loose seeds. The professionals inside the operating room are an oncologist, a radiologist, a physicist, a nurse and an anesthesiologist. The oncologist and the physicist contact directly the loaded needle with radioactive seeds and two types of measurements were taken: total body and extremities (finger) dose. The rest of the team operates at long distances, but measurements were made. To measure total body equivalent dose we use a Berthold Umo LB 123 coupled with a LB 1236-H10 detector, and we recorded dose, time and distance from implant location. Finger dosemeters are thermo -luminescent dosimeter (TLD) rings that were controlled over one month. Results: 50 cases (average number of applications per year) were analysed for extremities measurements and 9 cases for total body measurements (in this case, the results were extrapolated for 50 cases), with an average of 26.1 mCi total activity per implant (in a range of 17.4 - 40.3 mCi). The finger dose was 1.8 mSv for the oncologist and 1.9 mSv for the physicist. The interpolation of total body equivalent dose for the oncologist was 24 mSv, for the radiologist 6 mSv and 9 mSv for the physicist. The rest of the team did not receive anything but background radiation. The annual national limit dose for workers is 20 mSv for total body irradiation, and 500 mSv for extremities. Conclusion: In conclusion we may say that during interstitial permanent prostate brachytherapy implants, total doses received for all groups are not significant when compared to annual limits for Portuguese laws 1. Even so, our main goal is always to get the less possible dose (ALARA principle). References: 1. Decreto Lei n. 180/2002 de 8 de Agosto. (authors)

  9. Quality of life after permanent prostate implant

    Purpose: To report on the quality of life in patients who have received a permanent transperineal ultrasound guide prostate implant. There is increasing recognition that prostate cancer therapy impacts significantly on the patients ability to pursue relational, occupational and social interests. With the substantially expanded patient role in directing treatment for prostate cancer, the importance of examining quality of life outcomes in addition to survival has been underscored. Materials and Methods: 51 sequential patients with clinically localized prostate cancer who underwent permanent prostate implantation from September 1995 to October 1996 were evaluated. All patients were clinically staged as T1c or T2a and received implant with Iodine 125 or Palladium 103 as definitive treatment. Data was collected using the EORTC genitourinary group questionnaire and supplemental questions during an interview. Results: Urinary symptoms such as nocturia, frequency and dysuria were the most pronounced in the first two months after implant and then decreased in the majority of patients. The EORTC questionnaire was administered at 6 months and examined urinary quality, sexual quality and perception of symptoms. With regard to urinary quality, 17% had mild dysuria at 6 months and 40% noted that they urinated more frequently than pre implant. No patient had hematuria and 0 % were incontinent. 3% stated that they had occasional loss of minimal urine with severe urgency. Only 2% required intermittent self catheterization after implant secondary to obstructive symptoms. Over 90% were on an alpha blocker post implant for a minimum of 6 weeks. 0% reported psychological distress and 3% noted a disruption in social or family life. 15% experienced some fatigue and 10% noted a decreased functional status but only 1% a decreased role function. Additional questions addressed lifestyle and work issues. 100% would have an implant again as definitive treatment and 98% would recommend the

  10. Permanent Breast Seed Implant Dosimetry Quality Assurance

    Keller, Brian M., E-mail: Brian.Keller@sunnybrook.ca [Department of Medical Physics, Sunnybrook Health Sciences Center, Toronto, ON (Canada); Department of Radiation Oncology, University of Toronto, Sunnybrook Health Sciences Center, Toronto, ON (Canada); Ravi, Ananth [Department of Medical Physics, Sunnybrook Health Sciences Center, Toronto, ON (Canada); Sankreacha, Raxa [Carlo Fidani Regional Cancer Center, Mississauga, ON (Canada); Pignol, Jean-Philippe [Department of Radiation Oncology, University of Toronto, Sunnybrook Health Sciences Center, Toronto, ON (Canada)

    2012-05-01

    Purpose: A permanent breast seed implant is a novel method of accelerated partial breast irradiation for women with early-stage breast cancer. This article presents pre- and post-implant dosimetric data, relates these data to clinical outcomes, and makes recommendations for those interested in starting a program. Methods and Materials: A total of 95 consecutive patients were accrued into one of three clinical trials after breast-conserving surgery: a Phase I/II trial (67 patients with infiltrating ductal carcinoma); a Phase II registry trial (25 patients with infiltrating ductal carcinoma); or a multi-center Phase II trial for patients with ductal carcinoma in situ (3 patients). Contouring of the planning target volume (PTV) was done on a Pinnacle workstation and dosimetry calculations, including dose-volume histograms, were done using a Variseed planning computer. Results: The mean pre-implant PTV coverage for the V{sub 90}, V{sub 100}, V{sub 150}, and V{sub 200} were as follows: 98.8% {+-} 1.2% (range, 94.5-100%); 97.3% {+-} 2.1% (range, 90.3-99.9%), 68.8% {+-} 14.3% (range, 32.7-91.5%); and 27.8% {+-} 8.6% (range, 15.1-62.3%). The effect of seed motion was characterized by post-implant dosimetry performed immediately after the implantation (same day) and at 2 months after the implantation. The mean V{sub 100} changed from 85.6% to 88.4% (p = 0.004) and the mean V{sub 200} changed from 36.2% to 48.3% (p < 0.001). Skin toxicity was associated with maximum skin dose (p = 0.014). Conclusions: Preplanning dosimetry should aim for a V{sub 90} of approximately 100%, a V{sub 100} between 95% and 100%, and a V{sub 200} between 20% and 30%, as these numbers are associated with no local recurrences to date and good patient tolerance. In general, the target volume coverage improved over the duration of the seed therapy. The maximum skin dose, defined as the average dose over the hottest 1 Multiplication-Sign 1-cm{sup 2} surface area, should be limited to 90% of the

  11. Permanent Breast Seed Implant Dosimetry Quality Assurance

    Purpose: A permanent breast seed implant is a novel method of accelerated partial breast irradiation for women with early-stage breast cancer. This article presents pre- and post-implant dosimetric data, relates these data to clinical outcomes, and makes recommendations for those interested in starting a program. Methods and Materials: A total of 95 consecutive patients were accrued into one of three clinical trials after breast-conserving surgery: a Phase I/II trial (67 patients with infiltrating ductal carcinoma); a Phase II registry trial (25 patients with infiltrating ductal carcinoma); or a multi-center Phase II trial for patients with ductal carcinoma in situ (3 patients). Contouring of the planning target volume (PTV) was done on a Pinnacle workstation and dosimetry calculations, including dose–volume histograms, were done using a Variseed planning computer. Results: The mean pre-implant PTV coverage for the V90, V100, V150, and V200 were as follows: 98.8% ± 1.2% (range, 94.5–100%); 97.3% ± 2.1% (range, 90.3–99.9%), 68.8% ± 14.3% (range, 32.7–91.5%); and 27.8% ± 8.6% (range, 15.1–62.3%). The effect of seed motion was characterized by post-implant dosimetry performed immediately after the implantation (same day) and at 2 months after the implantation. The mean V100 changed from 85.6% to 88.4% (p = 0.004) and the mean V200 changed from 36.2% to 48.3% (p 90 of approximately 100%, a V100 between 95% and 100%, and a V200 between 20% and 30%, as these numbers are associated with no local recurrences to date and good patient tolerance. In general, the target volume coverage improved over the duration of the seed therapy. The maximum skin dose, defined as the average dose over the hottest 1 × 1-cm2 surface area, should be limited to 90% of the prescription dose to minimize delayed skin toxicity.

  12. Study of photon angular distribution from a new Best 2300 series 125I source for interstitial brachytherapy

    125I seeds employed for permanent and temporary interstitial implants exhibit significant radiation fluence anisotropy due to self absorption in the marker and oblique filtration through the encapsulation jacket. A silver wire 125I seed (Model 6711), introduced in 1983 by 3M Company, failed to improve the photon distribution anisotropy. In addition to the known 125I photon spectrum, the new seed emitted two silver characteristic x-rays, lowering the mean photon energy from 28.4 to 27.4 keV. A double wall uniform thickness encapsulated 125I source, laser welded at one end, has been developed for clinical use. The source uses a carbon coated thin tungsten filament for enhanced radiographic visualization. Measurements made by NaI and intrinsic Ge detectors indicate that the 2300 series 125I source emits a pure 125I spectrum. The angular dependence of individual photon peaks and total photon spectrum as well as the corresponding anisotropy factors were measured. The 4π averaged anisotropy factor for the total radiation fluence is 0.92 compared to 0.87 for model 6711 seed. The dose distribution around the new 125I source in water is very isotropic. (author). 11 refs., 8 figs., 2 tabs

  13. Oblate band in 125I

    The iodine isotopes belonging to the transitional region with Z ≥ 50 and N ≤ 82, have been the subject of extensive theoretical and experimental research as they exhibit various coexisting structures. The levels of 125I were studied via 123Sb (α, 2nγ) 125I fusion-evaporation reaction at 30-MeV beam energy

  14. Iodine-125 Seed Implantation (Permanent Brachytherapy for Clinically Localized Prostate Cancer

    Saika,Takeshi

    2008-02-01

    Full Text Available From January 2004 to March 2007, 308 patients with clinically localized prostate cancer were treated using iodine-125 (125I seed implantation (permanent brachytherapy at Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences. We evaluated the treatment’s effi cacy and morbidity in 300 prostate cancer patients who were followed up for more than 1 month after brachytherapy. Based on the National Comprehensive Cancer Network (NCCN guidelines, patients with a prostate volume of less than 40 ml in transrectal ultrasound imaging were classifi ed as low or intermediate risk. The median patient age was 67 years (range 50 to 79 years, the median prostate-specific antigen (PSA value before biopsy was 6.95 ng/ml (range 1.13 to 24.7 ng/ml, and the median prostate volume was 24.33 ml (range 9.3 to 41.76 ml. The median follow-up was 18 months (range 1 to 36 months and the PSA levels decreased in almost all patients after brachytherapy. Although 194 of 300 patients (64.7% complained of diffi culty in urination, pollakisuria/urgency, miction pain, and/or urinary incontinence, all of which might be associated with radiation prostatitis during the fi rst month after brachytherapy, these symptoms gradually improved. 125I seed implantation brachytherapy is safe and eff ective for localized prostate cancer within short-term follow up.

  15. MR and CT image fusion for postimplant analysis in permanent prostate seed implants

    Purpose: To compare the outcome of two different image-based postimplant dosimetry methods in permanent seed implantation. Methods and materials: Between October 1999 and October 2002, 150 patients with low-risk prostate carcinoma were treated with 125I and 103Pd in our institution. A CT-MRI image fusion protocol was used in 21 consecutive patients treated with exclusive brachytherapy. The accuracy and reproducibility of the method was calculated, and then the CT-based dosimetry was compared with the CT-MRI-based dosimetry using the dose-volume histogram (DVH) related parameters recommended by the American Brachytherapy Society and the American Association of Physicists in Medicine. Results: Our method for CT-MRI image fusion was accurate and reproducible (median shift 100 = 82% vs. 88%, p 90 = 96% vs. 115%, p < 0.05. Those results depend on the institutional implant technique and reflect the importance of lowering inter- and intraobserver discrepancies when outlining prostate and organs at risk for postimplant dosimetry. Conclusions: Computed tomography-MRI fused images allow accurate determination of prostate size, significantly improving the dosimetric evaluation based on DVH analysis. This provides a consistent method to judge a prostate seed implant's quality

  16. Validation of implant stability: A measure of implant permanence

    Neha Mall; B Dhanasekar; I. N. Aparna

    2011-01-01

    Implant stability is a requisite characteristic of osseointegration. Without it, long-term success cannot be achieved. Continuous monitoring in a quantitative and objective manner is important to determine the status of implant stability. Measurement of implant stability is a valuable tool for making decisions pertaining to treatment protocol and also improves dentist-patient communication. Owing to the invasive nature of histological analysis, various others methods have been proposed like r...

  17. Permanent and temporary pacemaker implantation after orthotopic heart transplantation

    Bacal Fernando

    2000-01-01

    Full Text Available PURPOSE:To determine the indication for and incidence and evolution of temporary and permanent pacemaker implantation in cardiac transplant recipients. METHODS: A retrospective review of 114 patients who underwent orthotopic heart transplantation InCor (Heart Institute USP BR between March 1985 and May 1993. We studied the incidence of and indication for temporary pacing, the relationship between pacing and rejection, the need for pemanent pacing and the clinical follow-up. RESULTS: Fourteen of 114 (12%heart transplant recipients required temporary pacing and 4 of 114 (3.5% patients required permanent pacing. The indication for temporary pacing was sinus node dysfunction in 11 patients (78.5% and atrioventricular (AV block in 3 patients (21.4%. The indication for permanent pacemaker implantation was sinus node dysfunction in 3 patients (75% and atrioventricular (AV block in 1 patient (25%. We observed rejection in 3 patients (21.4% who required temporary pacing and in 2 patients (50% who required permanent pacing. The previous use of amiodarone was observed in 10 patients (71.4% with temporary pacing. Seven of the 14 patients (50% died during follow-up. CONCLUSION: Sinus node dysfunction was the principal indication for temporary and permanent pacemaker implantation in cardiac transplant recipients. The need for pacing was related to worse prognosis after cardiac transplantation.

  18. An analysis of brachytherapy with computed tomography-guided permanent implantation of Iodine-125 seeds for recurrent nonkeratin nasopharyngeal carcinoma

    Shen X

    2015-05-01

    Full Text Available Xinying Shen,1,2 Yong Li,2 Yanfang Zhang,2 Jian Kong,2 Yanhao Li1 1Department of Interventional Radiology, Nanfang Hospital, Southern Medical University, Guangzhou, 2Department of Interventional Radiology, Shenzhen People’s Hospital, The Second Clinical Medical College of Jinan University, Shenzhen, People’s Republic of China Background: 125I seed implantation is a new method in treatment of nasopharyngeal carcinoma (NPC, and it is worthwhile to evaluate its feasibility. In this study, we performed brachytherapy with computed tomography (CT-guided permanent implantation of 125I seeds in the treatment of patients with the recurrence of NPC.Methods: A total 30 patients (20 male and ten female at the median age of 55 (range 25–80 years were diagnosed with recurrent nonkeratin NPC, with a total 38 lesions and a short disease-free interval (median ~11 months after primary radiotherapy alone or combined with chemotherapy. Patients received CT scan, starting from 2 months after the treatment. Follow-up was conducted for ~2–38 months to observe the local control rate and overall survival rate. We also analyzed the possible correlation between survival periods and the status of recurrent tumors.Results: The local control rates at 6, 12, 24, 30, and 36 months after the procedure of 125I seed implantation were 86.8%, 73.7%, 26.3%, 15.8%, and 5.3%, respectively. The overall 1-, 2-, and 3-year survival rates were 80.0% (24/30, 30.0% (9/30, and 6.7% (2/30, respectively, with a median survival period of 18 months (17.6±8.6 months. Interestingly, the survival periods of the patients who had primary radiotherapy with or without chemotherapy were 15.8±7.9 and 24.3±7.9 months, respectively. Kaplan–Meier survival analysis demonstrated that χ2 (log rank was 7.555, with very significant difference (P<0.01. The survival periods of patients in tumor stages I, II, III, and IV were 25.4±8.7, 19.8±9.4, 16.1±4.5, and 12.8±7.8 months, respectively, with

  19. The effect of the radial function on I-125 seeds used for permanent prostate implantation

    The purpose of this study was to evaluate the integrity of eight commercially-available low-activity Iodine-125 (125I) seeds for their radial function g(r) and its effect on the dose delivered to the adjacent critical structures when used in permanent prostate implants (PPI). Ten previously treated patients were retrospectively used in this comparison. The Amersham Health Oncura seed was used to peripherally design an isodose distribution with urethral and anterior rectal wall sparing. Plan criteria included minimum coverage of 144 Gy to the planning target volume (PTV), ≤ 70% dose to 150% of the PTV volume (V150-PTV), and the quantity of needles ≤ 70% of the size of the PTV, in cc. Upon completion of the Oncura plan, the seed type was changed and the activity was adjusted until the V100-PTV for each of the other 7 seed types matched the V100-PTV defined by the Oncura seed. Computed tomography (CT)-based postimplant dosimetry was used to determine the dose to 40% (D40) of the bulb of the penis (in Gy). Dose-volume histograms (DVH) were used to evaluate the differences to V100 (in %) and D40 (in Gy) of the anterior rectal wall and bulb of the penis, and V100 (in %) of the urethra. The data was tabulated. Radioactive 125I sources included in this study were 125I Source 2301 (Best); I-Plant (MedTech), IoGold (Mentor), Oncura (Amersham Health), ProstaSeed (UroCor), SelectSeed (Nucletron), SourceTech (Bard), and Symmetra (UroMed). The sizes of the PTV for the 10 patients ranged from 18.82 cc to 48.99 cc. The Oncura seed was used as the reference seed and all other seed types were normalized to it for data comparison. It was determined that the dose rate constant (xwedge) and anisotropy factor (phi) contribute to the activity needed to achieve comparable V100-PTV doses, but a strong dependence on the radial function g(r) was found to effect the doses to the critical structures studied. Values of g(r) at 4 cm were calculated and the IoGold and SourceTech seeds were

  20. Nuclear lesions produced by 125I decay

    125I decay induced DNA damage was investigated in Chinese hamster ovary (CHO) cells which had incorporated 125I-iododeoxyuridine (125IUdR) into their DNA. 125I decays were accumulated in frozen cells. DNA strand breaks produced by low numbers (0--1,200 decays per cell) of 125I decays were assayed using the alkaline unwinding technique and the alkaline filter elution technique. Approximately 300 125I decays reduced the relative damage to 50%. DNA protein cross links were not detected after accumulation of 125I decay. The production of DNA double strand breaks by 125I decay was assayed by the neutral filter elution technique at pH 9.6 and 7.2 after accumulating 100--5,000 decays per cell. No alkali labile lesions were detected. Approximately 3,000 125I decays were required to reduce the mean value of the fractions to 50%. In all the assays, DNA damage induction data were fit to a straight line by regression analysis except at very low numbers of accumulated 125I decays where an initial drop in the fraction of DNA retained on the filter was observed. This drop suggests multiple chromatin fragmentation is produced by 125I decay

  1. 125I粒子植入对面神经超微结构影响的动物实验%Ultrastructural study on the facial nerve of rabbit after 125I seed implantation

    左健; 宋铁砾; 鞠向群; 郑磊; 蔡志刚; 张建国

    2011-01-01

    目的 探讨 125I放射性粒子不同处方剂量近距离照射对家兔面神经超微结构的影响,旨为临床提供参考.方法 将大耳白兔54只随机分为3个实验组:40 Gy组、80 Gy组、120 Gy组,每组18只动物;每只动物自身对照,将 125I粒子植入一侧腮腺区面神经周围,另一侧作为对照植入粒子空壳.每组分别于2、4、6个月时取面神经干做透射电镜观察.结果 对照组:术后2、4、6个月均可见面神经轴膜连续、轴膜下轻度水肿,髓鞘局部松散.实验组:术后2个月均可见面神经轴膜下水肿、髓鞘松散,其中80 Gy组可见巨噬细胞和新生神经纤维,120 Gy组可见板层分离及新生神经纤维;4个月均可见面神经板层分离、髓鞘松散,其中40、80 Gy组可见胶原增生及轴膜下水肿; 6个月均可见新生神经纤维、髓鞘松散,其中80、120 Gy组可见板层分离、轴膜下水肿.结论 家兔面神经在接受40、80及120 Gy 125I照射后,面神经超微结构存在一定的损伤,面神经受照射剂量越大损伤程度越重;但在120 Gy 125I照射6个月后,髓鞘与轴突的完整性和连续性仍基本保持.%Objective To investigate the ultrastructural variation of the facial nerve of rabbit with different dosage of 125I seed brachytherapy. Methods Fifty-four big ear rabbits were divided into 3 groups randomly and given 40 Gy, 80 Gy, 120 Gy respectively. Radioactive seeds were implanted in one side of parotid gland, the other side was implanted with vacant shell as a control group. The facial nerves were obtained 2, 4, 6 months respectively after operation and the histological ultrastructural changes observed by electromicroscope. Results In the control group,epineurium was continuous, there was slight pitting edema under the epineurium, and axonal myelin was loose. In the test groups, there was slight pitting edema under the epineurium, and axonal myelin sheath was loose at 4th month. Macrophage and regenerated fibers were

  2. Reevaluation of the indications for permanent pacemaker implantation after transcatheter aortic valve implantation

    Bjerre Thygesen, Julie; Loh, Poay Huan; Cholteesupachai, Jiranut; Franzen, Olaf; Søndergård, Lars

    2014-01-01

    AIMS: Conduction abnormalities (CA) requiring permanent pacemaker (PPM) are a well-known complication after transcatheter aortic valve implantation (TAVI). This study aimed to determine the incidence of TAVI-related PPM and reevaluate the indications for PPM after the periprocedural period. METHO...

  3. Routine chest radiography after permanent pacemaker implantation: Is it necessary?

    Edwards N

    2005-01-01

    Full Text Available Background and Aims: Chest radiographs (CXRs are performed routinely after permanent pacemaker implantation to identify pacemaker lead position and exclude pneumothorax. We assessed the clinical value and need for this procedure. Design: Retrospective analysis of pacemaker data and CXRs following permanent pacemaker insertion between December 2002 and February 2004. Materials and Methods: Post-procedural CXRs were available in 125/126 consecutive patients after either first endocardial pacemaker implantation or insertion of at least one new lead. Subclavian vein puncture was used for venous access in all cases. CXRs were examined to establish the incidence of pneumothorax and assess pacing lead positions. The clinical records were examined in all patients who had subsequent CXRs or a further pacemaker procedure to identify the indication for these and to establish whether CXR had influenced patient management. Results: In total, 192 post-procedural CXRs were performed, either postero-anterior (PA and/or lateral views. Ventricular and/or atrial pacing lead contour and electrode position was considered radiographically appropriate in 86% CXRs. Fourteen per cent of post-procedural radiographs were considered to have radiologically sub-optimal pacemaker lead positioning. None of the patients with these "abnormal" radiographs experienced subsequent pacemaker complications or had further radiographs recorded at a later date. Later repeat CXRs were performed in 16 patients (13% but only 3 patients (2% had pacing abnormalities as the primary indication. All three had satisfactory pacing lead position on initial post-implantation and later radiographs, but required further procedures for lead re-positioning. Iatrogenic pneumothorax occurred in one patient (incidence 0.8% in our series. CXR confirmed the clinical diagnosis and allowed an assessment of size to guide treatment. Conclusion: Routine CXR after permanent pacemaker insertion is not necessary in

  4. Role of TPS in 125I brachytherapy for orbital tumors

    Objective: To investigate the role of TPS in 125I brachytherapy for orbital tumors. Methods: Sixty-six patients with orbital tumor treated with 125I seeds from 2005 to 2009 were retrospectively analyzed. Forty-three patients were treated using TPS guided brachytherapy and the prescribed dose was 140 Gy. Other 23 patients were treated without TPS but simply implanted with 125I seeds at 1 cm intervals in parallel with each other intraoperatively. CT and TPS quality verification were performed postoperatively in all patients. Also, CT and (or) MRI examination were performed at 3, 6, 12 and 24 months after brachytherapy for follow-up. χ2 test and Kaplan-Meier survival analysis with log-rank significance test were used with SPSS 17.0. Results: A total of 1070 125I seeds were implanted in 66 cases, on average, (16.2 ± 7.3) seeds for each patient. The satisfaction rates of postoperative quality verification in patients with and without TPS pre-plans were 79.07% (34/43) and 43.48% (10/23) respectively (χ2=8.542, P=0.003). Ten patients were lost in follow-up. Local recurrence rates in patients with favorable postoperative quality verification were 0 (0/37) in 3 months, 6.25% (2/32) in 6 months, 13.64% (3/22) in 12 months and 3/9 in 24 months respectively, which were significantly different from those (5.26% (1/19), 16.67% (3/18), 30.77% (4/13), 6/6) in the patients with inferior postoperative quality verification (χ2=9.017, P=0.0003). Conclusions: TPS plays an important role in 125I brachytherapy for orbital tumors. Also, postoperative quality verification by TPS may help predict the local recurrence after brachytherapy. (authors)

  5. Tumor therapy with 125I-octreotide and 125I-UdR

    Purpose: To determine the tumor cell damage effect with Auger-electron emitter 125I in different chemical states. Methods: (1) [Tyr3] octreotide (TOC) and UdR are labeled with 125I,respectively. (2) Receptor analysis of 125I-TOC on small cell lung cancer (SCLC) NCI-H446 cell lines is performed comparing with normal lymph cells. NCI-H446 cells added various dose of 125I-TOC are incubated for different time with 125I-Nal and non-labeled TOC as control. The capacity of NCI-H446 cell lines bound and internalization of 125I TOC are determined. The radiation damage of tumor cells is measured by MTF methods. (3) The killing effects of 125I-UdR in human pancreatic cancer cell line Bax-Pc and Sca-BER bladder carcinoma cells are evaluated with the similar methods. I-UdR penetrating into the Sca-BER cell nucleus is observed with confocal microscope. The grow suppression and clonogenic formation of Sca-BER cells after incubation with 125I-UdR are analyzed. Proliferation fraction and S phase cell fraction of Sca-BER cell added 125I-UdR is measured with flow cytometric analysis. Results: (1) Kd=(0.56∼2.0) x 10-11 mol/L and Bmax=(1.17∼2.0) x 105 cell site are obtained by receptor analysis of 125I-TOC on NCI-H446 cells. Comparatively, the difference between total binding and non-specific binding is low and there is no saturation of specific binding for normal lymphocyte. About 50% of 125I-TOC is internalized into the NCI-H446 cell nucleus at 24h after incubation. The damige of NCI-H446 cells by 125I-TOC is clearly observed. (2) The penetration amount of 125I-UdR into cell nucleus increases with the incubate time when the concentration of 125I-UdR is in the range of 10∼500 kBq/mL and reaches the peak fraction of 94% at 36 h after incubation. The radioactivity of 125I-UdR is then achieved equelibration and no more increased with time. The linear correlation with γ=0.867∼0.978 between the concentration of 125I-UdR in cell nucleus and the incubation time is observed before

  6. Preparation of 125I FSH hormone

    Labelling of human FSH of pituitary origin with 125I and its purification are described. Suitable parameters are selected for the use of radioimmunologic technique for FSH dosage in human serum. (author)

  7. Dual-chamber implantable cardioverter-defibrillator. Is it useful in patient with permanent atrial fibrillation?

    Porres-Aracama, José M; Cerezuela, José Luis; García-Urra, Francisco; Luque-Lezcano, Oscar; Herrero, Vicente

    2016-08-01

    In patients with permanent atrial fibrillation (AF) and implantable cardioverter-defibrillator (ICD) implant indication, a single-chamber device is the choice because AF does not provide interesting information for the treatment. It is very unusual to find patients with permanent AF that coexist with atrial tachycardia with various degree of Atrioventricular block. PMID:27525075

  8. CT guided 125I seed brachytherapy for recurrent rectum cancer

    Objective: To investigate the technological feasibility, efficacy and morbidity of CT guided 125I seed implantation for recurrent rectum cancer. Methods: Twenty-three patients with recurrent rectum cancer were treated with CT guided interstitial 125I seed brachytherapy. In 20 patients the procedure was performed under epidural anesthesia and 3 patients under local anesthesia. Treatment planning system was used to calculate the number of seeds, the space distribution and the introduction of the seeding needles. Matched peripheral dose (MPD) of 121I seed implantation ranged from 90-120 Gy for patients who had had external radiotherapy, and 140- 160 Gy for those who had not. The planning target volume(PTV) was clinical target volume(CTV) plus 1 cm margin. The range of radioactivity of the 125I seeds was 18.5-25.9 MBq. All these 23 patients had CT scan at 5 mm intervals after implantation for quality evaluation, together with routine chest, pelvic X-ray films within 24-48 hours after seed implantation. Three patients received three-dimensional conformal radiation therapy(3DCRT) to a total dose of 45-50 Gy, with 2-3 Gy/f. Follow-up time was from 3 to 28 months. Results: All patients was able to tolerate seed implantation well. Complete pain relief was observed in 12/15, and partial relief in 2/15 and no response in 1/15, with a response rate of 93%. The local control rate was 87%. The 1- and 2-year survival rate was 93% and 50% respectively. Two of four patients have died of dissemination to the lung after 8 and 12 months. One seed has migrated into the pelvis without causing any untoward morbidity. Conclusion: CT guided 125I seed implantation for recurrent rectum cancer is safe, minimally invasive, causing only mild morbidity. It possesses a high efficacy, yet it should be given in combination with extemal beam radiation and chemotherapy, should distant metastasis be observed. (authors)

  9. 125I decay in synthetic oligodeoxynucleotides

    The availability of synthetic oligodeoxynucleotides provides the opportunity to study the effects of 125I in DNA with added precision and detail, compared to an earlier study (Martin and Haseltine, Science 214, 296, 1981). The authors have designed a template/primer system which enables incorporation of 125IdC into a defined location in a 31mer. The main advantage of this approach is that relatively large amounts (a few μCi) of DNA with both 32P and 125I can be produced quite easily. Consequently, when 125I-induced DNA damage is analyzed on DNA sequencing gels, the distribution of 32P-labeled cleavage products can be determined more accurately, following accumulation of decay events under various conditions (e.g. temperature, buffer components, free radical scavengers). The results of preliminary experiments suggest that the yield of DNA strand breaks per decay approaches one, at least for the 125I labeled strand. Extension of this experimental approach will also enable investigation of the nature of the terminii (e.g. phophoryl-versus phophorylglycollate) at either side of 125I decay-induced DNA strand breaks. The question of energy migration is also being investigated in the oligodeoxynucleotide system, by studying the effects of inclusion of BrUdR nucleotides at various distances from the 125IdC

  10. Current research and progress of radioactive 125I seed in the treatment of malignant tumor

    Radioactive 125I seed implantation has been paid more and more attention and studied by national and international scholars due to its minimal invasivity, high local tumor control rate and low complications. In the clinical treatment, to achieve the best treatment effect, the clinician should minimize the risk of possible 125I related complications. Making an accurate implantation plan by using the type -B ultrasonic and CT technique appropriately is essential. In this paper, we summarized that the application status of the 125I seed implantation technique in the treatment of malignant tumor. We also discussed the safety of its clinical applications. This review can provide a reliable basis for future standardized seed implantation treatment for malignant tumors. (authors)

  11. Quality indicators for permanent I-125 prostate seed implants : seven years post implant dosimetry evaluation

    Full text: The aim of the current work is to assess the progress of prostate implant quality via post implant dosimetry over a 7-year time period. The roles of post implant dosimetry (PID) after permanent 1-125 implant are to: identify suboptimal implants; assess the dosimetric quality indicators and evaluate dose to organs at risk. The 7-years PID learning-curve shows clear changes in dosimetric trend. Beside the expected improvement in technique the following factors were investigated: the replacement of the computed tomography (CT)-delineation based PID with ultrasound (US)-CT fusion based, and the evolution and influence of parameters such as 090 and V I 00. The correlation between dosimetric parameters and clinical outcome was also evaluated. Results A study on 30 patients showed manual target contouring on CT tends to overestimate the prostate volume when compared to ultrasound data (mean difference 38.3%), translating to CT based D90 values being lower than US-CT D90 by an average of 6%. There was 4.7% patient relapse and urinary retention was reported in 2.7% of the patients. CT-based PID was found less reliable than US-CT fusion due to target overestimation. This result shows the biased interpretation of low D90 based on CT targeting and may not relate to patient relapse data. The low urinary retention statistics are in accordance with the PID data for the organ, as only 5.2% of patients had their PID D I 0 >218 Gy, i.e. above recommended GEC-ESTRO guidelines. Besides the 'learning' component, the 7-years PID D90 curve is influenced by PID technique.

  12. Renal catabolism of 125I-glicentin

    The renal catabolism of 125I-glicentin has been studied in vivo by the disappearance of this peptide from the plasma of bilaterally nephrectomized, ureteral-ligated, or normal rats and by using tubular microinfusion techniques. In addition the catabolism of glicentin by the isolated, perfused kidney has been studied. Results from in vivo studies demonstrated that half-disappearance time was lower in control (59.5 +/- 1.8 min) than in bilaterally nephrectomized rats (97.2 +/- 2.6 min), and this value was significantly higher than that of ureteral-ligated animals (83.2 +/- 1.1 min, P less than 0.005). Microinfusion experiments revealed that when 125I-glicentin was injected into the proximal tubule, no trichloroacetic-precipitable radioactivity was recovered in the urine, whereas most of inulin injected was recovered. By contrast most of the 125I-glicentin injected into the distal tubule was recovered in the urine. In isolated kidney experiments, organ clearance rate of 125I-glicentin averaged 0.88 +/- 0.10 ml/min, a value significantly higher than that of glomerular filtration rate (0.72 +/- 0.06 ml/min, P less than 0.005, paired data), and both parameters showed a close linear relationship (r = 0.90). Urinary clearance of glicentin was negligible. These results demonstrate that the kidney plays a major role in the catabolism of glicentin, mainly by glomerular filtration and tubular catabolism. The site of tubular catabolism appears to be the proximal tubule. Peritubular uptake was minimal

  13. Continuous and low-energy 125I seed irradiation changes DNA methyltransferases expression patterns and inhibits pancreatic cancer tumor growth

    Gong Yan-fang

    2011-04-01

    Full Text Available Abstract Background Iodine 125 (125I seed irradiation is an effective treatment for unresectable pancreatic cancers. However, the radiobiological mechanisms underlying brachytherapy remain unclear. Therefore, we investigated the influence of continuous and low-energy 125I irradiation on apoptosis, expression of DNA methyltransferases (DNMTs and cell growth in pancreatic cancers. Materials and methods For in vitro 125I seed irradiation, SW-1990 cells were divided into three groups: control (0 Gy, 2 Gy, and 4 Gy. To create an animal model of pancreatic cancer, the SW 1990 cells were surgically implanted into the mouse pancreas. At 10 d post-implantation, the 30 mice with pancreatic cancer underwent 125I seed implantation and were separated into three groups: 0 Gy, 2 Gy, and 4 Gy group. At 48 or 72 h after irradiation, apoptosis was detected by flow cytometry; changes in DNMTs mRNA and protein expression were assessed by real-time PCR and western blotting analysis, respectively. At 28 d after 125I seed implantation, in vivo apoptosis was evaluated with TUNEL staining, while DNMTs protein expression was detected with immunohistochemical staining. The tumor volume was measured 0 and 28 d after 125I seed implantation. Results 125I seed irradiation induced significant apoptosis, especially at 4 Gy. DNMT1 and DNMT3b mRNA and protein expression were substantially higher in the 2 Gy group than in the control group. Conversely, the 4 Gy cell group exhibited significantly decreased DNMT3b mRNA and protein expression relative to the control group. There were substantially more TUNEL positive in the 125I seed implantation treatment group than in the control group, especially at 4 Gy. The 4 Gy seed implantation group showed weaker staining for DNMT1 and DNMT3b protein relative to the control group. Consequently, 125I seed implantation inhibited cancer growth and reduced cancer volume. Conclusion 125I seed implantation kills pancreatic cancer cells, especially

  14. Current status and prospect of 125I production

    125I nuclide is widely applied in many fields such as medical and biological research, radioimmunoassay, brachytherapy of cancers, etc. The processes and current status of 125I production, domestic market demand, and the prospect of 125I nuclide production with the existing reactors in China were briefly introduced. (author)

  15. Postenucleation orbits in retinoblastoma: treatment with 125I brachytherapy

    Purpose: Children with retinoblastoma that extends into or through the choroid, sclera, or optic nerve are at risk of developing orbital disease, as well as metastases. Previously, these enucleated orbits were treated with external beam radiotherapy in addition to chemotherapy. 125I brachytherapy for tumors in and around the eye was pioneered by Sealy in Cape Town, South Africa, in 1974. In 1983, he developed a technique to irradiate the contents of the orbit while limiting the dose to the bony orbit and eyelids. Methods and Materials: Six nylon tubes containing 125I seeds were implanted through the eyelids around the periphery of the orbit. Each contained a metal gutter that screens the outer part of the seeds from the bony orbit. A seventh unscreened tube was placed in the center, and a metal disc with 125I seeds on its posterior surface was secured beneath the eyelids. Between 1983 and 2000, 57 orbits were treated in 56 children with retinoblastoma. Thirty-six were treated prophylactically and 21, with tumor at the resection line of the nerve, extrascleral tumor, or metastases, were treated therapeutically. They received a median dose of 34 Gy in 70 h; 30 also received chemotherapy. Children with tumor at the resection line of the nerve also received treatment to the craniospinal axis. Results: The median follow-up of the 35 patients treated prophylactically was 35 months (range 0-187). Seven patients died, 6 of metastases, at a median of 10 months (range 4-29) after the implant. Eight of the 13 patients with microscopic extraocular tumor survived a median of 29 months (range 5-156). None of the 8 patients presenting with orbital tumor or metastases survived. No orbital recurrences developed in any of the patients. Cosmesis was considerably improved compared with previous forms of irradiation. Conclusion: Orbital brachytherapy is an effective method of irradiating the orbit to prevent recurrent tumor, the treatment time is short, and the cosmesis is much more

  16. Implant-supported prostheses versus conventional permanent and removable dentures

    Koszuta Agnieszka

    2014-06-01

    Full Text Available Social, economic and technological progress results in an increasing range of treatment and rehabilitation methods for patients with partial or complete edentulism. The role of the dentist is to inform the patient about the full range of available missing teeth treatment options leading to complete rehabilitation of the masticatory organ in agreement with the patient’s aesthetic and functional expectations. The aim of the paper was to identify the type of prostheses used by patients before opting for implantsupported teeth replacements, according to the patients’ age, sex, marital status, place of residence and education. The study covered 464 patients, women and men, aged 20-74, treated with dental implants. The patients answered questions in an anonymous questionnaire. The influence of the prosthetic replacement type according to age and marital status was highly statistically significant, whereas it was statistically significant according to sex, place of residence and education. The female respondents who previously used tissue-borne complete or partial dentures opted for implant treatment more frequently. The respondents younger than 40 and between 40-60 years of age who did not previously used any prosthetic replacements opted for implant treatment more frequently. The respondents who did not use any prosthetic replacements decided to undergo implant treatment most frequently, regardless of their marital status, education and place of residence. The patients opted for implant treatment to improve their quality of life, despite the high cost of such therapy.

  17. 125I Measurements for Occupational Exposure Assessment

    Silva, L.; Pinhão, N. R.

    2008-08-01

    Whenever there is a risk of occupational exposure to dispersible radioactive material, it is necessary to have a monitoring program to assess the effective dose arising from the intake of radionuclides by workers. In this paper we present our experience in bioassay measurements of 125I in urine samples of workers using high resolution gamma spectrometry. For a 24-hour excretion period, we found activity values of the order of one Bq and estimated the committed effective doses to be less than one μSv. Although very small, these values led to a re-evaluation and improvement of the laboratory safety conditions. We discuss the calibration procedure followed for the activity measurements, the estimation of the uncertainty in the excreted activity, the calculation of detection and quantification limits and estimation of performance indicators. Aspects regarding the spectral analysis, true coincidence summing and matrix effects are also considered.

  18. CT-guided percutaneous perineal permanent implants with I-125

    The authors have combined the principles of CT-guided percutaneous biopsy and biplane fluoroscopy in performing outpatient percutaneous pelvic implantations of I-125 seeds for the treatment of unresectable or recurrent tumors of the pelvis, utilizing a transperineal approach. The technique allows implantations up to a depth of 16 cm from the perineum. No complications have been encountered. Twelve procedures have been performed. The types of tumor treated include five cases of recurrent carcinoma of the rectum, five cases of unresectable carcinoma of the prostate, one case of recurrent sarcoma of the rectum, and one case of adenocarcinoma of unknown origin involving the pelvic wall

  19. Self-expandable stent loaded with 125I seeds: Feasibility and safety in a rabbit model

    Objective: To evaluate technical feasibility and acute and subacute radiotolerance of a self-expandable stent loaded with 125I seeds in the rabbit esophagus. Methods: A self-expandable stent designed for esophageal application was made of 0.16 mm nitinol wire and loaded with 125I seeds (CIAE-6711). Twenty-seven stents with three different radioactive dosages (n = 9 in each dosage group) were implanted in the esophagus of healthy rabbits, while nine stents alone were used as controls. The stents were perorally deployed into the esophagus under fluoroscopic guidance. Radiological follow-up included plain chest film, CT scan, and barium esophagography which were undertaken in all rabbits of each group at 2, 4, and 8 weeks, respectively, which were correlated to histopathological findings. The stented esophageal segments along with their adjacent tissues were harvested for histopathological examinations. Results: The stent was successfully deployed into the targeted esophageal segment in all rabbits. Neither 125I seeds dislodged from the stent during the deployment, nor they did during the follow-up period. The greatest (16.2 Gy) absorbed dose was found in the tissue 10 mm from 125I seeds at 8 weeks. Slight epithelial hyperplasia on the stent surface and submucosal inflammatory process developed at 2 weeks, which reached the peak at 8 weeks after the procedure. Significant thickness of the esophageal muscular layer was found at 8 weeks only in the groups with 125I seeds. On radiologic follow-up, moderate strictures on both ends of the stents developed at 4 weeks and became severe at 8 weeks after the procedure in all groups. Conclusion: Deployment of a self-expandable stent loaded with 125I seeds is technically feasible and safe within the first 8 weeks. Acute and subacute radiotolerance of the treated esophagus and its adjacent tissues by 125I seeds is well preserved in a healthy rabbit model

  20. Dosimetric results in implant and post-implant and low rate in brachytherapy prostate cancer with loose seeds and attached

    The objective is determine differences dosimetry statistics on the dosimetry of the implant and post-implant in brachytherapy of low rate with implants permanent in prostate using seed of 125-I loose and attached Both in lives and in the post-prostatic plans dosimetric coverage is good and restrictions in urethra and rectum for both groups of patients are met. Not migrating with joined is evident, as well as better dosimetric homogeneity. (Author)

  1. I-123 metaiodobenzylguanidine cardiac scintigraphy in patients with an implanted permanent pacemaker

    Tl scintigraphic abnormalities have been reported in patients with an implanted permanent pacemaker, but little is known about the MIBG scintigraphic findings in such patients. This study was performed to assess the MIBG scintigraphic findings in patients with an implanted permanent pacemaker, and to test the hypothesis that imaging characteristics of MIBG scintigraphy differ according to its mode. Twelve patients (4 men and 8 women, mean age: 72.4±9.5 years), who had undergone the implantation of a permanent pacemaker for bradyarrhythmias, underwent MIBG scintigraphy. The patients were divided into VVI pacemaker and DDD pacemaker groups. The tomograms were divided into nine segments and the MIBG defect in each segment scored on a scale ranging from 0 (normal uptake) to 3 (no uptake). Total MIBG defect scores were generated by summing the scores for the nine segments in each patient. MIBG scintigraphic abnormalities were found in ten of the twelve patients. The six patients with the VVI pacemaker manifested MIBG scintigraphic abnormalities. These MIBG scintigraphic abnormalities were observed in all segments, particularly in the posterior segments. The mean total defect score of the VVI group was higher than that of the DDD group (14.8±9.8 vs 3.0±3.5, respectively p<0.05). Therefore, we conclude that despite several limitations of the study, MIBG scintigraphic abnormalities occur in patients with implanted permanent pacemakers, and that such abnormalities are more prominent with the VVI than DDD pacemaker. (author)

  2. Decontamination of 125I in Medical Laboratory

    A radiological laboratory for diagnoses was contaminated by 125I. A large-scale survey of gamma-radiation has been made in different locations of the floors and walls of the lab to determine the contaminated area and its activity. The activity level before decontamination for the wall and floor was 1400 and 2000 Bq/cm2 respectively. Decontamination was carried out by using ethyl alcohol, potassium permanganate, ethylene diamine tetracetic acid and tissue papers. Decontamination factor has been calculated and it was 175 and 200 for the wall and floor respectively. D and D computer code has been used to calculate Total Effective Dose Equivalent (TEDE). TEDE from the wall and floor before decontamination were 3.05 and 4.35 ( mSv/yr ) while after decontamination were 18 and 23μSv/yr respectively. These results are lower than the Egyptian and the international regulations (10 mSv/y for the public ) according to International Atomic Energy agency, IAEA, Safety Series, SS, no. 115 (1994).

  3. Optimization of 125I ophthalmic plaque brachytherapy

    Episcleral plaques containing 125I sources are often used in the treatment of ocular melanoma. Within four years post-treatment, however, the majority of patients experience some visual loss due to radiation retinopathy. The high incidence of late complications suggests that careful treatment optimization may lead to improved outcome. The goal of optimization would be to reduce the magnitude of vision-limiting complications without compromising tumor control. We have developed a three-dimensional computer model for ophthalmic plaque therapy which permits us to explore the potential of various optimization strategies. One simple strategy which shows promise is to maximize the ratio of dose to the tumor apex (T) compared to dose to the macula (M). By modifying the parameters of source location, activity distribution, source orientation, and shielding we find that the calculated T:M ratio can be varied by a factor of 2 for a common plaque design and posterior tumor location. Margins and dose to the tumor volume remain essentially unchanged

  4. The contamination on farm products from 125I

    The 125I contamination on 15 farm products have been investigated. The effects of 12 farm crops (wheat, bean, eggplants and other vegetables) contaminated by 125I during the growing stage on their fruits and seeds have been studied. The results show that the 125I radioactive substance is mainly concentrated on the fruit surface, and the radioactivity rapidly decreased towards its kernel. The fruits and seeds would not be contaminated when plants were contaminated in the seedling stage

  5. Computational Program of Isodose and TPS of 125I Seed for Brachytherapy

    Radioactive sources are widely used in several fields including for medical purposes. One use of radioactive sources in medical field is radiotherapy to cure the cancerous organs. Brachytherapy term is the radiotherapy where the radiation source is placed inside or as close as possible to the cancer needing treatment. In order to support the domestic application of 125I seeds in brachytherapy, a computational program for isodose and TPS (Treatment Planning System) calculation shall be available. The preparation of the such program has been successfully developed using Microsoft Visual Basic for Windows and its supporting tools. This program can display the two-dimensions-isodose contour of 1-20 125I seeds presented in direction of lateral, anterior (AP) and caodal. The dose rate at the distances of 1, 2, 3 and 4 cm from the center point assumed as (0,0) can also be calculated from 1 to 360 days after implantation of the 125I seeds. The entered data as well as the resulting calculation and the contour presentation can be saved and be quickly traced and redisplayed at any time necessarily. This computer program is hopefully able to assist physicians in the implementation of 125I seeds implantation for brachytherapy. (author)

  6. 组织间125I放射粒子植入治疗头颈部恶性肿瘤颈部淋巴结转移的临床应用%Clinical application of interstitial implantation of 125I radion in the treatment of cervical lymph node metastasis of head and neck malignancy

    李福生; 黄海; 徐绍年; 杜振广; 王亮

    2014-01-01

    目的:探讨组织间125I放射粒子植入治疗头颈部恶性肿瘤颈部淋巴结转移的价值。方法对21例头颈部恶性肿瘤颈部淋巴结转移患者进行125I放射粒子植入治疗,术前行TPS(computer-based treatment planning system)计划、根据计划在CT引导局部麻醉下行颈部淋巴结转移瘤125I放射粒子植入、术后复查CT进行质量验证。根据NRS评分对术前术后患者局部疼痛进行评估,按WHO标准对局部肿瘤控制疗效进行评价。结果随访7~29个月,21例患者均成功行手术治疗,术后3个月复查,完全缓解3例(14%)、部分缓解15例(71%)、病变稳定2例(10%)、病变进展1例(5%);6个月、1、2年的局部控制率(局部肿瘤无进展)分别为:84%、65%、39%;NRS疼痛评分术前、术后3个月、6个月分别为:(7.62±0.92)分,(2.81±0.68)分,(2.14±0.39)分(P<0.05)。3例患者术后出现发热,未超过38.5℃,3~5 d内恢复正常;3例皮肤黏膜1级急性放射性损伤,2例皮肤黏膜2级急性放射性损伤,无3~5级皮肤黏膜急性放射性损伤。所有患者未发生大出血、急性肺栓塞、窦道等严重并发症。结论组织间125I放射粒子植入治疗头颈部恶性肿瘤颈部淋巴结转移创伤小,并发症少,局部控制率较高,疼痛缓解明显,为不能手术的晚期头颈部恶性肿瘤颈部淋巴结转移的患者提供了一种新型治疗手段。%Objective To explore the value of interstitial implantation of 125I radion in the treatment of cervical lymph node metastasis of head and neck malignancy. Methods There were 21 patients with cervical lymph node metastasis of head and neck malignancy received 125I radion implantation. Computer-based treatment planning system (TPS) was operated before the surgery, and implantation of 125I radion was conducted under CT guidance and local anesthesia. Postoperative CT review was used for quality verification. Numerical rating scale (NRS) was used to assess patients

  7. Synthesis and binding of [125I2]philanthotoxin-343, [125I2]philanthotoxin-343-lysine, and [125I2]philanthotoxin-343-arginine to rat brain membranes

    125I2-iodinated philanthotoxin-343 (PhTX-343), [125I2]PhTX-343-arginine, and [125I2]PhTX-343-lysine were synthesized and evaluated as probes for glutamate receptors in rat brain synaptic membranes. It was found that these probes were not specific for the glutamate receptors but may be useful for investigating the polyamine binding site. Filtration assays with Whatman GF/B fiber glass filters were unsuitable because the iodinated PhTX-343 analogues exhibited high nonspecific binding to the filters, thus hindering detection of specific binding to membranes. When binding was measured by a centrifugal assay, [125I2]PhTX-343-lysine bound with low affinity (KD = 11.4 ± 2 microM) to a large number of sites (37.2 ± 9.1 nmol/mg of protein). The binding of [125I2]PhTX-343-lysine was sensitive only to the polyamines spermine and spermidine, which displaced [125I2]PhTX-343-lysine with Ki values of (3.77 ± 1.4) x 10(-5) M and (7.51 ± 0.77) x 10(-5) M, respectively. The binding was insensitive to glutamate receptor agonists and antagonists. Binding results with [125I2]PhTX-343-arginine were similar to those of [125I2]-PhTX-343-lysine. Considering the high number of toxin binding sites (10000-fold more than glutamate) in these membranes and the insensitivity of the binding to almost all drugs that bind to glutamate receptors, it is evident that most of the binding observed is not to glutamate receptors. On the other hand, PhTX analogues with photoaffinity labels may be useful in the isolation/purification of various glutamate and nicotinic acetylcholine receptors; they could also be useful in structural studies of receptors and their binding sites

  8. Impact of differences in ultrasound and computed tomography volumes on treatment planning of permanent prostate implants

    Purpose: Both ultrasound (US) and computerized tomography (CT) images have been used in the planning of prostate interstitial therapy. Ultrasound images more clearly define the apex and capsule of the prostate, while CT images define seed positions for postimplant dosimetry. Proper registration of the US volume with the CT volume is critical to the assessment of dosimetry. We therefore compared US and CT prostate volumes to determine if differences were significant. Methods and Materials: Ten consecutive patients entered in an interstitial implant program were studied by pretreatment US. In addition, pretreatment CT scans were obtained and three physicians independently outlined the dimensions of the prostate on these images. The patients subsequently underwent placement of radioactive 125I or 103Pd. Postimplant CT images were obtained the next day and the postimplant prostate volumes were outlined by the same three physicians. Seven of 10 patients underwent late CT scans 9-14 months postimplant for comparison of preimplant and immediate postimplant CT studies. Results: There were differences between US and CT volumes. Although the physician-to-physician variation was significant, the trends were consistent, with US prostate volume typically smaller (47%) than the preimplant CT volume and markedly smaller (120%) than the postimplant CT volume. Prostate volumes derived from late CT images did not consistently return to preimplant levels. Conclusions: Significant differences in volume of the prostate structure were found between US and CT images. The data suggests that: (a) Implants planned on CT tend to overestimate the size of the prostate and may lead to unnecessary implantation of the urogenital diaphragm and penile urethra. (b) Registration of initial US and postimplant CT prostate volumes required for accurate dosimetry is difficult due to the increased volume of prostate secondary to trauma. (c) Further study to determine the optimal time for the postimplant

  9. Online gamma-camera imaging of 103Pd seeds (OGIPS) for permanent breast seed implantation

    Permanent brachytherapy seed implantation is being investigated as a mode of accelerated partial breast irradiation for early stage breast cancer patients. Currently, the seeds are poorly visualized during the procedure making it difficult to perform a real-time correction of the implantation if required. The objective was to determine if a customized gamma-camera can accurately localize the seeds during implantation. Monte Carlo simulations of a CZT based gamma-camera were used to assess whether images of suitable quality could be derived by detecting the 21 keV photons emitted from 74 MBq 103Pd brachytherapy seeds. A hexagonal parallel hole collimator with a hole length of 38 mm, hole diameter of 1.2 mm and 0.2 mm septa, was modeled. The design of the gamma-camera was evaluated on a realistic model of the breast and three layers of the seed distribution (55 seeds) based on a pre-implantation CT treatment plan. The Monte Carlo simulations showed that the gamma-camera was able to localize the seeds with a maximum error of 2.0 mm, using only two views and 20 s of imaging. A gamma-camera can potentially be used as an intra-procedural image guidance system for quality assurance for permanent breast seed implantation

  10. Immunoreactivity of 125I-papain labelled by different methods

    Three different methods of papain iodination (with chloramine-T, lactoperoxidase and conjugation with Bolton-Hunter reagent) have been compared. The highest yield of 125I-papain could be obtained using lactoperoxidase which enabled to achieve the highest immunoreactivity. 125I-papain, labelled this way, is suitable for the radioimmunoassay of papain. (author)

  11. Preoperative CT analysis of the mandible and maxilla for permanent dental prosthetic implantation

    The Branemark technique for permanently implanting dental prostheses is becoming universally accepted. The surgeon requires detailed knowledge of the cross-sectional anatomy of the alveolar ridges and inferior alveolar nerve for safe placement of the titanium fixtures. Axial CT scans of the mandible and maxilla, with oblique and panoramic CT reformations, were obtained in more than 100 patients. This report describes the anatomic variations in the maxilla and mandible as they relate to dental implantation surgery. The authors demonstrate the utility of this technique in preoperative surgical planning and postoperative evaluation

  12. Safety handling of 125I in animal experiments

    Isotope 125I in animal experiments is used for several purposes. One major problem with using 125I is to handle it extremely carefully. The careful handling is required when using 125I in animal experiments because of its higher evaporation and difficulty for sealing. When conducting animal experiments white using 125I, we have encountered several serious problems but have devised new techniques and methods for a long time. In this paper, we will describe the safety handling for requirements based on our experiments. The newly devised safety handling procedures are the following: a device for protecting isotope contamination during the preparation of the injectable solution, collection method of airborne radioactivity from the animals that were injected, enhancing the method for autoradiography of the whole body, finding of elusion of 125I from the tissues during fixative process, estimation of the exposed time for light microscopic autoradiography. (author)

  13. Defect in Lung Perfusion and Ventilation Scanning of Patients with Permanent Transvenous Implantable Pacemaker

    Matsuura, Yuichiro; Tamura, Mutsuo; Yamashina, Hideki; Higo, Masanori; Fujii, Takanori; Shimamoto, Hiroyuki; Kinoshita, Hirofumi

    1984-01-01

    Lung perfusion and ventilation scanning with 99mTc-MAA and 81mKr-Gass were studied in 138 patients with permanent transvenous implantable pacemaker. There were observed segmental or subsegmental defects in lung perfusion and ventilation scanning which were considered to be probably lung embolism of 47 cases. The incidence of lung embolism was high during the first postoperative 6 months, and it also increased progressively with aging. The patient with ischemic heart disease or va...

  14. Metallic artifact mitigation and organ-constrained tissue assignment for Monte Carlo calculations of permanent implant lung brachytherapy

    Sutherland, J. G. H.; Miksys, N.; Thomson, R. M., E-mail: rthomson@physics.carleton.ca [Carleton Laboratory for Radiotherapy Physics, Department of Physics, Carleton University, Ottawa, Ontario K1S 5B6 (Canada); Furutani, K. M. [Department of Radiation Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905 (United States)

    2014-01-15

    Purpose: To investigate methods of generating accurate patient-specific computational phantoms for the Monte Carlo calculation of lung brachytherapy patient dose distributions. Methods: Four metallic artifact mitigation methods are applied to six lung brachytherapy patient computed tomography (CT) images: simple threshold replacement (STR) identifies high CT values in the vicinity of the seeds and replaces them with estimated true values; fan beam virtual sinogram replaces artifact-affected values in a virtual sinogram and performs a filtered back-projection to generate a corrected image; 3D median filter replaces voxel values that differ from the median value in a region of interest surrounding the voxel and then applies a second filter to reduce noise; and a combination of fan beam virtual sinogram and STR. Computational phantoms are generated from artifact-corrected and uncorrected images using several tissue assignment schemes: both lung-contour constrained and unconstrained global schemes are considered. Voxel mass densities are assigned based on voxel CT number or using the nominal tissue mass densities. Dose distributions are calculated using the EGSnrc user-code BrachyDose for{sup 125}I, {sup 103}Pd, and {sup 131}Cs seeds and are compared directly as well as through dose volume histograms and dose metrics for target volumes surrounding surgical sutures. Results: Metallic artifact mitigation techniques vary in ability to reduce artifacts while preserving tissue detail. Notably, images corrected with the fan beam virtual sinogram have reduced artifacts but residual artifacts near sources remain requiring additional use of STR; the 3D median filter removes artifacts but simultaneously removes detail in lung and bone. Doses vary considerably between computational phantoms with the largest differences arising from artifact-affected voxels assigned to bone in the vicinity of the seeds. Consequently, when metallic artifact reduction and constrained tissue

  15. Adverse reactions after cosmetic lip augmentation with permanent biologically inert implant materials.

    Hoffmann, C; Schuller-Petrovic, S; Soyer, H P; Kerl, H

    1999-01-01

    Augmentation of lips is a common aesthetic procedure that is mostly performed with alloplastic materials or autologous tissue. Various alloplastic injectable implants have been developed for soft tissue augmentation without surgery. Most biologic materials are resorbed within a few months, fluid silicone may migrate, and autologous fat is not ideal for fine contouring of the lips. The search for a biocompatible, permanent, nontoxic, and biologically inert filler material led to the development of some new materials for subdermal or intradermal implantation. Recently Bioplastique, Artecoll, and Gore-Tex have been well established and recommended by many authors. Although these materials meet most of the characteristics that constitute an ideal injectable prosthetic material, we describe 3 examples of adverse reactions after their implantation into lips. PMID:9922021

  16. Synthesis and application of PLGA labeled with 125I

    2006-01-01

    The weight loss in vivo degradation of poly (lactide-co-glycolide) (PLGA) radiolabeled with 125I was investigated. PLGA with molecular weight (Mw) of 84000(LA/GA=85/15) were labeled with 125I in the chloroform media by circularly heating and round films of about 15 mm in diameter were formed. The composition and Mw of the 125I-PLGA were characterized by 1H-NMR and viscosimeter. The weight loss of this copolymer in vitro and in vivo degradation was quantified by determining radioactivity of materials. The results indicated that PLGA exhibited significantly faster degradation in vivo than that of in vitro conditions.

  17. Histology study on the dorsal root ganglia of rats with 125I seed brachytherapy at intervertebral foramen

    Objective: To investigate the effect of the histological changes on rat dorsal root ganglia (DRG) after 125I seed brachytherapy.Methods Twelve adult male Sprague-Dawley rats (150-180 g each) were randomly divided into 6 groups,125I seeds with different activities of 0 (Titanium shell), 14.8, 18.5, 22.2, 25.9 and 29.6 MBq were implanted to 6 groups of rats respectively and the behavioral changes of rats were observed. The rats were killed in different periods after implantation,the morphological changes in DRG and surrounding muscle tissue were observed with an Olympus BX51 optical microscope and then the irradiation doses were estimated. Results: After 125I seed implantation, the movement function of rats was not affected and the weight of rats gained after 7 days. After the titanium shell implantation, very few mild swelling was induced in neuroganglion cells that still had clear nucleolus and normal cytoplasm. At 14 days after 18.5 MBq seed implantation, cell swelling was more serious and cell dehydrating, nuclear condensation and nuclear fragmentation appeared after 30 days. At 60 days after 29.6 MBq of seed implantation, nuclear dissolution and cytoplasmic shrinkage were induced in a large number of cells.In general, the severity of fibrosis was aggravated with the time post-irradiation and the dose in the muscles around the ganglion. Conclusions: After 125I seed implantation,the injury degree of DRG tissue is dose-dependent, and the 125I seed irradiation would have analgesic effect on releasing intractable pain. (authors)

  18. Systemic administration of kainic acid induces selective time dependent decrease in [125I]insulin-like growth factor I, [125I]insulin-like growth factor II and [125I]insulin receptor binding sites in adult rat hippocampal formation

    Administration of kainic acid evokes acute seizure in hippocampal pathways that results in a complex sequence of functional and structural alterations resembling human temporal lobe epilepsy. The structural alterations induced by kainic acid include selective loss of neurones in CA1-CA3 subfields and the hilar region of the dentate gyrus followed by sprouting and permanent reorganization of the synaptic connections of the mossy fibre pathways. Although the neuronal degeneration and process of reactive synaptogenesis have been extensively studied, at present little is known about means to prevent pathological conditions leading to kainate-induced cell death. In the present study, to address the role of insulin-like growth factors I and II, and insulin in neuronal survival as well as synaptic reorganization following kainate-induced seizure, the time course alterations of the corresponding receptors were evaluated. Additionally, using histological preparations, the temporal profile of neuronal degeneration and hypertrophy of resident astroglial cells were also studied. [125I]Insulin-like growth factor I binding was found to be decreased transiently in almost all regions of the hippocampal formation at 12 h following treatment with kainic acid. The dentate hilar region however, exhibited protracted decreases in [125I]insulin-like growth factor I receptor sites throughout (i.e. 30 days) the study. [125I]Insulin-like growth factor II receptor binding sites in the hippocampal formation were found to be differentially altered following systemic administration of kainic acid. A significant decrease in [125I]insulin-like growth factor II receptor sites was observed in CA1 subfield and the pyramidal cell layer of the Ammon's horn at all time points studied whereas the hilar region and the stratum radiatum did not exhibit alteration at any time. A kainate-induced decrease in [125I]insulin receptor binding was noted at all time points in the molecular layer of the dentate

  19. Radioactive 125I seeds inhibit cell growth and epithelial-mesenchymal transition in human glioblastoma multiforme via a ROS-mediated signaling pathway

    Glioblastoma multiforme (GBM) is the most common primary central nervous system neoplasm in adults. Radioactive 125I seed implantation has been widely applied in the treatment of cancers. Moreover, previous clinical trials have confirmed that 125I seeds treatment was an effective therapy in GBM. We sought to investigate the effect of 125I seed on GBM cell growth and Epithelial-mesenchymal transition (EMT). Cells were exposed to irradiation at different doses. Colony-formation assay, EdU assay, cell cycle analysis, and TUNEL assay were preformed to investigate the radiation sensitivity. The effects of 125I seeds irradiation on EMT were measured by transwell, Boyden and wound-healing assays. The levels of reactive oxygen species (ROS) were measured by DCF-DA assay. Moreover, the radiation sensitivity and EMT were investigated with or without pretreatment with glutathione. Additionally, nude mice with tumors were measured after treated with radiation. Radioactive 125I seeds are more effective than X-ray irradiation in inhibiting GBM cell growth. Moreover, EMT was effectively inhibited by 125I seed irradiation. A mechanism study indicated that GBM cell growth and EMT inhibition were induced by 125I seeds with the involvement of a ROS-mediated signaling pathway. Radioactive 125I seeds exhibit novel anticancer activity via a ROS-mediated signaling pathway. These findings have clinical implications for the treatment of patients with GBM by 125I seeds

  20. Personal monitoring in the radiochemical production of 125I

    To estimate occupational exposure during the radiochemical production of 125I, measurements, of 125I deposited in the thyroids of personnel were carried out, beginning in 1986. Each measurement was designed to control later values, which were based on: the thyroid dose accumulated during the year prior to the measurement and during the monitoring period, the committed annual thyroid dose assessed during 240 days before the measurement, and the dose that would be received after complete decay of the measured activity of 125I in the thyroid. Due to the improvement in safety in the production process, quarterly thyroid doses to personnel decreased approximately three-fold during the first year of monitoring. Data on individual quarterly 125I thyroid content and doses over 1.5 years of control for 20 workers are presented. Average annual thyroid doses of personnel varied from 15 to 30 mSv.y-1 in 1987-1992. (Author)

  1. A study on recombinant human interleukin 2 radioiodinated with 125I (125I-rIL-2) for RIA

    RIL-2 was labelled with 125I by Iodogen method. The products were purified by HPLC. Analysis of each radiolabelled preparation showed that greater than 95% of the radioiodine was associated with a single protein peak. The specific activity of radioiodinated rIL-2 was approximately 2.2 x 1016-2.8 x 1016 Bq/mol. The 125I-rIL-2 was designed for quantitating human IL-2 with sensitive radioimmunoassay (RIA). The bioactivity of 125I-rIL-2 is good

  2. Synthetic heparinoids labelled with 125I and 35S

    Sederel, L.C.; Kolar, Z.; Does, van der, Leen; Bantjes, A.

    1982-01-01

    The labelling of a water-soluble synthetic polyelectrolyte, having anticoagulant activity, has been studied. The polyelectrolyte is derived from cis-1,4-polyisoprene and contains N-sulfate and carboxylate groups. [125I]-Iodination of the polyelectrolyte, using the Chloramine-T method and an electrolytic method, resulted in a [125I]-labelled polyelectrolyte from which release of the label occurred. Resulfation of a partially desulfated polyelectrolyte with a [35S]-sulfur trioxide trimethylamin...

  3. 125I-labelled cobalamin derivative compatible with intrinsic factor

    A 125I-labelled derivative of cobalamin (vitamin B12) is described which is compatible with intrinsic factor in binding assays. The derivative, [125I]cyanocobalamin-d-iodohistamide, can be readily prepared with a specific activity of 1400 Ci/g. Used as a substitute for [57Co]cyanocobalamin in binding assays, the new derivative can reduce counting times and decrease costs in such assays. (Auth.)

  4. An automated, fast and accurate registration method to link stranded seeds in permanent prostate implants

    The geometry of a permanent prostate implant varies over time. Seeds can migrate and edema of the prostate affects the position of seeds. Seed movements directly influence dosimetry which relates to treatment quality.We present a method that tracks all individual seeds over time allowing quantification of seed movements. This linking procedure was tested on transrectal ultrasound (TRUS) and cone-beam CT (CBCT) datasets of 699 patients. These datasets were acquired intraoperatively during a dynamic implantation procedure, that combines both imaging modalities.The procedure was subdivided in four automatic linking steps. (I) The Hungarian Algorithm was applied to initially link seeds in CBCT and the corresponding TRUS datasets. (II) Strands were identified and optimized based on curvature and linefits: non optimal links were removed. (III) The positions of unlinked seeds were reviewed and were linked to incomplete strands if within curvature- and distance-thresholds. (IV) Finally, seeds close to strands were linked, also if the curvature-threshold was violated. After linking the seeds an affine transformation was applied. The procedure was repeated until the results were stable or the 6th iteration ended.All results were visually reviewed for mismatches and uncertainties. Eleven implants showed a mismatch and in 12 cases an uncertainty was identified. On average the linking procedure took 42 ms per case.This accurate and fast method has the potential to be used for other time spans, like Day 30, and other imaging modalities. It can potentially be used during a dynamic implantation procedure to faster and better evaluate the quality of the permanent prostate implant. (note)

  5. An automated, fast and accurate registration method to link stranded seeds in permanent prostate implants

    Westendorp, Hendrik; Nuver, Tonnis T.; Moerland, Marinus A.; Minken, André W.

    2015-10-01

    The geometry of a permanent prostate implant varies over time. Seeds can migrate and edema of the prostate affects the position of seeds. Seed movements directly influence dosimetry which relates to treatment quality. We present a method that tracks all individual seeds over time allowing quantification of seed movements. This linking procedure was tested on transrectal ultrasound (TRUS) and cone-beam CT (CBCT) datasets of 699 patients. These datasets were acquired intraoperatively during a dynamic implantation procedure, that combines both imaging modalities. The procedure was subdivided in four automatic linking steps. (I) The Hungarian Algorithm was applied to initially link seeds in CBCT and the corresponding TRUS datasets. (II) Strands were identified and optimized based on curvature and linefits: non optimal links were removed. (III) The positions of unlinked seeds were reviewed and were linked to incomplete strands if within curvature- and distance-thresholds. (IV) Finally, seeds close to strands were linked, also if the curvature-threshold was violated. After linking the seeds an affine transformation was applied. The procedure was repeated until the results were stable or the 6th iteration ended. All results were visually reviewed for mismatches and uncertainties. Eleven implants showed a mismatch and in 12 cases an uncertainty was identified. On average the linking procedure took 42 ms per case. This accurate and fast method has the potential to be used for other time spans, like Day 30, and other imaging modalities. It can potentially be used during a dynamic implantation procedure to faster and better evaluate the quality of the permanent prostate implant.

  6. Preparation of 5-Iodo-2'- deoxyuridine labelled with 125 I

    5-Iodo-2'-deoxyuridine (IUdR), an analogue of thymidine is taken up by the proliferating cells during DNA synthesis. When IUdR is labelled with 125 I, due to Auger electrons from 125 I, this analogue of thymidine is very effective in cell destruction when is internalized. Recently, radioiodinated (125 I and 123 I) IUdR is considered a potential therapeutic agent, for treatment of cancer.125 I-IUdR was prepared by direct radioiodination of 2'-deoxyuridine (UdR), using chloramine T method. The radioiodination reaction was studied by varying the reaction parameters such as temperature and reaction time. The yield was improved by heating the reaction mixture to 65 deg. C for 10 min. Purification of 125 I-IUdR was carried out by gel filtration over a Sephadex G 25 column using 0.05 M citrate buffer (pH = 6). The yield of the reaction as well as the radiochemical purity were determined by paper electrophoresis using Whatman chromatography paper No.1, 0.05 M phosphate buffer at 13 V/cm. The analyse time was 1 h. The yield of radioiodination reaction was ≅70% and the radiochemical purity of 125 I-IUdR prepared by this method was: 91-92%. (authors)

  7. The factor analysis of the incidence of pneumothorax after CT-guided 125I radioactive seed implantation for lung cancer%CT引导下125I粒子植入治疗肺癌术后气胸发生率的相关因素分析

    霍小东; 杨景魁; 闫卫亮; 郑广钧; 柴树德; 孟娜; 杨瑞杰; 王俊杰

    2014-01-01

    Objective To analyze the impact factors of incidence of pneumothorax after CT guided puncture with radioactive 125I seed implantation in lung cancer patients.Methods 821 cases with lung cancer were treated with CT-guided percutaneous with radioactive particles implantation.198 cases of pneumothorax patients were collected.The impact factors of incidence of pneumothorax were analyzed by parallel unconditioned logistic regression.Results 24.1% (198/821) of cases had pneumothorax after CT guided puncture.Single variate analysis showed that the incidence of pneumothorax was ralated with seven factors,such as patients with the average depth of implanted needle,whether patients with COPD(chronic obstructive pulmonary diseases),atelectasis,implantation pin number and operation time,puncture angle,and the diameter of the tumor(x2 =10.293,11.463,5.310,8.868,13.348,9.326,16.504,P <0.05).176 patients of intercurrent COPD with postoperative pneumothorax suffered from 65 cases.The cases of distance between the chest wall and needle less than 6 cm(205 cases),8-12 cm(378 cases)and greater than 12 cm (238 cases),the postoperative pneumothorax occurred in 29 (14.1%),98 (25.9%),71 (29.8%)cases,respectively.The number of needles were less than 5(183 cases),5-10 (408 cases),more than 10 (230 cases),the postoperative pneumothorax occurred in 31 (16.9%),92 (22.5 %),75 (32.6%),respectively.The surgery time was less than 10 min(198 cases),10-20 min(412 cases)and more than 30 min(211 cases),the postoperative pneumothorax occurred in 27(13.6%),101 (24.5%),70(33.2%) respectively.19 cases(14.4%) with COPD (132 case) suffered from pneumothorax.The multivariate logistic regression analysis showed that the prior four factor were risk factors of pneumothorax (OR =1.676,2.147,1.827,2.368,P <0.05),and the last one is protective factor(OR =0.367,P < 0.05).Conclusions COPD disease history,long distance between lesion and chest wall,plenty of needles surgery time can affect

  8. A comparative study of 19-iodocholesterol-''125I 3-acetate and Na''125I in liquid scintillation measurements

    A comparative study of performance of 19-iodocholesterol-''125I 3-acetate and sodium iodine samples labelled with ''125 I is presented for liquid scintillation counting measurements. Quench effect, count rate stability and spectral evolution of samples have been followed for several weeks in Toluene, Hisafe II, Instagel, Dioxane-naphthalene and Toluene-alcohol scintillators. Organic samples have negligible quench effect in the interval of I''-concentration of 0-90 ug and inorganic samples only show a very small variation, lower than 12%, for Dioxane-naphthalene, in the same range of concentration. Satisfactory stability is obtained in general for both, organic and inorganic samples, but small counting losses, 0.03% for 19-iodocholesterol-''125I 3-acetate samples in Toluene-alcohol and 0.04% for Na''125I samples in Dioxane-naphthalene and Toluene-alcohol, have been reported. (Author) 8 refs

  9. Dosimetric results in implant and post-implant and low rate in brachytherapy prostate cancer with loose seeds and attached; Resultados dosimetricos en el implante y post-impante en braquiterapia de baja tasa en cancer de prostata con semillas sueltas y unidas

    Juan-Senabre, X. J.; Albert Antequera, M.; Lopez-Tarjuelo, J.; Santos Serra, A.; Perez-Mestre, M.; Sanchez Iglesias, A. L.; Conde Moreno, A. J.; Gonzalez Vidal, V.; Beltran Persiva, J.; Muelas Soria, R.; Ferrer Albiach, C.

    2015-07-01

    The objective is determine differences dosimetry statistics on the dosimetry of the implant and post-implant in brachytherapy of low rate with implants permanent in prostate using seed of 125-I loose and attached Both in lives and in the post-prostatic plans dosimetric coverage is good and restrictions in urethra and rectum for both groups of patients are met. Not migrating with joined is evident, as well as better dosimetric homogeneity. (Author)

  10. Apical Ballooning Syndrome (Takotsubo Cardiomyopathy after Permanent Dual-Chamber Pacemaker Implantation

    Armando Gardini

    2012-01-01

    Full Text Available Apical ballooning syndrome, also called takotsubo cardiomyopathy, has been recently reported. It may mimic acute myocardial infarction and is typically observed in postmenopausal women after stressful events. A 75-year-old female after permanent dual chamber pacemaker implant complained of chest pain with repolarization alterations suggesting acute myocardial ischemia. Echocardiography showed a left ventricle with akinesia of the apical portions and reduced global systolic function. The patient was treated with antithrombotic agents and intravenous nitrates. No coronary lesions were found at angiography. At ventriculography, a typical takotsubo-like shape of the left ventricle was observed. The clinical and echocardiographic picture normalized at discharge.

  11. Evaluation of physician eye lens doses during permanent seed implant brachytherapy for prostate cancer

    Treatment of low grade prostate cancer with permanent implant of radioactive seeds has become one of the most common brachytherapy procedures in use today. The implant procedure is usually performed with fluoroscopy image guidance to ensure that the seeds are deployed in the planned locations. In this situation the physician performing the transperineal implant is required to be close to the fluoroscopy unit and dose to the eye lens may be of concern. In 1991 the International Commission on Radiological Protection (ICRP) provided a recommended dose limit of 150 mSv yr−1 for occupational exposures to the lens of the eye. With more long term follow-up data, this limit was revised in 2011 to 20 mSv yr−1. With this revised limit in mind, we have investigated the dose to the lens of the eye received by physicians during prostate brachytherapy seed implantation. By making an approximation of annual workload, we have related the dose received to the annual background dose. Through clinical and phantom measurements with thermoluminescent dosimeters, it was found that the excess dose to the physician’s eye lens received for a conservative estimate of annual workload was never greater than 100% of the annual background dose. (paper)

  12. Nursing care of patients with prostate cancer accepting permanent 125I radion implantation treatment%125I放射性粒子永久植入治疗前列腺癌的护理

    郭红霞; 郝海龙

    2010-01-01

    @@ 前列腺癌是中老年男性生殖泌尿系统常见的恶性肿瘤.我国前列腺癌的发病率与欧美比较相对较低,但呈逐渐上升趋势[1].1983年美国Charyulu发明经会阴超声引导治疗前列腺癌技术,奠定了近代放射性粒子治疗前列腺癌的基础[2].与传统的前列腺癌的治疗方法相比,它具有创伤小、出血少、疗效好等优点[3].我院2004年1月-2009年1月采用经直肠超声(TRUS)引导下125I粒子植入术治疗前列腺癌病人31例,疗效较好.现将护理总结如下.

  13. Dosimetry of ophthalmic applications using 125I seed sources

    Intraocular melanoma is the most common primary malignancy of the eye and radiation therapy using ophthalmic plaque has proved successful for its management. The dose prescription point recommended for 125I eye plaque therapy is usually 5 mm from tumour base centre for tumours with 5 mm or less height and tumour apex, otherwise. A computational programme was written to generate data for the dosimetry of eye plaque therapy using 125I seeds. Variation of central axis depth dose and isodose distributions at reference depth have been studied for different diameter plaques. The reference dose rate chosen for a clinical application, based on treatment planning software, was compared with that derived from the data generated in the present study. The dosimetry data generated and presented in this paper will help pre-planning of ophthalmic applications, using 125I seeds. (author)

  14. Computer assisted treatment planning for 125I ophthalmic plaque radiotherapy

    This paper describes a computer program for planning the treatment of ocular tumors with 125I plaques. The program permits the input of the tumor configuration into a model eye and facilitates the viewing of the relative geometry of the tumor and various eye structures in different perspectives. Custom-designed 125I plaques can be localized onto the globe, and dose distributions can be calculated and superimposed on the eye structures in any plane or on the inner eye surface. The program allows efficient evaluation of the plaque design in terms of radiation dose distribution relative to the tumor and critical structures

  15. Implantation port-catheter permanent indwelling of pulmonary artery in treating lung metastasis from HCC

    Objective: To observe the efficacy of a percutaneous implantation port-catheter permanent indwelling pulmonary artery for regional chemotherapy of the metastatic lung cancer from HCC. Methods: Between 1995 and 1999, 62 patients (42 males, 20 females; mean age 46 years) suffering from the metastatic lung cancer from HCC underwent percutaneous implantation of port-catheter permanent indwelling pulmonary artery using the right subclavian vein. In 19 patients with metastatic tumor located on one side of the lung, an indwelling catheter was placed into the ipsilateral side pulmonary artery. With metastasis of both sides, the catheter was inserted into the main trunk of pulmonary artery. The regimens of the chemotherapy were 5-FU + CDDP + MMC(FDM) or 5-FU + CDDP + MMC(FDA). Results: The interventional procedure was successfully completed in all 62 cases (100%). The complications occurred in 8% cases, including infections (3.2%), unhealed wound (1.6%) and pneumothorax (3.2%). The treatment effects of 3-months after the procedure were as follows: the obvious decrease of lung tumor size was 35.5%; stable disease (SD) 32.3% and progressive disease (PD) 32.3%. 6 months follow-up: 12 patients were dead (12/62) and the others are still doing well. The response rates were 22.6%, partial response (PR) 32.3%; stable disease (SD) 25.8% and progressive disease (PD) 32.3%. Conclusions: The percutaneous implantation techniques of pulmonary arterial port-catheter could be a good method in the treatment of metastatic lung cancer from HCC because of it is simple, with few complications and positive effect

  16. Stereotactic iodine-125 brachytherapy for brain tumors: temporary versus permanent implantation

    Stereotactic brachytherapy (SBT) has been described in several publications as an effective, minimal invasive and safe highly focal treatment option in selected patients with well circumscribed brain tumors <4 cm. However, a still ongoing discussion about indications and technique is hindering the definition of a clear legitimation of SBT in modern brain tumor treatment. These controversies encompass the question of how intense the irradiation should be delivered into the target volume (dose rate). For instance, reports about the use of high does rate (HDR) implantation schemes (>40 cGy/h) in combination with adjuvant external beam radiation and/or chemotherapy for the treatment of malignant gliomas and metastases resulted in increased rates of radiation induced adverse tissue changes requiring surgical intervention. Vice versa, such effects have been only minimally observed in numerous studies applying low dose rate (LDR) regiments (3–8 cGy/h) for low grade gliomas, metastases and other rare indications. Besides these observations, there are, however, no data available directly comparing the long term incidences of tissue changes after HDR and LDR and there is, furthermore, no evidence regarding a difference between temporary or permanent LDR implantation schemes. Thus, recommendations for effective and safe implantation schemes have to be investigated and compared in future studies

  17. A comparative study of 19-iodo cholesterol-125I 3-acetate and Na 125I in liquid scintillation measurements

    A comparative study of performance of 19-iodo cholesterol 125I 3-acetate and sodium iodide samples labeled with 125I is presented for liquid scintillation counting measurements. Quench effect, count rate stability and spectral evolution of samples have been followed for several weeks in Toluene, Hisafe II, Instagel, Dioxane-naphthalene and Toluene-alcohol scintillators. Organic samples have negligible quench effect in the interval of I concentration of 0-90 μg and inorganic samples only show a very small variation, lower than 12%, for Dioxane-naphthalene, in the same range of concentration. Satisfactory stability is obtained in general for both, organic and inorganic samples, but small counting losses, 0.03% for 19-iodocholesterol 1 I 3-acetate samples in Tolue ne-alcohol and 0 .04% for Na 125I samples in Dioxane-naphthalene and Toluene-alcohol, have been reported. (Author) 8 refs

  18. Carbon cartridge standards for 125I and suggested applications.

    Tries, M A; Ring, J P; Chabot, G E

    1997-09-01

    Carbon cartridge standards were prepared to assess the activity of 125I incident on, and adsorbed in, cartridge samples during air sampling. Each cartridge standard consisted of an 125I-spiked filter paper at a known depth, ranging from 0 to 19 mm, embedded in approximately 34 g of 20-30 mesh activated carbon contained within a 6.35 cm diameter by 2.22 cm deep metal cartridge with screened openings. The total counting efficiency values range from 17.8 to 20.8% for cartridges counted at 3.2 mm from a thin-crystal NaI(Tl) detector. The standards were analyzed using a front/back counting technique, and fitting functions were developed relating the front/back net counts ratio and counting efficiency to the 125I depth of burial. A method for determining sample activity that accounts for exponential radioiodine loading in cartridge samples is compared to a less complicated technique that assumes all the radioiodine is located at an equivalent depth of burial that is based on the sample front/back net counts ratio. In addition, methods are presented for determining airborne 125I activity for constant and variable concentrations. Variable concentrations are assumed to occur in a fume hood duct by one or more bulk releases as a result of iodinations that are performed during a given sampling interval. The two methods are shown to have maximum relative deviations ranging from -16 to +16%. PMID:9287093

  19. Radiotoxicity of intracellular 67Ga, 125I and 3H

    L1210 leukaemia cells were labelled with various doses of 67Ga-citrate, 3H-thymidine, or 125I-iododeoxyuridine to evaluate the cytocidal effects of the intracellular decay of the three radionuclides. Based on radioisotope incorporation data, cellular dimensions, and intracellular radioisotope distributions (3H and 125I intranuclear, 67Ga cytoplasmic) the rates of deposition of cellular, nuclear, and cytoplasmic energy were calculated. In terms of energy absorption/cell, 67Ga (LD50: 2250 keV/hr; 69 rad/hr) was much less toxic than either 3H (LD50: 325 keV/hr; 10 rad/hr) or 125I (LD50: 50 keV/hr; 1.5 rad/hr). In terms of energy absorption/nucleus, 67Ga and 3H produced almost identical effects (LD50: 230 versus 255 keV/hr; 22.2 versus 24.6 rad/hr), but 125I remained much more toxic (LD50: 40 keV/hr; 3.9 rad/hr). (author)

  20. Bypassing the learning curve in permanent seed implants using state-of-the-art technology

    Purpose: The aim of this study was to demonstrate, based on clinical postplan dose distributions, that technology can be used efficiently to eliminate the learning curve associated with permanent seed implant planning and delivery. Methods and Materials: Dose distributions evaluated 30 days after the implant of the initial 22 consecutive patients treated with permanent seed implants at two institutions were studied. Institution 1 (I1) consisted of a new team, whereas institution 2 (I2) had performed more than 740 preplanned implantations over a 9-year period before the study. Both teams had adopted similar integrated systems based on three-dimensional (3D) transrectal ultrasonography, intraoperative dosimetry, and an automated seed delivery and needle retraction system (FIRST, Nucletron). Procedure time and dose volume histogram parameters such as D90, V100, V150, V200, and others were collected in the operating room and at 30 days postplan. Results: The average target coverage from the intraoperative plan (V100) was 99.4% for I1 and 99.9% for I2. D90, V150, and V200 were 191.4 Gy (196.3 Gy), 75.3% (73.0%), and 37.5% (34.1%) for I1 (I2) respectively. None of these parameters shows a significant difference between institutions. The postplan D90 was 151.2 Gy for I1 and 167.3 Gy for I2, well above the 140 Gy from the Stock et al. analysis, taking into account differences at planning, results in a p value of 0.0676. The procedure time required on average 174.4 min for I1 and 89 min for I2. The time was found to decrease with the increasing number of patients. Conclusion: State-of-the-art technology enables a new brachytherapy team to obtain excellent postplan dose distributions, similar to those achieved by an experienced team with proven long-term clinical results. The cost for bypassing the usual dosimetry learning curve is time, with increasing team experience resulting in shorter treatment times

  1. [Permanent endocardiac electrostimulation. Considerations on 511 implantations and reimplantations in 7 years of practice].

    Mangiameli, S; Circo, A; Vanaria, D; Lombardo, D; Scalisi, A; Genovese, G; Galassi, A

    1977-06-30

    Permanent pacemakers were implanted and reimplanted in a total of 511 patients (mostly men) during a period of about 7 yr. Mean age was 67.9 yr. The cephalic route was used in nearly every case, with subclavicular implantation of the generator. Mean hospital stay was 7.6 days. Ventricular inhibition pacemakers were used in over 84% and fixed-frequency models in 7%. Mean pacemaker life was 24.1 months, with longer periods in the last months of the period of observation. The evaluation of battery run-down and recent and long-term complications is discussed, together with a particular type of decubitus of electrolytic origin. Hospital mortality was 2%. Survival was 91% at 1 yr and 54% at 6 yr. Emphasis is placed on the fact that subjects continue to be heart patients. Their well-being depends on psychological and general medical care, together with help from their, families and society, quite apart from cardiological attention. PMID:876509

  2. Scintillation proximity radioimmunoassay utilizing 125I-labeled ligands

    A unique type of radioimmunoassay is described that does not require centrifugation or separation. Microbeads containing a fluorophor are covalently linked to antibody. When an 125I-labeled antigen is added it binds to the beads and, by its proximity, the emitted short-range electrons of the 125I excite the fluorophor in the beads. The light emitted can be measured in a standard scintillation counter. Addition of unlabeled antigen from tissue extracts displaces the labeled ligand and diminishes the fluorescent signal. Application of scintillation proximity immunoassay to tissue enkephalins, serum thyroxin, and urinary morphine is described. Applications of the principle to study the kinetics of interaction between receptors and ligands are discussed

  3. Preparation of 19 iodocholesterol labelled with 125I

    A new method of synthesis of 19-iodocholesterol labelled with 125I from commercial cholesterol is described. Its high chemical (96%) and radiochemical (99,9%) purities high yield and short time of preparation permit us to dispose or a more accessible labelled compound, which results appropriate for clinical investigations and in the diagnosis of disturbances of the suprarenal glands. (author). 2 figs., 9 refs

  4. Preparation of 19-iodocholesterol labelled with 125 I

    In this paper a new method of synthesis of 19-iodo cholesterol labelled with ''125 I, from commercial cholesterol, is described. Its high chemical (96%) and radiochemical (99.9%) purities high yield and short time of preparation permit us to dispose or a more accessible labelled compound, which results appropriates for clinical investigations and in the diagnosis of disturbances of the suprarenal glands. (Author) 9 refs

  5. Production of 125I seed sources for brachytherapy uses

    The production of radioactive sources of 125I, used mainly for the brachytherapy of prostate and ocular cancer, is a work that is being carried out in the plant of production of radioisotopes (PPR) of the Nuclear Center Racso of the IPEN. The employed methodology is based on the 125I physical-chemistry adsorption at silver wires coated with palladium. In the realization of the tests, it has been considered the procedure used by India and Iran participants of this CRP. In the execution of this work, the 131I radioisotope is been used simulating the 125I, because in the PPR-IPEN we produce the 131I. In total 50 samples were used, they were divided in ten groups. In first place with nine working groups, the optimum conditions for work for the coating of the silver wires with palladium were obtained, these being the following: simple method, employing PdCl2 0.1 m, pH of 5.5 to 6.5 and a temperature of 100 deg. C. Later on, a series of tests were carried out to determine the appropriate parameters for the adsorption of 131I in the previously treated wires, these being the following: carrier concentration of Ki 0.03 m, time of adsorption of 6 hours, and temperature of 70 deg. C. Finally, the percentage of 131I adsorption was obtained in the silver wires tried previously with palladium chloride solution of 98.24%. The control of leachability was made, having very good results. To confirm these previously mentioned parameters, a test was made with ten pieces of silver wires, corresponding to the group 10, giving the confirmation as a result of these. Also, samples of the titanium tube have been sent for test with microplasma welding to a French company: air welding liquidates export. With these results obtained, subsequently the production of these radioactive sources will be carried out employing 125I as a radioisotope. (author)

  6. 125I-interleukin-8 radiolabelling and in vivo distribution

    To study the radioiodinating condition of interleukin-8 (IL-8) and observe its biodistribution in mice for understanding the possibility of its application in nuclear medicine, the authors labelled IL-8 with 125I using Bolton-Hunter reagent, and the distributions in mice at 5 min, 30 min, 1h, 6h and 24h after injection of 125I-IL-8 were measured. The blood clearance curve was obtained and fitted with the two-compartment model. The results showed that 125I-IL-8 was obtained with a labeling efficiency of 12.2% ± 6.5% and a radiochemical purity of 91.4% ± 6.5%. Its specific activity was 14.8 kBq/μg IL-8. A fast phase half-life T1/2α of 0.32 h and a slow phase half-life T1/2β of 8.01 h were calculated from the blood clearance curve. The uptakes of radioactivities in kidneys and lung had the peaks of 85.87%ID/g and 16.17%ID/g at 30 min after intravenous injection, respectively. The uptakes in liver and spleen were 12.05%ID/g and 8.97%ID/g as the maximum at 5 min after injection. The clearance in blood and other organs was fast. Except for kidneys and lung, 125I-IL-8 was less than 1%ID/g 24 h after administration. It is concluded that radioiodinated IL-8 is a promising radiopharmaceutical in nuclear medicine, especially for imaging infection. But to enhance the labeling efficiency of radioiodinated IL-8 and to decrease its in vivo deiodination are the subjects necessary to be further investigated. (authors)

  7. 125I-interleukin-8: radiolabeling and distribution in mice

    Purpose: To study the radioiodinating condition of interleukin-8 (IL-8) and observe its biodistribution in mice for understanding the possibility of its application in nuclear medicine. Methods: IL-8 is labeled by 125I with Bolton-hunter regent and the distribution in mice at 5 min, 30 min, 1h, 6h and 24h after injection of 125I -IL-8 are meseared. The blood clearance curve is obtained and fitted with two-compartment model. Results: 125I-IL-8 is obtained with a labeling efficiency of 12.2%±6.5% and radiochemical purity of 91.4%±6.5%. Its specific activity is 14.8 kBq/μg IL-8. A fast phase half-life Tl/2α of 0.32 h and slow phase half - life T1/2β of 8.01 h are calculated from blood clearance curve. The uptakes of radioactivities in kidneys and lung have the peaks of 85.87% ID /g and 16.17% ID/g at 30 min after intravenous injection, respectively. The uptakes in liver and spleen are 12.05% ID /g and 8.97% ID/g as the maximum at 5 min after injection. The clearance in blood and other organ is fast. Except for kidneys and lung, 125I -IL-8 is less than 1% ID/ g 24h after administration. Conclusion: Radioiodinated IL-8 is a promising radiopharmaceutical in nuclear medicine, especially for imaging infection. But to enhance the labeling efficiency of radioiodinated IL-8 and to decrease its in vivo deiodination are necessary. (authors)

  8. Detection of thrombocyte antibodies by 125I labeled protein A

    Protein A from Staphylococcus aureus interacts in a specific manner with most subclasses of human IgG. In the present study a method is described which utilizes Protein A labeled with 125I for the detection of antibody sensitization of platelets. The clinical applicability of the test for detection of in vivo or in vitro sensitization is demonstrated in three patients with platelet antibodies. (author)

  9. Long term results of 125I for treatment of hyperthyroidism

    125I emits very low energy conversion and Auger electrons. This radionuclide has been used in place of 131I with the hope of reducing the incidence of post treatment hypothyroidism. 303 of 360 patients treated have been reviewed. Originally very large doses of 125I were prescribed (751-1,600 μCi/g) but 9 out of 15 patients (60%) became hypothyroid, therefore 4 smaller therapeutic regimes were employed. (1) 55 patients received doses of 200 μCi or less/g thyroid, 69% are euthyroid and 24% hypothyroid after an average of 33 months from treatment. (2) 87 patients received doses of 201-350 μCi/g thyroid, 67% are euthyroid and 21% hypothyroid after an average follow up of 30 months. (3) 70 patients received doses of 351-500 μCi/g thyroid, 77% are euthyroid and 18% hypothyroid 36 months after treatment and (4) 76 patients received doses of 501-750 μCi/g, 41% are euthyroid and 56% hypothyroid 49 months after therapy. No long term complications such as thyroid cancer or leukaemia have occurred but because 125I does not eliminate or reduce the incidence of post treatment hypothyroidism it probably should not be used in preference to 131I for the routine treatment of hyperthyroidism

  10. 125I Labelling of Protein Using Immobilized Enzyme

    For an effective solid-phase labelling of protein with 125I, studies on the immobilization of lactoperoxidase (LPO) on the inner wall of polystyrene tubes were carried out. Labelling of bovine serum albumin (BSA) and insulin was also practiced using the LPO immobilized tubes. The immobilized enzyme of about 2.5 μ g/tube was sufficient for small scale labelling since the results of radio-paper chromatography of the labelling mixture of insulin indicated that the yields were sufficiently high (80%) even in the reactions conducted at room temperature for 60 sec. The results of the Sephadex column chromatography indicated that the labelled products were not contaminated with LPO-125I, and the radiochemical purity of the products was more than 90%. In considering the general trend that the 125I labelled protein obtained by using LPO maintains its intactness better than those obtained by using chloramine-T, together with the tendency of yield enhancing with increase of reactants-concentration, the LPO immobilized tube method is estimated to be one of the simple methods of labelling. The product might be applicable without further purification.

  11. Labeling Lanreotide with 125I and 188Re

    Lanreotide is a new somatostatin analogue. It can bind to human somatostatin receptor (hSSTR) subtype 2 through 5 with high affinity and to hSSTR subtype I with low affinity. We investigate labeling condition, quality control and stability in vitro of 125I-Lanreotide and 188Re-lanreotide respectively. (A) Lanreotide is labeled with 125I using Chloramine T. The effect of reaction condition (such as reaction time, pH value, Lanreotide amount, quantity of Chloramine T and reaction volume) on labeling yield is investigated in detail. (B) The labeling yield and radiochemical purity (RP) is measured with paper chromatography (PC) and Sep-Pak C18 Cartridge. (C) The stability of 125I-Lanreotide in vitro is investigated by labeling compound incubating for 48 hours at 37 deg C in the 0.9% sodium chloride solution and RP is tested by PC at specific time intervals. (D) Lanreotide is labeled directly with 188Re via the mixture of citrate and tartate using stannous chloride as reduced agent. The influence of reaction conditions such as pH, temperature, amount of stannous chloride, amount of Lanreotide and reaction time on labeling yield is investigated in detail. At the time, the stability in vitro quality control and animal test are evaluated

  12. The Anderson nomograms for permanent interstitial prostate implants: a briefing for practitioners

    Purpose: The objective of this report is to re-evaluate the role of the Anderson nomograms in treatment planning for permanent prostate implants. The incentive for revisiting this topic concerns three issues: (1) Although nomograms continue to be used in many centers for ordering seeds, few centers use them during treatment planning; (2) Whereas nomograms were designed to deliver a minimum peripheral dose for a uniform distribution of seeds in the gland, many practitioners use peripheral seed loading patterns to reduce urethral toxicity; and (3) As preoperative and intraoperative treatment planning is becoming standard, the apparent role of nomograms is diminished. The nomogram method is reviewed in terms of: (1) total activity predicted, (2) target coverage (as planned in the operating room and as calculated from postimplant computed tomography studies), and (3) reproducibility (i.e., patient-to-patient and planner-to-planner variability). In each case, the computer-optimization system for intraoperative planning currently in use at our institution was taken as the 'gold standard'. Methods and Materials: We compared for the same patient the results of nomogram planning to those yielded by genetic algorithm (GA) optimization in terms of total activity predicted (n=20 cases) and percent target coverage (n=5 cases). Furthermore, we examined retrospectively the dosimetry of 61 prostate implants planned with the GA (n=27) and the current implementation of Anderson nomograms (n=34). Results: Nomogram predictions of the total activity required are in good agreement (within 10%) with the GA-planned activity. However, computer-optimized plans consistently yield superior plans, as reflected in both pre- and postimplant analyses. We find also that user (specifically, treatment planner) implementation of the nomograms may be a major source of variability in nomogram planning - a difficulty to which robust computer optimization is less prone. Conclusions: Nomograms continue to

  13. Class solution for inversely planned permanent prostate implants to mimic an experienced dosimetrist

    The purpose of this paper is to present a method for the selection of inverse planning parameters and to establish a set of inverse planning parameters (class solution) for the inverse planning included in a commercial permanent prostate implant treatment planning system. The manual planning of more than 750 patients since 1996 led to the establishment of general treatment planning rules. A class solution is tuned to fulfill the treatment planning rules and generate equivalent implants. For ten patients, the inverse planning is compared with manual planning performed by our experienced physicist. The prostate volumes ranged from 17 to 51 cc and are implanted with low activity I-125 seeds. Dosimetric indices are calculated for comparison. The inverse planning needed about 15 s for each optimization (400 000 iterations on a 2.5 GHz PC). In comparison, the physicist needed about 20 min to perform each manual plan. A class solution is found that consistently produces dosimetric indices equivalent or better than the manual planning. Moreover, even with strict seed placement rules, the inverse planning can produce adequate prostate dose coverage and organ at risk protection. The inverse planning avoids implant with seeds outside of the prostate and too close to the urethra. It also avoids needles with only one seed and needles with three consecutive seeds. This reduces the risk of complication due to seed misplacement and edema. The inverse planning also uses a smaller number of needles, reducing the cause of trauma. The quality of the treatment plans is independent of the gland size and shape. A class solution is established that consistently and rapidly produces equivalent dosimetric indices as manual planning while respecting severe seed placement rules. The class solution can be used as a starting point for every patient, dramatically reducing the time needed to plan individual patient treatments. The class solution works with inverse preplanning, intraoperative

  14. Labeling Lanreotide with 125I and 188Re. China

    Lanreotide (D-β-Nal-Cys-Try-D-Trp-Lys-Val-Cys-Thr-NH2) is a new somatostatin analogue. It can bind to human somatostatin receptor (hSSTR) subtype 2 through 5 with high affinity and to hSSTR subtype 1 with low affinity. We investigate labeling condition, quality control and stability in vitro of 125I-Lanreotide and 188Re-lanreotide respectively. (A) Lanreotide is labeled with 125I using Chloramine T. The effect of reaction condition (such as reaction time, pH value, Lanreotide amount, quantity of Chloramine T and reaction volume) on labeling yield is investigated in detail. (B) The labeling yield and radiochemical purity (RP) is measured with paper chromatography (PC) and Sep-Pak C18 Cartridge. For PC method, 125I-Lanreotide is spotted on the Whatman No.1 paper and developed in the mixture of CH3CH2CH2CH2OH and CH3CH2OH and NH4OH (v/v/v=5:2:1), the Rf value of every component in the mobile phase is given in table 1. For Sep-Pak C18 Cartridge methods each cartridge is washed with 10 ml of ethanol followed by 10 ml of iso-CH3CH2CH2OH solution. Aliquots of 0.1 mI sample is loaded onto the cartridge, unbound peptide (sodium iodine-125) is eluted with 5 ml of 0.5mol/L sodium acetate solution, 125I-Lanreotide is eluted with 5 mI of 95% aqueous ethanol solution. (C) The stability of 125I-Lanreotide in vitro is investigated by labeling compound incubating for 48 hours at 37 deg. C in the 0.9% sodium chloride solution and RP is tested by PC at specific time intervals. (D) Lanreotide is labeled directly with 188Re via the mixture of citrate and tartate using stannous chloride as reduced agent. The influence of reaction conditions such as pH, temperature, amount of stannous chloride, amount of Lanreotide and reaction time on labeling yield is investigated in detail. At the time, the stability in vitro quality control and animal test are evaluated

  15. Autoradiographic comparison of [125I]epidepride and [125I]NCQ 298 binding to human brain extrastriated dopamine receptors

    Extrastriatal D2-dopamine receptors can be visualized in the monkey and human brain using the benzamides [11C]- and [76Br]FLB 457 in PET and [123I]epidepride in SPECT but not with the salicylamide analogues [76Br]FLB 463 and [123I]NCQ 298. To clarify the background for the differences in binding seen in vivo, we have compared the in vitro binding of [125I]epidepride and [125I]NCQ 298, using human whole hemisphere autoradiography. The images obtained with any radioligand showed detailed distribution with very dense binding in the putamen and the caudate nucleus and with the same detailed extrastriatal distribution. Thus, the divergent results obtained in vivo cannot be explained by different binding properties of the extrastriatal receptors

  16. Preparation of 19-iodo cholesterol labelled with 125 I; Preparacion del 19-yodocolesterol marcado con 125 I

    Rodriguez, L.; Rebollo, D. V.; Ruiz, J. M.

    1986-07-01

    In this paper a new method of synthesis of 19-iodo cholesterol labelled with ''125 I, from commercial cholesterol, is described. Its high chemical (96%) and radiochemical (99.9%) purities high yield and short time of preparation permit us to dispose or a more accessible labelled compound, which results appropriates for clinical investigations and in the diagnosis of disturbances of the suprarenal glands. (Author) 9 refs.

  17. Design and synthesis of [(125)I]Pyricoxib: A novel (125)I-labeled cyclooxygenase-2 (COX-2) inhibitors.

    Tietz, Ole; Dzandzi, James; Bhardwaj, Atul; Valliant, John F; Wuest, Frank

    2016-03-15

    Cyclooxygenase-2 (COX-2) is the key enzyme in the prostaglandin synthesis pathway which is involved in various pathophysiological conditions. The enzyme is membrane bound and located inside of the endoplasmic reticulum and nuclear membrane. Effective perfusion of inhibitors to the active site requires lipophilic drugs, which consequently display high unspecific background accumulation, for example, in fatty tissues. The objective of this work was the development of a small molecule radiolabeled with a long-lived iodine radioisotope to enable longer imaging times and better target-to-background ratios. A group of iodinated compounds (8-10) was synthesized and identified as selective COX-2 inhibitors (COX-2 IC50=0.85-13 μM). Molecular docking results provided the theoretical support for the experimental COX-2 inhibition data. Furthermore, a novel (125)I-containing trifluoro-pyrimidine compound ([(125)I]Pyricoxib) was prepared via radioiododestannylation reaction as potent and selective COX-2 inhibitor. Radiosynthesis of [(125)I]Pyricoxib was accomplished with innovative fluorous chemistry using fluorous chloroamine-T (F-CAT) as novel oxidizing agent in high radiochemical yields of 91 ± 4%. PMID:26898334

  18. Synthesis and radioimmunological characterization of testosterone-3-carboxymethyloxime-tyramine-125 I (T-3-Cmo-Ty-125 I)

    The paper presents the synthesis and radioimmunological characterization of testosterone-3-carboxymethyloxime-tyramine-15 I (T-3-CMO-Ty-125 I), a reagent used as marker in radioimmunoassay (RIA) of steroid hormones. Some of the most adequate techniques of analyzing the steroid hormones are RIA and ELISA (enzyme linked immunosorbent assay) due to their sensitivity and specificity. These techniques do not require advanced purification of the sample. In the view of developing a sensitive RIA technique for assaying the testosterone-3-carboxymethyloxime-tyramine-125 I it is necessary to obtain the reagents as anti-testosterone antibody and radioactive labeled testosterone. The carboxy derivative of the steroid hormone was activated with ethylchloroformiate and tributylamine in dioxan and coupled with tyramine-125 I. Tyramine was labelled by chloramine method. The marker was purified by thin layer chromatography and extracted in methylic alcohol. Radioimmunological characterization of the marker was carried out with the help of the anti testosterone antibody obtained in our laboratory. (authors)

  19. Ultracompact, completely implantable permanent use electromechanical ventricular assist device and total artificial heart.

    Honda, N; Inamoto, T; Nogawa, M; Takatani, S

    1999-03-01

    An ultracompact, completely implantable permanent use electromechanical ventricular assist device (VAD) and total artificial heart (TAH) intended for 50-60 kg size patients have been developed. The TAH and VAD share a miniature electromechanical actuator that comprises a DC brushless motor and a planetary roller screw. The rotational force of the motor is converted into the rectilinear force of the roller screw to actuate the blood pump. The TAH is a one piece design with left and right pusher plate type blood pumps sandwiching an electromechanical actuator. The VAD is one half of the TAH with the same actuator but a different pump housing and a backplate. The blood contacting surfaces, including those of the flexing diaphragm and pump housing, of both the VAD and TAH were made of biocompatible polyurethane. The diameter, thickness, volume, and weight of the VAD are 90 mm, 56 mm, 285 cc, and 380 g, respectively, while those of the TAH are 90 mm, 73 mm, 400 cc, and 440 g, respectively. The design stroke volume of both the VAD and TAH is 60 cc with the stroke length being 12 mm. The stroke length and motor speed are controlled solely based on the commutation signals of the motor. An in vitro study revealed that a maximum pump flow of 7.5 L/min can be obtained with a pump rate of 140 bpm against a mean afterload of 100 mm Hg. The power requirement ranged from 4 to 6 W to deliver a 4-5 L/min flow against a 100 mm Hg afterload with the electrical-to-hydraulic efficiency being 19-20%. Our VAD and TAH are the smallest of the currently available devices and suitable for bridge to transplant application as well as for permanent circulatory support of 50-60 kg size patients. PMID:10198717

  20. Development of procedure using plasma welding process to produce 125I seeds

    The prostate cancer, which is the second cause of death by cancer in men, overcome only by lung cancer, is a problem of public health in Brazil. Brachytherapy is among the possible available treatments for prostate cancer, in which small seeds containing 125I radioisotope are implanted in the prostate. The seed consists of a titanium sealed capsule with 0.8 mm external diameter and 4.5 mm length, containing a central silver wire with adsorbed 125I. The plasma arc welding is one of the viable techniques for the sealing process. The equipment used in this technique is less costly than in other processes. The main objective of this work was the development and the validation of the welding procedure using plasma welding process and the elaboration of a sealing routine according to Good Manufacturing Practices. The development of this work has presented the following phases: cut and cleaning of the titanium material, determination of the welding parameters, development of a device for holding the titanium tube during the welding process, validation of sealed sources according to ISO 2919 Sealed Radioactive Sources - General Requirements and Classification, leakage test according to ISO 9978 Sealed Radioactive Sources - Leakage Test Methods and metallographic assays. The developed procedure, to seal 125I seeds using plasma welding process, has shown to be efficient, satisfying all the established requirements of ISO 2919. The results obtained in this work have given the possibility to establish a routine production process according to the orientations presented in resolution RDC number 59 - Good Manufacturing Practices do Medical Products of the ANVISA - Brazilian Nacional Agency of Sanitary Surveillance. (author)

  1. Poster — Thur Eve — 41: Considerations for Patients with Permanently Implant Radioactive Sources Requiring Unrelated Surgery

    Permanent implant of sealed radioactive sources is an effective technique for treating cancer. Typically, the radioactive sources are implanted in and near the disease, depositing dose locally over several months. There may be instances where these patients must undergo unrelated surgical procedures when the radioactive material remains active enough to pose risks. This work explores these risks, discusses strategies to mitigate those risks, and describes a case study for a permanent I-125 prostate brachytherapy implant patient who developed colo-rectal cancer and required surgery 6 months after brachytherapy. The first consideration is identifying the risk from unwarranted radiation to the patient and staff before, during, and after the surgical procedure. The second is identifying the risk the surgical procedure may have on the efficacy of the brachytherapy implant. Finally, there are considerations for controlling for radioactive substances from a regulatory perspective. After these risks are defined, strategies to mitigate those risks are considered. These strategies may include applying the concepts of ALARA, the use of protective equipment and developing a best practice strategy with the operating room team. We summarize this experience with some guidelines: If the surgical procedure is near (ex: 5 cm) of the implant; and, the surgical intervention may dislodge radioisotopes enough to compromise treatment or introduces radiation safety risks; and, the radioisotope has not sufficiently decayed to background levels; and, the surgery cannot be postponed, then a detailed analysis of risk is advised

  2. Particle-rotor-model calculations in 125I

    Hariprakash Sharma; B Sethi; P Banerjee; Ranjana Goswami; R K Bhandari; Jahan Singh

    2001-07-01

    Recent experimental data on 125I has revealed several interesting structural features. These include the observation of a three quasiparticle band, prolate and oblate deformed bands, signature inversion in the yrast positive-parity band and identification of the unfavoured ℎ11/2 band showing very large signature splitting. In the present work, particle-rotor-model calculations have been performed for the ℎ11/2 band, using an axially symmetric deformed Nilsson potential. The calculations reproduce the experimental results well and predict a moderate prolate quadrupole deformation of about 0.2 for the band.

  3. Intercomparison of ionisation chamber measurements from {sup 125}I seeds

    Davies, J.B. [Australian Nuclear Science and Technology Organisation, New Illawarra Road, Building 23, Lucas Heights, NSW 2234 (Australia); Institute of Medical Physics, University of Sydney, NSW 2006 (Australia); E-mail: jbd@ansto.gov.au; Enari, K.F. [Cancer Care Centre, St George Hospital, Kogarah, NSW 2217 (Australia); Baldock, C. [Institute of Medical Physics, University of Sydney, NSW 2006 (Australia)

    2007-05-15

    The reference air kerma rates of a set of individual {sup 125}I seeds were calculated from current measurements of a calibrated re-entrant ionisation chamber. Single seeds were distributed to seven Australian brachytherapy centres for the same measurement with the user's instrumentation. Results are expressed as the ratio of the reference air kerma rate measured by the Australian Nuclear Science and Technology Organisation (ANSTO) to the reference air kerma rate measured at the centre. The intercomparison ratios of all participants were within {+-}5% of unity.

  4. Radio synthesis and in vivo evaluation of two α7 nAChRs radioligands. [125I]CAIPE and [125I]IPPU

    The radio synthesis and in vivo evaluation of two α7 nAChRs radioligands [125I]CAIPE and [125I]IPPU were reported. They were obtained from their tributyltin precursors with high radio chemical yields ([90 %) and good radio chemical purities ([95 %). Biodistribution and blockade studies of [125I]CAIPE showed that the accumulation of radioactivity in the mouse brain was specific and selective. (author)

  5. 125I iothalamate an ideal marker for glomerular filtration

    The triiodinated angiographic contrast medium, iothalamate (usually labelled 125I), has been used extensively as a marker for glomerular filtration. The authors have studied the renal handling of 125I iothalamate (IOT) in vivo and in vitro in several species. In renal cortical slices from chicken, rabbit, rat, and monkey, the tissue-to-medium ratio of IOT was twice that of 51Cr-EDTA (EDTA) at 37 degrees C; a difference that was abolished at 0 degree C and markedly reduced by added o-iodohippurate or iodipamide. In five chickens the steady-state renal clearance of IOT (CIOT) was twice that of EDTA (CEDTA) or 3H inulin (C1); a difference that was abolished by administration of 100 mg/kg/hr of novobiocin, an organic anion transport inhibitor. CEDTA was similar to C1 before as well as after transport inhibition. Utilizing the Sperber technique the mean apparent tubular excretion fraction (ATEF) of IOT was 8%, while that of EDTA was 1%. After novobiocin coinfusion (new steady-state) ATEFIOT was significantly reduced and not different from that of EDTA (-1%). In the same animals the total urinary recovery of IOT was 84 and 57% before and after novobiocin, respectively, while corresponding values for EDTA was unchanged by the inhibitor. In seven rats the renal extraction of IOT was reduced from 29 to 17% by coinfusion of probenecid (5 mg/kg/hr). Corresponding extractions were 82 to 34% and 22% (unchanged) for PAH and EDTA, respectively

  6. Studies on characteristics of dosimetry for 125I ophthalmic applicator

    Isodose curves for 125I ophthalmic application in different geometry and activity can be obtained using the empirical formula based on suitable geometric model. The results of surface dose rate determined with lithium fluoride (LiF) thermoluminescent dosimeter (TLD's) chips in water-organic glass phantom and air had no obvious difference and the surface dose rate and its uniformity, (3.46 +- 0.011) and (0.178 +- 0.15) nGy/h·107Bq were obtained. Count measurements and dose determinations for the front and back etc. of the ophthalmic applicator with BaF2 scintillation detector and LiF TLD's had revealed the space distribution of dose for 125I ophthalmic applicator in which dose on the back was less than 0.1% of that on the front. The distribution of the absorbed dose rate along the eye axis had been measured using LiF TLD's in water-organic glass phantom. The measured and calculated dose data indicated that when measuring distances were larger than about 5 mm the experimental results agreed with those from calculation within the range of error, otherwise the measured values were lower, still it could be explained by experimental conditions

  7. Dosimetric characterization of the GammaClip™169Yb low dose rate permanent implant brachytherapy source for the treatment of nonsmall cell lung cancer postwedge resection

    Purpose: A novel 169Yb low dose rate permanent implant brachytherapy source, the GammaClip™, was developed by Source Production and Equipment Co. (New Orleans, LA) which is designed similar to a surgical staple while delivering therapeutic radiation. In this report, the brachytherapy source was characterized in terms of “Dose calculation for photon-emitting brachytherapy sources with average energy higher than 50 keV: Report of the AAPM and ESTRO” by Perez-Calatayud et al. [Med. Phys. 39, 2904–2929 (2012)] using the updated AAPM Task Group Report No. 43 formalism.Methods: Monte Carlo calculations were performed using Monte Carlo N-Particle 5, version 1.6 in water and air, the in-air photon spectrum filtered to remove photon energies below 10 keV in accordance with TG-43U1 recommendations and previously reviewed 169Yb energy cutoff levels [D. C. Medich, M. A. Tries, and J. M. Munro, “Monte Carlo characterization of an Ytterbium-169 high dose rate brachytherapy source with analysis of statistical uncertainty,” Med. Phys. 33, 163–172 (2006)]. TG-43U1 dosimetric data, including SK, D-dot (r,θ), Λ, gL(r), F(r, θ), φan(r), and φan were calculated along with their statistical uncertainties. Since the source is not axially symmetric, an additional set of calculations were performed to assess the resulting axial anisotropy.Results: The brachytherapy source's dose rate constant was calculated to be (1.22 ± 0.03) cGy h−1 U−1. The uncertainty in the dose to water calculations, D-dot (r,θ), was determined to be 2.5%, dominated by the uncertainties in the cross sections. The anisotropy constant, φan, was calculated to be 0.960 ± 0.011 and was obtained by integrating the anisotropy factor between 1 and 10 cm using a weighting factor proportional to r−2. The radial dose function was calculated at distances between 0.5 and 12 cm, with a maximum value of 1.20 at 5.15 ± 0.03 cm. Radial dose values were fit to a fifth order polynomial and dual exponential

  8. An algorithm for efficient metal artifact reductions in permanent seed implants

    Xu Chen; Verhaegen, Frank; Laurendeau, Denis; Enger, Shirin A.; Beaulieu, Luc [Departement de Radio-Oncologie et Centre de Recherche en Cancerologie, Universite Laval, Centre Hospitalier Universitaire de Quebec, 11 Cote du Palais, Quebec, Quebec G1R 2J6 (Canada) and Departement de Genie Electrique et Genie Informatique, Laboratoire de Vision et Systemes Numeriques, Universite Laval, Quebec, Quebec G1K 7P4 (Canada); Department of Radiation Oncology (MAASTRO), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht 6201 BN (Netherlands) and Oncology Department, Montreal General Hospital, McGill University, 1650 Cedar Avenue, Montreal, Quebec H3G 1A4 (Canada); Departement de Genie Electrique et Genie Informatique, Laboratoire de Vision et Systemes Numeriques, Universite Laval, Quebec, Quebec G1K 7P4 (Canada); Departement de Radio-Oncologie et Centre de Recherche en Cancerologie, Universite Laval, Centre Hospitalier Universitaire de Quebec, 11 Co circumflex te du Palais, Quebec, Quebec G1R 2J6 (Canada); Departement de Radio-Oncologie et Centre de Recherche en Cancerologie, Universite Laval, Centre Hospitalier Universitaire de Quebec, 11 Cote du Palais, Quebec, Quebec G1R 2J6 (Canada) and Departement de Physique, de Genie Physique et d' Optique, Universite Laval, Quebec, Quebec G1K 7P4 (Canada)

    2011-01-15

    Purpose: In permanent seed implants, 60 to more than 100 small metal capsules are inserted in the prostate, creating artifacts in x-ray computed tomography (CT) imaging. The goal of this work is to develop an automatic method for metal artifact reduction (MAR) from small objects such as brachytherapy seeds for clinical applications. Methods: The approach for MAR is based on the interpolation of missing projections by directly using raw helical CT data (sinogram). First, an initial image is reconstructed from the raw CT data. Then, the metal objects segmented from the reconstructed image are reprojected back into the sinogram space to produce a metal-only sinogram. The Steger method is used to determine precisely the position and edges of the seed traces in the raw CT data. By combining the use of Steger detection and reprojections, the missing projections are detected and replaced by interpolation of non-missing neighboring projections. Results: In both phantom experiments and patient studies, the missing projections have been detected successfully and the artifacts caused by metallic objects have been substantially reduced. The performance of the algorithm has been quantified by comparing the uniformity between the uncorrected and the corrected phantom images. The results of the artifact reduction algorithm are indistinguishable from the true background value. Conclusions: An efficient algorithm for MAR in seed brachytherapy was developed. The test results obtained using raw helical CT data for both phantom and clinical cases have demonstrated that the proposed MAR method is capable of accurately detecting and correcting artifacts caused by a large number of very small metal objects (seeds) in sinogram space. This should enable a more accurate use of advanced brachytherapy dose calculations, such as Monte Carlo simulations.

  9. Chemical Species and Content Analysis of 125I in Bok-choy and Ipomoea Aquatica Forsk

    Iodine has been long known as an indispensable element in the synthesis of thyroid hormones. Severe iodine deficiency in diet leads to iodine deficiency disorders in humans. An isotope tracer experiment was carried out to study the chemical species and content analysis of 125I absorbed by the Bok-choy and Ipomoea Aquatica Forsk. The results showed that inorganic 125I, organic 125I and residual 125I have been detected in Bok-choy and Ipomoea Aquatica Forsk. In Bok-choy,the inorganic 125I content is the most which up to 42.48%, and except for residual 125I the organic 125I content is taken up to 7.91%. But in Ipomoea Aquatica Forsk, the content of 125I ranks as residual 125I > the inorganic 125I > organic 125I followed by 64.97%, 28.36% and 6.66%. The consists of inorganic 125I is I-, IO3-and I2 in both Bok-choy and Ipomoea Aquatica Forsk, and I-is the main chemical species. The protein-125I was the main form of organic iodine which respectively amounts to 22.43% and 8.68% of total iodine, the content of amylose-125I was the least which was 0.78% and 0.40% in both Bok-choy and Ipomoea Aquatica Forsk, and the content of the nucleic acid-125I is between them. The results showed that Bok-choy and Ipomoea Aquatica Forsk can enriched Iodine in environment. so, they could be cultivated as iodine vegetable. (authors)

  10. Pharmacokinetics and organ distribution of 125I-aprindine

    An attempt was made to label aprindine hydrochloride with I-125 by means of an exchange reaction. Organ distribution was determined in 10 rats where radioactivity was measured in the lung, heart, liver, kidney, spleen, brain, transverse muscle tissue and bone sections 5, 10, 30 and 60 min following i.v. injection. The high organ concentration was found in the lung, and also the maximum ratio organ: blood radioactivity was found for this organ. Whole body activity measurements revealed a half-life of nearly 6 hr. Excretion occurred primarily via the faeces. The pharmacokinetic properties of 14C- and 125I-aprindine hydrochloride do not therefore differ significantly. A whole body scintiscanning was carried out on an additional 12 rats and 6 rabbits. This revealed a marked enrichment in the lung compared to other organs in the time period 5 to 10 min. An image of relatively good quality was obtained compared to that of conventional perfusion scintiscanning with 131I-HSA. It is assumed that 125I-aprindine hydrochloride is concentrated in the lung parenchyma and is therefore largely unaffected by the immediate perfusion conditions. This is also confirmed in preliminary studies with 131I-aprindine in the scintiscanning of rabbits where voids of pneumonia activity are shown in the aprindine scintigram whereas with the perfusion method these are not. As expected, the reverse was shown to be true following experimental pulmonary embolism where voids were seen in the perfusion scintigram whilst the 131I-aprindine scintigram revealed hardly any areas of drops in activity. These properties possibly offer an improved diagnostic procedure for differentiating between pneumonia and lung infarct by combination with perfusion scintiscanning. (orig./MG)

  11. Metabolism and placental transfer of /sup 125/I-proinsulin and /sup 125/I-tyrosylated C-peptide in the pregnant rhesus monkey

    Gruppuso, P.A.; Susa, J.B.; Sehgal, P.; Frank, B.; Schwartz, R.

    1987-10-01

    /sup 125/I-Proinsulin or /sup 125/I-tyrosylated-C-peptide (/sup 125/I-tyr-CP) was administered to pregnant Rhesus monkeys by bolus followed by constant infusion to examine placental transfer of these peptides. At the end of each infusion, fetuses were exsanguinated in situ via the umbilical vein. The bolus-constant infusion technique produced a steady state in maternal plasma of immunoprecipitable label, measured using excess insulin or C-peptide antiserum. In animals infused with /sup 125/I-proinsulin, analysis of umbilical venous plasma revealed no apparent transfer to the fetus of immunoprecipitable label. In animals infused with /sup 125/I-tyr-CP, 3-13% of the umbilical venous plasma radioactivity was immunoprecipitable, representing 1.4-5.8% of the immunoprecipitable radioactivity in maternal plasma at delivery. Gel filtration chromatography of umbilical venous plasma revealed that the immunoprecipitated moiety was a fragment of /sup 125/I-tyr-CP. Analysis of maternal plasma showed that the predominant peak of radioactivity represented intact C-peptide. A peak corresponding to the fetal immunoprecipitable peak was also present. Analysis of simultaneous maternal arterial and uterine vein plasma samples showed that degradation of /sup 125/I-tyr-CP occurred across the uterus. Studies in one nonpregnant and three postpartum animals indicated that pregnancy increased the rate of metabolism of /sup 125/I-tyr-CP. When /sup 125/I-tyr-CP was incubated with trophoblastic cells in culture, degradation to a species corresponding on gel filtration to the immunoprecipitable fetal metabolite was found. We conclude that proinsulin, like insulin, does not traverse the placenta. Immunoreactive fragments of C-peptide do cross, however, and pregnancy alters the metabolism of /sup 125/I-tyr-CP, probably owing to placental degradation.

  12. Metabolism and placental transfer of 125I-proinsulin and 125I-tyrosylated C-peptide in the pregnant rhesus monkey

    125I-Proinsulin or 125I-tyrosylated-C-peptide (125I-tyr-CP) was administered to pregnant Rhesus monkeys by bolus followed by constant infusion to examine placental transfer of these peptides. At the end of each infusion, fetuses were exsanguinated in situ via the umbilical vein. The bolus-constant infusion technique produced a steady state in maternal plasma of immunoprecipitable label, measured using excess insulin or C-peptide antiserum. In animals infused with 125I-proinsulin, analysis of umbilical venous plasma revealed no apparent transfer to the fetus of immunoprecipitable label. In animals infused with 125I-tyr-CP, 3-13% of the umbilical venous plasma radioactivity was immunoprecipitable, representing 1.4-5.8% of the immunoprecipitable radioactivity in maternal plasma at delivery. Gel filtration chromatography of umbilical venous plasma revealed that the immunoprecipitated moiety was a fragment of 125I-tyr-CP. Analysis of maternal plasma showed that the predominant peak of radioactivity represented intact C-peptide. A peak corresponding to the fetal immunoprecipitable peak was also present. Analysis of simultaneous maternal arterial and uterine vein plasma samples showed that degradation of 125I-tyr-CP occurred across the uterus. Studies in one nonpregnant and three postpartum animals indicated that pregnancy increased the rate of metabolism of 125I-tyr-CP. When 125I-tyr-CP was incubated with trophoblastic cells in culture, degradation to a species corresponding on gel filtration to the immunoprecipitable fetal metabolite was found. We conclude that proinsulin, like insulin, does not traverse the placenta. Immunoreactive fragments of C-peptide do cross, however, and pregnancy alters the metabolism of 125I-tyr-CP, probably owing to placental degradation

  13. Prostate dose calculations for permanent implants using the MCNPX code and the Voxels phantom MAX

    Reis Junior, Juraci Passos dos; Silva, Ademir Xavier da, E-mail: jjunior@con.ufrj.b, E-mail: Ademir@con.ufrj.b [Coordenacao dos Programas de Pos-Graduacao de Engenharia (COPPE/UFRJ), RJ (Brazil). Programa de Engenharia Nuclear; Facure, Alessandro N.S., E-mail: facure@cnen.gov.b [Comissao Nacional de Energia Nuclear (CNEN), Rio de Janeiro, RJ (Brazil)

    2010-07-01

    This paper presents the modeling of 80, 88 and 100 of {sup 125}I seeds, punctual and volumetric inserted into the phantom spherical volume representing the prostate and prostate phantom voxels MAX. Starting values of minimum and maximum activity, 0.27 mCi and 0.38 mCi, respectively, were simulated in the Monte Carlo code MCNPX in order to determine whether the final dose, according to the integration of the equation of decay at time t = 0 to t = {infinity} corresponds to the default value set by the AAPM 64 which is 144 Gy. The results showed that consider sources results in doses exceeding the percentage discrepancy of the default value of 200%, while volumetric consider sources result in doses close to 144 Gy. (author)

  14. Autoradiographic comparison of [125I]epidepride and [125I]NCQ 298 binding to human brain extrastriated dopamine receptors.

    Hall, H; Halldin, C; Jerning, E; Osterlund, M; Farde, L; Sedvall, G

    1997-07-01

    Extrastriatal D2-dopamine receptors can be visualised in the monkey and human brain using the benzamides [11C]- and [76Br]FLB 457 in PET and [123I]epidepride in SPECT but not with the salicylamide analogues [76Br]FLB 463 and [123I]NCQ 298. To clarify the background for the differences in binding seen in vivo, we have compared the in vitro binding of [125I]epidepride and [123I]NCQ 298, using human whole hemisphere autoradiography. The images obtained with any radioligand showed detailed distribution with very dense binding in the putamen and the caudate nucleus and with the same detailed extrastriatal distribution. Thus, the divergent results obtained in vivo cannot be explained by different binding properties of the extrastriatal receptors. PMID:9290072

  15. 125I-TOC和125I-F-PGA放射化学纯度的测定%Determination of Radiochemical Purity of 125 I-TOC and 125 I-F-PGA

    杨科亚; 范我; 张友九; 许玉杰; 朱然; 胡明江

    2006-01-01

    为比较3种测定125I标记的奥曲肽(TOC)和叶酸-青霉素酰化酶复合物(F-PGA)的放射化学纯度(RCP)的方法是否具有一致性,采用Iodogen法对TOC和F-PGA进行放射性碘标记,并用高效液相色谱法(HPLC)、三氯醋酸(TCA)沉淀法和纸层析法测定标记物的放射化学纯度(RCP),其中TCA沉淀法设4种蛋白浓度以观察其对RCP测定的影响.结果表明,HPLC和纸层析法均能有效分离标记物和游离碘,且HPLC测定这种标记物的RCP最为精确可信.在TCA沉淀法中,用0.2%的小牛血清白蛋白(BSA)测得的RCP最低,而用其它3个BSA浓度测得的RCP则无明显差异(P>0.05);当RCP<10%时,TCA沉淀法与纸层析法测得的RCP间无明显差异(P>0.05),而要高于HPLC(P<0.01);当RCP>10%时,对125I-TOC而言,TCA沉淀法要略低于HPLC和纸层析(P<0.05),但后2种方法无明显差异(P>0.05),且对125I-F-PGA而言,3种方法无明显差异(P>0.05).3种方法两两之间显著相关(r=0.996~0.999,P<0.001).

  16. Binding cells of 125I-iodoamphetamine in rat liver

    We recently reported that transrectal or intestinal portal scintigraphy with 123I-iodoamphetamine (IMP) could be a useful method for the non-invasive and quantitative evaluation of the portosystemic shunt in portal hypertension, but what cells in the liver trap IMP has not been clarified. This study was aimed at elucidating whether IMP was extracted by parenchymal cells, sinusoidal endothelial cells, Kupffer cells or fat storing cells. Each type of liver cell was isolated from rats and cultured. The cells were incubated with 125I-IMP and the radioactivity of the lysate was determined. Nonspecific binding was assessed in the presence of an excess of unlabeled IMP, and specific binding was determined by subtracting the nonspecific from total binding. Specific binding observed in parenchymal cells, endothelial cells and Kupffer cells was 70.2±0.4, 4.2±1.4 and 2.3±0.8 pmol/well, respectively, but no specific binding was observed in fat storing cells. The binding in parenchymal cells was much higher than that in endothelial cells or Kupffer cells (p<0.005). In addition, the binding to parenchymal cells reached equilibrium within 20 min and was not saturable over the concentration range tested (0.5-10 μM). These findings indicate that IMP is mostly extracted by parenchymal cells in the liver. (author)

  17. Optimization of sup 125 I ophthalmic plaque brachytherapy

    Astrahan, M.A.; Luxton, G.; Jozsef, G.; Liggett, P.E.; Petrovich, Z. (Univ. of Southern California School of Medicine, Los Angeles (USA))

    1990-11-01

    Episcleral plaques containing {sup 125}I sources are often used in the treatment of ocular melanoma. Within four years post-treatment, however, the majority of patients experience some visual loss due to radiation retinopathy. The high incidence of late complications suggests that careful treatment optimization may lead to improved outcome. The goal of optimization would be to reduce the magnitude of vision-limiting complications without compromising tumor control. We have developed a three-dimensional computer model for ophthalmic plaque therapy which permits us to explore the potential of various optimization strategies. One simple strategy which shows promise is to maximize the ratio of dose to the tumor apex (T) compared to dose to the macula (M). By modifying the parameters of source location, activity distribution, source orientation, and shielding we find that the calculated T:M ratio can be varied by a factor of 2 for a common plaque design and posterior tumor location. Margins and dose to the tumor volume remain essentially unchanged.

  18. Simulation of strand break induction by DNA incorporated 125I

    Monte Carlo calculation of 125I Auger cascades has provided electron spectra for individual decays with kinetic energies determined by Dirac-Fock methods. For these Auger electrons, track structures in liquid water have been generated and superimposed on a straight DNA plasmid model with atomic coordinates taken from X ray diffraction studies. Due to its high geometrical resolution, this DNA model makes it possible to localize the energy deposition or/and radical production events relative to the submolecular units of the DNA strands (base, sugar, phosphate). Furthermore, it is possible to distinguish between events inside (direct) and outside (indirect, radical production) of the atomic volumes of the DNA. On the basis of different assumptions for the effectiveness of strand break induction by direct hits and by OH· and H· radicals, the yields for single- and double strand breaks, as well as the strand break distribution as a function of the distance from the decay site, has been evaluated and compared with experimental and theoretical results from the literature

  19. Study on non-coplanar intensity modulated radiation therapy in esophageal carcinoma implanted with permanent cardiac pacemaker

    The aim is to evaluate the physical dose distributions in esophageal carcinoma implanted with permanent cardiac pacemaker treated with non-coplanar intensity modulated radiation therapy (no-co-IMRT). Eight patients with esophageal carcinoma implanted cardiac pacemaker proven by histology were treated by IMRT. For each patient, we designed two IMRT plans by Eclipse IMRT inverse plan system: non-coplanar IMRT plan (3 coplanar fields and 2 non-coplanar fields) and coplanar IMRT plan (5 coplanar fields). The same physical parameter was applied to the same patient in both plans. Plans were evaluated in terms of dose-volume histogram, conformity index, homogeneity index monitor unit and control points. The results showed that no-co-IMRT plan could significantly reduce the max dose of implantable cardiac pacemaker and the wires (p<0.05), but no significant difference was found between no-co-IMRT plan and co-IMRT plan in target volume and other normal tissues Compared with co-IMRT plan, the monitor unit (MU) and control points of no-co-IMRT plan were not increased significantly (p>0.05). These findings indicate that the technique of no-co-IMRT can obtain the fewer max dose of implantable cardiac pacemaker and the wires during intensity modulated radiation therapy of esophageal carcinoma. (authors)

  20. A Radiation Badge Survey for Family Members Living With Patients Treated With a 103Pd Permanent Breast Seed Implant

    Purpose: Sixty-seven patients with early-stage breast cancer were treated in a Phase I/II clinical trial using a 103Pd permanent breast seed implant as adjuvant radiotherapy after breast-conserving surgery. We report the dose received by family members living with these patients and compare measured doses with theoretical worst-case scenario estimates. Methods and Materials: Exposure-rate measurements were taken at 1 m from the patient by using a calibrated low-energy survey meter. Landauer (Landauer Inc., Glenwood, IL) Luxel badges, with sensitivity of 0.01 mSv, were given to family members to wear after the implantation. Badge readings for 33 spouses and 28 other family members were used to estimate effective doses, and these were compared with theory. Results: Average preimplantation planning target volume from computed tomography was 50.3 ml (range, 18.0-96.7 ml), and average preimplantation distance between the skin and the most anterior planning target volume margin was 0.57 cm. The average maximum exposure rate was measured to be 2.4 ± 1.1 mR/h, and average measured dose to a spouse was 0.99 ± 1.0 mSv. The calculated exposure rates and spousal doses using preimplantation computed tomography scan data overestimated those measured. Average measured family member dose (excluding spouses) was 0.20 ± 0.58 mSv. Conclusions: Based on measured and calculated spousal doses, a permanent breast seed implant using 103Pd is safe for the public. However, it is recommended that extra precautions in the way of a breast patch be used when patients with an implant will be in the vicinity of toddlers or pregnant women

  1. 125I-LSD: a high sensitivity ligand for serotonin receptors

    125I-labeled receptor ligands offer unique advantages over their 3H-labeled counterparts. Carrier-free 125I-labeled ligands can be synthesized with specific activities of up to 2170 Ci/mmol while (mono) tritium labeled ligands are limited to 29 Ci/mmol. Therefore, 125I-labeled ligands can be approximately 70-fold more sensitive than 3H-labeled ligands in detecting receptor sites. In addition, 125I-labeled ligands emit relatively energetic X-rays and γ-rays which are readily detected by gamma counting equipment. The authors report here the serotonergic binding properties of 125I-LSD the first reported 125I-labeled ligand for serotonin receptors. (Auth.)

  2. 125I disk source using charcoal activated polyurethane foam rubber mat

    Uniform 125I disk sources were prepared as a reference source to calibrate NaI(Tl) scintillation detector to measure 125I activity on a filter of air monitor in a laboratory. The base of the disk source was a charcoal activated polyurethane foam rubber mat of 75 mm in diameter, 2 mm in thickness. 125I disk sources of approximate 0.5 kBq, 1 kBq, and 10 kBq were obtained through immersing disks in ethanol solution containing Na125I of 0.5 kBq/ml, 1 kBq/ml and 10 kBq/ml, respectively, and then drying up them. The uniformity of the distribution of 125I on the disk source was estimated by analyzing the autoradiograph of the disk source using an imaging analyzer. The radioactivity of 125I was distributed uniformly on the surface of the disk source within an uncertainty of about 10%. (author)

  3. Novel Injectable Interpenetrating Polymer Network as a Semi-Permanent Injectable Implant for Soft Tissue Augmentation

    Leung, Joanne C.

    2015-01-01

    Injectable fillers have been widely used for soft tissue augmentation in cosmetic procedures, as well as minimally invasive treatment for medical conditions such as urinary and fecal incontinence, vesicoureteral reflux and vocal cord repair. The market for injectable fillers is a multibillion dollar industry worldwide, and each FDA-approved injectable filler has its own drawbacks, namely, lack of durability for temporary fillers, and difficulty in injection for semi-permanent to permanent...

  4. Binding and degradation of (/sup 125/I)human growth hormone in rat adipocytes

    Gorin, E.; Grichting, G.; Goodman, H.M.

    1984-08-01

    Iodinated human growth hormone (( /sup 125/I)hGH) binds to both specific and nonspecific sites on the surface of adipocytes isolated from the epididymal fat of normal rats. When adipocytes were incubated at 37 C with 1 nM (/sup 125/I)hGH, specific binding increased for 30-60 min and thereafter remained approximately constant as long as the hormone was present in the medium. About 90% of the /sup 125/I released was soluble in 5% trichloroacetic acid and was in the form of iodotyrosine. The rate of /sup 125/I release from specific binding sites decreased by a factor of 4 when the temperature was lowered from 37 to 17 C. Replacement of some of the sodium chloride in the buffer with 25 mM ammonium chloride had little or no effect on the amount on /sup 125/I that bound to cells when (/sup 125/I)hGH was present in the medium, but completely blocked the release of /sup 125/I from cells transferred to hormone-free medium. Ammonium chloride also significantly reduced both the release of /sup 125/I from nonspecific binding sites and the amount of /sup 125/I recovered in trichloroacetic acid-soluble form. Cloroquine, leupeptin, or colchicine nearly doubled the specific binding of (/sup 125/I)hGH after 180 min and markedly slowed the release of /sup 125/I when cells were transferred to hormone-free medium. All of these agents also significantly reduced the rate of release of /sup 125/I from nonspecific binding sites. Incubation of adipose tissue from hypophysectomized rats with ammonium chloride, leupeptin, or colchicine failed to alter the ability of GH to increase glucose oxidation, induce refractoriness, or promote lipolysis in the presence of theophylline.

  5. Influence of glucose and urea on 125I transport across an anion exchange paper membrane

    In order to study the influence of glucose and urea on the 125I transport across an anion exchange paper membrane, the transmembrane potential, the fluxes, and the concentrations of 125I, glucose and urea within the membrane were measured in the Na125I concentration-cell system containing glucose or urea. Glucose and urea increased the membrane/solution distribution of the iodide ion, but scarcely affected the diffusion process of iodide ion within the membrane

  6. Binding and degradation of [125I]human growth hormone in rat adipocytes

    Iodinated human growth hormone [( 125I]hGH) binds to both specific and nonspecific sites on the surface of adipocytes isolated from the epididymal fat of normal rats. When adipocytes were incubated at 37 C with 1 nM [125I]hGH, specific binding increased for 30-60 min and thereafter remained approximately constant as long as the hormone was present in the medium. About 90% of the 125I released was soluble in 5% trichloroacetic acid and was in the form of iodotyrosine. The rate of 125I release from specific binding sites decreased by a factor of 4 when the temperature was lowered from 37 to 17 C. Replacement of some of the sodium chloride in the buffer with 25 mM ammonium chloride had little or no effect on the amount on 125I that bound to cells when [125I]hGH was present in the medium, but completely blocked the release of 125I from cells transferred to hormone-free medium. Ammonium chloride also significantly reduced both the release of 125I from nonspecific binding sites and the amount of 125I recovered in trichloroacetic acid-soluble form. Cloroquine, leupeptin, or colchicine nearly doubled the specific binding of [125I]hGH after 180 min and markedly slowed the release of 125I when cells were transferred to hormone-free medium. All of these agents also significantly reduced the rate of release of 125I from nonspecific binding sites. Incubation of adipose tissue from hypophysectomized rats with ammonium chloride, leupeptin, or colchicine failed to alter the ability of GH to increase glucose oxidation, induce refractoriness, or promote lipolysis in the presence of theophylline

  7. Biodistribution of 125I labeled recombinant macrophage migration inhibitory factors in inflammatory model of mice

    To evaluate 125I labeled recombinant macrophage migration inhibitory factors (rMIF) for the scintigraphic imaging of inflammation, rMIF was labeled with 125I by Iodo- gen method. 125I-rMIF was isolated by Sephadex G25 column. The stability, immune specificity of 125I-rMIF and its biodistribution in inflammatory model of mice were studied. The labeling yield of 125I-rMIF was 96.5%. It was stable within 48 h at room temperature. The biodistribution results showed that the 125I-rMIF was metabolized by the liver, the radioactivity clearance mainly happened in the kidney and the speed of the blood clearance was rapid. After caudal vein iniection with 125I-rMIF, the ratio of radioactivity uptake between inflammatory limb (target) and contra lateral healthy limb (non target)(T/NT) were 1.42, 1.35, 2.18 and 2.05 at 0.5, 1, 6, 24 h respectively. 125I-rMIF had the capability of locating the inflammatory foci. The advance of it is more obviously at the late stage than that at the early stage. 125I-rMIF may be a potential agent for the diagnosis of concealed and subacute inflammatory disease. (authors)

  8. First report of a permanent breast 103Pd seed implant as adjuvant radiation treatment for early-stage breast cancer

    Purpose: A new technique of adjuvant partial breast irradiation using 103Pd permanent breast seed implants (PBSI) is presented. The procedure is performed in a single 1-hour session under local anesthesia. Methods and Materials: Patients referred to a single institution for adjuvant radiotherapy after lumpectomy for an infiltrating ductal carcinoma ≤3 cm in diameter, surgical margin ≥2 mm, no extensive in situ carcinoma, no lymphovascular invasion, and minimal or negative lymph node involvement were offered a PBSI. Results: Between May and December 2004, 31 eligible patients underwent CT scan and ultrasound simulations assessing PBSI feasibility. Fifteen were excluded because of feasibility issues, and 16 received PBSI. A minimal peripheral dose of 90 Gy was prescribed to the planning target volume corresponding to the clinical target volume identified on the CT scan plus a margin of 1 cm. The procedure was well tolerated; 56% of the patients reported no pain during the procedure, and 46% of the patients developed National Cancer Institute Common Toxicity Criteria Grade 1 acute reaction. None experienced toxicity Grade 2 or 3. Conclusions: Permanent breast seed implantation seems feasible and well tolerated on these preliminary clinical data and represents an ultimate step in the reduction of treatment fraction for partial breast irradiation

  9. 125I brachytherapy in the palliation of painful bone metastases from lung cancer after failure or rejection of conventional treatments

    Gilani, Saba; Zhong, Zhihui; Zhang, Tao; Zhang, Fujun; Gao, Fei

    2016-01-01

    Purpose This study sought to assess the safety and effect of 125I seed implantation for palliation of painful bone metastases from lung cancer after failure or rejection of conventional treatments. Materials and Methods 89 patients with painful bone metastases secondary to lung cancer were consented and enrolled in this study from June 2013 to May 2015. All patients had failed or refused conventional treatments underwent percutaneous CT-guided 125I seed implantation. The Brief Pain Inventory (BPI) was used to measure pain intensity prior to treatment (T0), 2, 4, 6, 8 and 12 weeks (T2, T4, T6, T8 and T12) after treatment in a 24-hour period. Analgesic, quality of life (QOL) scores and complications were also recorded. Four patients were excluded as they were lost to follow-up or had incomplete data. Results 85 patients with 126 bone metastases from lung cancer were treated. There were significantly lower scores after treatment in the visual analog scale (VAS) and analgesic. The VAS scores for worst pain was 6.3±1.8 at T0. At T2, T4, T6, T8 and T12, the score in a 24-hour period decreased to 4.9±1.2 (Pmetastases from lung cancer after failure or rejection of conventional treatments. PMID:26919235

  10. Determination of the specific activity of carrier-free 125I preparations by neutron activation analysis

    Heydorn, Kaj

    Chemical methods are unsuitable for the determination of the specific activity of commerical125I preparations because of the unknown chemical state of the iodine in solutions more than a few weeks old.125I and127I were determined in samples from seven different manufacturers by instrumental neutron...

  11. Digital monitor of 125I in thyroid glands of human being

    A new digital monitor of 125I in thyroid glands is described. This instrument is used to measure the activity of 125I in thyroid glands of human being directly, rapidly, and accurately. Furthermore, it can calculate and display the intake, committed dose equivalent and committed effective dose equivalent

  12. Evaluation of murine placental degradation and transfer of [125I]iodo-epidermal growth factor

    Since epidermal growth factor (EGF) has been postulated to play a role in embryonic and fetal growth, a study was undertaken to assess the placental degradation and transfer of maternally administered EGF. Approximately 5 ng of purified [125I]iodo-EGF were injected iv into day 10, day 13, or day 17 pregnant CD-1 mice; radioactivity in plasma, placentas, and conceptuses was measured up to 2 h after injection. The time course analysis revealed an initial rapid decline in total plasma radioactivity followed by an increase that was maximal by approximately 30 min. Gel filtration (G-15, G-50) chromatography of plasma revealed that by 5 min, radioactivity was associated with free 125I and with material much larger than EGF. No apparent degradation of [125I]iodo-EGF occurred after direct incubation with maternal plasma. Placental radioactivity had an initial phase of decay between 1 and 5 min followed by an increase that became maximal between 30 and 60 min. Extracts of placentas made with 4 M urea in 0.2 M Tris-HCl, pH 8.0, and taken 1-30 min after injection revealed radioactivity coeluting predominantly with [125I]iodo-EGF at 1 min but shifting to mostly free 125I by 30 min. Uptake of radioactivity by conceptuses was not evident until about 15 min, and only free 125I was detected in extracts; the same results were obtained when 5 micrograms unlabeled EGF were injected simultaneously with [125I]iodo-EGF. Incubation of placental mince with [125I]iodo-EGF yielded [125I]MIT as the apparent major radioactive degradation product. Formation of [125I]MIT in vitro was both time- and temperature-dependent. At 37 C, marked formation of [125I]MIT was observed; at 22 C, only a negligible amount was formed after incubation of mince with [125I]iodo-EGF for 60 min. Incubation of [125I]iodo-EGF with kidney mince yielded predominantly free 125I

  13. Preimplant factors affecting postimplant CT-determined prostate volume and the CT/TRUS volume ratio after transperineal interstitial prostate brachytherapy with 125I free seeds

    The aim was to identify preimplant factors affecting postimplant prostate volume and the increase in prostate volume after transperineal interstitial prostate brachytherapy with 125I free seeds. We reviewed the records of 180 patients who underwent prostate brachytherapy with 125I free seeds for clinical T1/T2 prostate cancer. Eighty-one (45%) of the 180 patients underwent neoadjuvant hormonal therapy. No patient received supplemental external beam radiotherapy. Postimplant computed tomography was undertaken, and postimplant dosimetric analysis was performed. Univariate and multivariate analyses were performed to identify preimplant factors affecting postimplant prostate volume by computed tomography and the increase in prostate volume after implantation. Preimplant prostate volume by transrectal ultrasound, serum prostate-specific antigen, number of needles, and number of seeds implanted were significantly correlated with postimplant prostate volume by computed tomography. The increase in prostate volume after implantation was significantly higher in patients with neoadjuvant hormonal therapy than in those without. Preimplant prostate volume by transrectal ultrasound, number of needles, and number of seeds implanted were significantly correlated with the increase in prostate volume after implantation. Stepwise multiple linear regression analysis showed that preimplant prostate volume by transrectal ultrasound and neoadjuvant hormonal therapy were significant independent factors affecting both postimplant prostate volume by computed tomography and the increase in prostate volume after implantation. The results of the present study show that preimplant prostate volume by transrectal ultrasound and neoadjuvant hormonal therapy are significant preimplant factors affecting both postimplant prostate volume by computed tomography and the increase in prostate volume after implantation

  14. Experimental and clinical treatment of bladder cancer with 125I-iododeoxyuridine

    Radionuclide can cause auger effect through disintegration low-energy electron (125I-iododeoxyuridine (125I-UdR) is an efficient carrier inducting 125I to cell nucleolus, it is incorporated into DNA specificity only in S-phase cells. A series of studies show that 125I can absorb more likely to tumor cells, instead of the normal cell division, thus effectively splitting radiotherapy of malignant lesions. As bladder is a natural lumen, it has a unique easy perfusion and observational. 125I-UdR can kill effiently and selectively the cells of bladder turnout, reducing markedly the ratio of its recurrence of surgical treatment of patients with bladder cancer, so as to improve the survival rate. It can be used as a surgical adjuvant treatment method, is expected to be a safe, efficient and less adverse reaction the new therapies for bladder cancer treatment. (authors)

  15. Method of separating (125I)-L-thyroxine from mixture obtained by radioiodination

    (125I)-L-thyroxine is separated by gel filtration on a column from the mixture of (125I)-L-thyroxine, (125I)-L-3,5,3'-triiodothyronine and (125I)-. The column is packed with a non-polar gel such as polydextran with particle size 25 to 100 μm. The mixture 1,2-propanediol/distilled water/concentrated (26%) aqueous ammonia solution, or 1,2-propanediol/concentrated (26%) aqueous ammonia solution is used as eluent. The concentration of the eluate containing (125I)-L-thyroxine is adjusted with distilled water such as to establish a 50 vol.% concentration of 1,2-propanediol. (E.S.)

  16. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer

    Purpose/Objective: To develop and disseminate the American Brachytherapy Society (ABS) recommendations for the clinical quality assurance and guidelines of permanent transperineal prostate brachytherapy with 125I or 103Pd. Methods and Materials: The ABS formed a committee of experts in prostate brachytherapy to develop consensus guidelines through a critical analysis of published data supplemented by their clinical experience. The recommendations of the panels were reviewed and approved by the Board of Directors of the ABS. Results: Patients with high probability of organ-confined disease are appropriately treated with brachytherapy alone. Brachytherapy candidates with a significant risk of extraprostatic extension should be treated with supplemental external beam radiation therapy (EBRT). Patient selection guidelines were developed. Dosimetric planning of the implant should be carried out for all patients before seed insertion. A modified peripheral loading is preferred. The AAPM TG-43 recommendations requiring a change in prescription dose for 125I sources should be universally implemented. The recommended prescription doses for monotherapy are 145 Gy for 125I and 115-120 Gy for 103Pd. The corresponding boost doses (after 40-50 Gy EBRT) are 100-110 Gy and 80-90 Gy, respectively. Clinical evidence to guide selection of radionuclide (103Pd or 125I) is lacking. Post implant dosimetry and evaluation must be performed on all patients. It is suggested that the dose that covers 90% (D90) and 100% (D100) of the prostate volume and the percentage of the prostate volume receiving the prescribed dose (V100) be obtained from a dose-volume histogram (DVH) and reported. Conclusion: Guidelines for appropriate patient selection, dose reporting, and improved quality of permanent prostate brachytherapy are presented. These broad recommendations are intended to be technical and advisory in nature, but the ultimate responsibility for the medical decisions rests with the treating

  17. Postimplantation dosimetric analysis of permanent transperineal prostate implantation: improved dose distributions with an intraoperative computer-optimized conformal planning technique

    Purpose: To compare the target coverage and dose to normal tissues after I-125 transperineal permanent implantation (TPI) of the prostate in 90 patients treated with one of three different transperineal techniques. Methods and Materials: Detailed postimplant dosimetric evaluations of permanent I-125 implantation procedures were performed on 30 consecutive patients treated between 1995-1996 who underwent TPI using a preplanning CT-based technique, on 30 consecutive patients treated in 1997-1998 who underwent an ultrasound-guided approach with intraoperative determination of seed distribution based on an I-125 nomogram, and on 30 consecutive patients in 1998-1999 who underwent TPI with intraoperative computer-based 3-dimensional conformal optimization. For all three techniques, postimplant CT scans were obtained 4-6 hours after TPI. Dosimetric parameters included V100, V90, V150, D100, D90, D80, as well as maximal and average doses to the urethra and rectal wall. These parameter outcomes are reported as a percentage of the prescription dose. Results: The intraoperative 3D-optimized technique (I-3D) provided superior target coverage with the prescription dose for all dosimetric variables evaluated compared to the other treatment techniques. The median V100, V90, and D90 values for the I-3D technique were 96%, 98%, and 116%, respectively. In contrast, the V100, V90, and D90 values for the CT preplan and ultrasound manual optimization approaches were 86%, 89%, and 88%, respectively and 88%, 92%, and 94%, respectively (I-3D versus other techniques: p < 0.001). The superior target coverage with the I-3D technique was also associated with a higher cumulative implant activity required by the optimization program. A multivariate analysis determined that the treatment technique (I-3D versus other approaches) was an independent predictor of improved target coverage for each parameter analyzed (p < 0.001). In addition, higher cumulative implant activities and smaller prostate

  18. Side effects of permanent I125 prostate seed implants in 667 patients treated in Leeds

    Purpose: To report the side effects and complications after I-125 seeds prostate implant after 8.5 years experience. Methods and materials: Six hundred and sixty seven (667) patients were treated between March 1995 and December 2001. The median follow up is 31 months with a maximum of 98.2 months. Morbidity data were collected from a review of patient case-notes. Patients also provided prospective data on urinary symptoms using the International Prostate Symptom Score (IPSS) scoring chart before treatment and at regular follow up. Patients were also sent a questionnaire detailing symptoms and side effects following their brachytherapy. This enabled them to record urinary, bowel and sexual function side effects independently. Logistic regression analysis was carried out to identify the risk of catheterisation in relation to the pre-implant prostate volume and potential implant factors such as the number of seeds and needles and implant dose. Result: The urinary symptom score rises in the first few months after implantation and returns to within one or two points of the pre-treatment score within one year. Nine patients reported incontinence prior to treatment and 15, 12 and 10 patients reported incontinence 6, 12 and 24 months after treatment, respectively. Catheterisation was reported in 97 (14.5%) patients. At six months 84.9% of patients reported no change in bowel function and 78.9% at 12 months. 6.4% of patients complained of some increased bowel frequency at 6 months and 5.7% at 12 months. 402 (77.2%) patients reported being fully potent before treatment and that this fell to 32.4% after treatment. Logistic regression showed that the most significant factors which correlate with the probability of catheterisation are the pre-treatment prostate volume and the number of seeds and needles implanted. Conclusion: The side effects and complications after prostate brachytherapy as reported here and elsewhere confirm that the treatment is not only convenient but also

  19. Development of procedure using plasma welding process to produce {sup 125}I seeds; Desenvolvimento de procedimento utilizando processo de soldagem plasma para confeccao de sementes de {sup 125}I

    Feher, Anselmo

    2006-07-01

    The prostate cancer, which is the second cause of death by cancer in men, overcome only by lung cancer, is a problem of public health in Brazil. Brachytherapy is among the possible available treatments for prostate cancer, in which small seeds containing {sup 125}I radioisotope are implanted in the prostate. The seed consists of a titanium sealed capsule with 0.8 mm external diameter and 4.5 mm length, containing a central silver wire with adsorbed {sup 125}I. The plasma arc welding is one of the viable techniques for the sealing process. The equipment used in this technique is less costly than in other processes. The main objective of this work was the development and the validation of the welding procedure using plasma welding process and the elaboration of a sealing routine according to Good Manufacturing Practices. The development of this work has presented the following phases: cut and cleaning of the titanium material, determination of the welding parameters, development of a device for holding the titanium tube during the welding process, validation of sealed sources according to ISO 2919 Sealed Radioactive Sources - General Requirements and Classification, leakage test according to ISO 9978 Sealed Radioactive Sources - Leakage Test Methods and metallographic assays. The developed procedure, to seal {sup 125}I seeds using plasma welding process, has shown to be efficient, satisfying all the established requirements of ISO 2919. The results obtained in this work have given the possibility to establish a routine production process according to the orientations presented in resolution RDC number 59 - Good Manufacturing Practices do Medical Products of the ANVISA - Brazilian Nacional Agency of Sanitary Surveillance. (author)

  20. Bone Marrow Derived Adult Stem Cell Implantation: A Possible Permanent Treatment Modality for Type 2 Diabetics

    R.S. KAHLON; M.K. Manchanda; P. KANWAL

    2011-01-01

    Introduction: Diabetes is one of the most prevalent chronic disease that exists in the world. Type 2Diabetes is the predominant type of diabetes. Management is basically limited to exercise, diet and oralhypoglycemic drugs before insulin therapy has to be instituted. But bone marrow derived stem cellimplantation into the islets has shown very encouraging results for diabetics.Methods: Bone marrow derived stem cells when implanted in the pancreas leads to regeneration ofinsulin producing Beta ...

  1. (125I)Iodoazidococaine, a photoaffinity label for the haloperidol-sensitive sigma receptor

    A carrier-free radioiodinated cocaine photoaffinity label, (-)-3-(125I)iodo-4-azidococaine [(125I)IACoc], has been synthesized and used as a probe for cocaine-binding proteins. Photoaffinity labeling with 0.5 nM (125I)IACoc resulted in selective derivatization of a 26-kDa polypeptide with the pharmacology of a sigma receptor in membranes derived from whole rat brain, rat liver, and human placenta. (125I)IACoc labeling of the 26-kDa polypeptide was also inhibited by 10 μM imipramine, amitriptyline, fluoxetine, benztropine, and tetrabenazine. The size of the (125I)I-ACoc-labeled proteins is consistent with the size of proteins photolabeled in guinea pig brain and liver membranes by using the sigma photolabel azido-[3H]DTG. Kinetic analysis of (125I)IACoc binding to rat liver microsomes revealed two sites with Kd values of 19 and 126 pM, respectively. The presence or absence of proteolytic inhibitors during membrane preparation did not alter the size of the photolabeled sigma receptor, indicating that the 26-kDa polypeptide was not derived from a larger protein. In summary, (125I)IACoc is a potent and highly specific photoaffinity label for the haloperidol-sensitive sigma receptor and will be useful for its biochemical and molecular characterization

  2. Exploration of dopamine transporter and D2 receptors in morphine dependent rats through 125I-β-CTT, 125I-IBZM cerebral autoradiography and the biodistribution study

    Objective: To explore the variation of cerebral dopamine (DA) transmitting system in morphine dependent (MD) rats using dopamine transporter (DAT) and D2 receptors imaging agent. Methods: MD model rats were established by using a two-compartment (C1 and C2-morphine conditioned compartment) apparatus for assessing morphine conditioned place preferences in rats. 125I-2β-carbomethoxy-3β-(4-iodophenyl) tropane (125I-β-CIT) and 125I-3-iodo-2-hydroxy-6-methoxy-N[(1-ethyl-2-pyrrolidinyl) methyl] benzamide (125I-IBZM) cerebral DAT and D2 receptor autoradiography and biodistribution study were used to evaluate the variation of DAT and D2 receptors in morphine dependent rats. Results: The mean time of MD rats entering from C1 to C2 was (0.84 +- 0.50) min after 6 days' conditioned place preference training, shorter than that of the control group [(2.40 +- 1.10) min, P 125I-β-CIT uptake ratio of striatum (ST)/cerebellum (CB) and nucleus acumens (NAC)/CB in MD group were 4.76 +- 0.92 and 2.72 +- 0.96, significantly lower than that of control group (5.92 +- 0.67 and 4.16 +- 0.56, P 125I-IBZM uptake ratio in MD group were 4.11 +- 0.56 and 2.64 +- 0.25, lower than that in control group (5.43 +- 0.74 and 3.49 +- 0.65, P 125I-β-CIT, 125I-IBZM biodistribution study also showed that the DAT and D2 binding sites were reduced in ST of MD group by (21.68 +- 11.11)% and (18.69 +- 9.97)% comparing to the controls, respectively. Conclusions: The DAT and D2 receptors in both ST and NAC were all involved and reduced to some extent in morphine dependent model rats, the DAT and D2 receptor imaging agent could reflect the variation of DAT and D2receptors, this would afford the theoretical basis for D2 receptors and DAT imaging in study on preventing drug addiction and on its abstinence

  3. Permanent prostate implant using high activity seeds and inverse planning with fast simulated annealing algorithm: A 12-year Canadian experience

    Purpose: To report outcomes and toxicity of the first Canadian permanent prostate implant program. Methods and Materials: 396 consecutive patients (Gleason ≤6, initial prostate specific antigen (PSA) ≤10 and stage T1-T2a disease) were implanted between June 1994 and December 2001. The median follow-up is of 60 months (maximum, 136 months). All patients were planned with fast-simulated annealing inverse planning algorithm with high activity seeds ([gt] 0.76 U). Acute and late toxicity is reported for the first 213 patients using a modified RTOG toxicity scale. The Kaplan-Meier biochemical failure-free survival (bFFS) is reported according to the ASTRO and Houston definitions. Results: The bFFS at 60 months was of 88.5% (90.5%) according to the ASTRO (Houston) definition and, of 91.4% (94.6%) in the low risk group (initial PSA ≤10 and Gleason ≤6 and Stage ≤T2a). Risk factors statistically associated with bFFS were: initial PSA >10, a Gleason score of 7-8, and stage T2b-T3. The mean D90 was of 151 ± 36.1 Gy. The mean V100 was of 85.4 ± 8.5% with a mean V150 of 60.1 ± 12.3%. Overall, the implants were well tolerated. In the first 6 months, 31.5% of the patients were free of genitourinary symptoms (GUs), 12.7% had Grade 3 GUs; 91.6% were free of gastrointestinal symptoms (GIs). After 6 months, 54.0% were GUs free, 1.4% had Grade 3 GUs; 95.8% were GIs free. Conclusion: The inverse planning with fast simulated annealing and high activity seeds gives a 5-year bFFS, which is comparable with the best published series with a low toxicity profile

  4. Incidence of seed migration to the chest, abdomen, and pelvis after transperineal interstitial prostate brachytherapy with loose 125I seeds

    The aim was to determine the incidence of seed migration not only to the chest, but also to the abdomen and pelvis after transperineal interstitial prostate brachytherapy with loose 125I seeds. We reviewed the records of 267 patients who underwent prostate brachytherapy with loose 125I seeds. After seed implantation, orthogonal chest radiographs, an abdominal radiograph, and a pelvic radiograph were undertaken routinely to document the occurrence and sites of seed migration. The incidence of seed migration to the chest, abdomen, and pelvis was calculated. All patients who had seed migration to the abdomen and pelvis subsequently underwent a computed tomography scan to identify the exact location of the migrated seeds. Postimplant dosimetric analysis was undertaken, and dosimetric results were compared between patients with and without seed migration. A total of 19,236 seeds were implanted in 267 patients. Overall, 91 of 19,236 (0.47%) seeds migrated in 66 of 267 (24.7%) patients. Sixty-nine (0.36%) seeds migrated to the chest in 54 (20.2%) patients. Seven (0.036%) seeds migrated to the abdomen in six (2.2%) patients. Fifteen (0.078%) seeds migrated to the pelvis in 15 (5.6%) patients. Seed migration occurred predominantly within two weeks after seed implantation. None of the 66 patients had symptoms related to the migrated seeds. Postimplant prostate D90 was not significantly different between patients with and without seed migration. We showed the incidence of seed migration to the chest, abdomen and pelvis. Seed migration did not have a significant effect on postimplant prostate D90

  5. Combination of bilateral pelvic lymphadenectomy, permanent iodine-125 implantation, and percutaneous irradiation of the locally confined prostatic cancer. Pt. 1

    Since the beginning of 1981, 32 patients at an age of 52 to 72 years who suffered from a locally confined adenocarcinoma of the prostate were treated by permanent implantation of I-125 seeds. 25 patients were evaluated after a median observation period of 30 months. The first group consisting of 19 patients was submitted to a combined percutaneous and interstitial treatment, the other 6 patients were initially treated only by interstitial therapy because of severe complications observed in the meantime. After bilateral pelvic staging lymphadenectomy, permanent I-125 seeds were implanted into the patients of stage T1, T2, early T3 and pN0-1, in case of microscopic lymph node manifestation without capsular perforation also into patients of stage pN2 and pN4. 8 weeks later the patients received a moving beam irradiation with 10 MV photons at the linear accelerator. The centre of the prostate was faded out by a specially constructed H absorber in such a way that the prescribed target dose of 36 Gy in 4 weeks to the 90%-isodose was only applied to a spherical surface around the implant. 1 patient died perioperatively from an embolism due to phlebothrombosis of the thigh. 22 out of the other 24 patients are in complete remission, 1 patient had a local recurrence in the right seminal vesicle which appeared 28 months after primary therapy, and 1 patient developed skeletal metastases. The objective side effects and late complications of our combined treatment are considerable with respect to their incidence as well as their severity: a slight or medium radioproctitis was found after a latent period of 1 to 2 years in 28% (5/18) of cases, after a latent time of about 1 1/2 to 2 years another 28% (5/18) developed subsequently to a proctitis an urethral stricture and an ulcer situated on the anterior rectum wall facing the prostate, and 4 patients presented finally a prostato-rectal fistula. (orig.)

  6. Effect of fentanyl on 125I-β-CIT uptake in mice brain

    Objective: To investigate the effect of fentanyl on 125I-2β-carbomethoxy-3β-(4-iodophenyl) tropane (125I-β-CIT) uptake in mice brain. Methods: 1) KM mice groups of five were given different doses of fentanyl, and 10 min or 1 h later were given a dose of 125I-β-CIT. 2)Two groups of animals were killed at 2 h after injection of 125I-β-CIT. 3)One group of animals were killed at 1 h after injection of 125I-β-CIT. Results: 1)In the striatum, frontal cortex, hippocampus, brain stem, cerebellum and whole brain, a dose-dependent increase in uptake (%ID/g or %ID) of 125I-β-CIT was detected at the fentanyl doses ranging from 125 to 300 μg/kg, and the uptakes of hippocampus and cerebellum were higher than that of the controls. There was a great difference in the value of %ID/g or %ID between the group treated with 250 μg/kg fentanyl and the control group; while at the doses from 12.5 to 100 μg/kg, a dose-dependent decrease in uptake in the same regions was observed and all the uptake levels were lower (hippocampus: except 62.5 and 12.5 μg/kg groups; brain stem: except 62.5 μg/kg group) than that of the controls. 2)The uptakes of 125I-β-CIT in the striatum, frontal cortex, hippocampus, brain stem, cerebellum and whole brain in the groups injected with 125I-β-CIT 10 min after fentanyl treatment were higher than that in the groups injected with 125I-β-CIT 1 h after fentanyl treatment. 3)The binding of 125I-β-CIT in the striatum, frontal cortex, hippocampus, brain stem, cerebellum and whole brain in the groups killed at 1 h after injection of 125I-β-CIT was higher than that in the control group, but without significant difference. Conclusion: Fentanyl may have different effects on 125I-β-CIT at various time points and doses

  7. In vivo study about specific captation of 125 I-insulin by rat brain structures

    The specific captation of 125 I-insulin was evaluated by brain structures, as olfactory bulbous, hypothalamus and cerebellum in rats, from in vivo experiences that including two different aspects: captation measure of 125 I-insulin after the intravenous injection of the labelled hormone, in fed rats and in rats with 48 h of fast or convulsion, procedure by the pentylene tetrazole; captation measure of 125 I-insulin after intra-cerebral-ventricular injection of the labelled hormone in fed rats. (C.G.C.)

  8. OER and RBE for 125I and 192Ir at low dose rate on mammalian cells

    The oxygen enhancement ratio (OER) for 125I and 192Ir as well as the relative biological effectiveness (RBE) at low dose rates (40-80 cGy h-1) were determined for B16 melanoma cells in culture. The OER was found to be 2.1±0.03 for 125I and 2.7±0.04 for 192Ir. The RBE for 125I relative to 192Ir was determined as 1.8±0.03 under aerated conditions and as 2.4±0.03 under hypoxia. 18 refs.; 5 figs.; 1 table

  9. Efficient radiolabeling of rutin with 125I and biodistribution study of radiolabeled rutin

    The purpose of the current research is to synthesize radiolabeled rutin for biodistribution study and SPECT/CT image of rutin. The optimized radiolabeling condition provided 125I-labeled rutin with 53.5 % of radiochemical yield. Most of orally administered 125I-labeled rutin was initially found in the stomach and small intestine and a portion of the product was then distributed in internal organs. While intravenously injected 125I-labeled rutin was accumulated in liver and then a large part of it was transferred to small intestine. The present results provided an efficient radiolabeling method of flavonoid glycoside as well as quantitative organ distribution of rutin. (author)

  10. Improvement Of The Absolute Activity Determination Technique Of '125I In The Thyroid

    A method for absolute determination of the activity of a 125I source based on the counting rate values of the 27 keV photons and the 54 keV coincidence photo-peak is given in the literature. We had shown in previous works, that this method, within certain limitations, diminishes the geometry dependence of the activity determination for 125I sources and for measuring the uptake of 125I in human thyroid. In the present work we present a farther improvement of the accuracy of the absolute determination method

  11. m-[125I]iodoaniline: a useful reagent for radiolabeling biotin

    Biotinyl-m-[125I]iodoanilide (BIA) was synthesized by coupling biotin to m-[125I]iodoaniline via a mixed anhydride reaction. m-[125I]Iodoaniline was produced from the tin precursor, which was prepared using a palladium catalyzed reaction of hexabutylditin with m-bromoaniline. The radioiodinated BIA derivative is characterized by a stable amide and/or intact ureido group on the biotin molecule, it may thus be a useful carrier for targeting radionuclides to avidin-conjugated antibodies previously localized on tumors. (author)

  12. Metabolism of 125I-labelled trypsin in man: evidence of recirculation.

    Lake-Bakaar, G; Rubio, C E; McKavanagh, S; Potter, B. J.; Summerfield, J A

    1980-01-01

    125I-labelled human trypsin metabolism has been investigated in man. Three subjects received 125I-trypsin and 131I-albumin intravenously. Against a background secretin infusion (1 U/kg/h), trypsin decayed biexponentially from the serum with half-lives of 17.5, 21, and 24 minutes for the rapid disappearance phase and 520, 540, and 560 minutes for the slow phase. Between 13% and 38% of the 125I injected was recovered from duodenal juice aspirated continously over 300 minutes. In contrast, less ...

  13. Distribution and levels of [125I]IGF-I, [125I]IGF-II and [125I]insulin receptor binding sites in the hippocampus of aged memory-unimpaired and -impaired rats

    The insulin-like growth factors (IGF-I and IGF-II) and insulin are localized within distinct brain regions and their respective functions are mediated by specific membrane receptors. High densities of binding sites for these growth factors are discretely and differentially distributed throughout the brain, with prominent levels localized to the hippocampal formation. IGFs and insulin, in addition to their growth promoting actions, are considered to play important roles in the development and maintenance of normal cell functions throughout life. We compared the anatomical distribution and levels of IGF and insulin receptors in young (five month) and aged (25 month) memory-impaired and memory-unimpaired male Long-Evans rats as determined in the Morris water maze task in order to determine if alterations in IGF and insulin activity may be related to the emergence of cognitive deficits in the aged memory-impaired rat. In the hippocampus, [125I]IGF-I receptors are concentrated primarily in the dentate gyrus (DG) and the CA3 sub-field while high amounts of [125I]IGF-II binding sites are localized to the pyramidal cell layer, and the granular cell layer of the DG. [125I]insulin binding sites are mostly found in the molecular layer of the DG and the CA1 sub-field. No significant differences were found in [125I]IGF-I, [125I]IGF-II or [125I]insulin binding levels in any regions or laminae of the hippocampus of young vs aged rats, and deficits in cognitive performance did not relate to altered levels of these receptors in aged memory-impaired vs aged memory-unimpaired rats. Other regions, including various cortical areas, were also examined and failed to reveal any significant differences between the three groups studied.It thus appears that IGF-I, IGF-II and insulin receptor sites are not markedly altered during the normal ageing process in the Long-Evans rat, in spite of significant learning deficits in a sub-group (memory-impaired) of aged animals. Hence, recently reported

  14. Isotope and Patient Age Predict for PSA Spikes After Permanent Prostate Brachytherapy

    Purpose: To evaluate prostate-specific antigen (PSA) spikes after permanent prostate brachytherapy in low-risk patients. Methods and Materials: The study population consisted of 164 prostate cancer patients who were part of a prospective randomized trial comparing 103Pd and 125I for low-risk disease. Of the 164 patients, 61 (37.2%) received short-course androgen deprivation therapy. The median follow-up was 5.4 years. On average, 11.1 post-treatment PSA measurements were obtained per patient. Biochemical disease-free survival was defined as a PSA level of ≤0.40 ng/mL after nadir. A PSA spike was defined as an increase of ≥0.2 ng/mL, followed by a durable decline to prespike levels. Multiple parameters were evaluated as predictors for a PSA spike. Results: Of the 164 patients, 44 (26.9%) developed a PSA spike. Of the 46 hormone-naive 125I patients and 57 hormone-naive 103Pd patients, 21 (45.7%) and 8 (14.0%) developed a PSA spike. In the hormone-naive patients, the mean time between implantation and the spike was 22.6 months and 18.7 months for 125I and 103Pd, respectively. In patients receiving neoadjuvant androgen deprivation therapy, the incidence of spikes was comparable between isotopes (125I 28.1% and 103Pd 20.7%). The incidence of spikes was substantially different in patients 125I and/or <65 years of age. Differences in isotope-related spikes are most pronounced in hormone-naive patients

  15. SU-E-J-166: Sensitivity of Clinically Relevant Dosimetric Parameters to Contouring Uncertainty During Post Implant Dosimetry of Prostate Permanent Seed Implants

    Mashouf, S [Sunnybrook Odette Cancer Centre, Toronto, ON (Canada); University of Toronto, Dept. of Radiation Oncology, Toronto, ON (Canada); Ravi, A; Morton, G; Song, W [Sunnybrook Odette Cancer Centre, Toronto, ON (Canada); University of Toronto, Dept. of Radiation Oncology, Toronto, ON (Canada); Sunnybrook Research Institute, Toronto, ON (Canada)

    2015-06-15

    Purpose: There is a strong evidence relating post-implant dosimetry for permanent seed prostate brachytherpy to local control rates. The delineation of the prostate on CT images, however, represents a challenge as it is difficult to confidently identify the prostate borders from soft tissue surrounding it. This study aims at quantifying the sensitivity of clinically relevant dosimetric parameters to prostate contouring uncertainty. Methods: The post-implant CT images and plans for a cohort of 43 patients, who have received I–125 permanent prostate seed implant in our centre, were exported to MIM Symphony LDR brachytherapy treatment planning system (MIM Software Inc., Cleveland, OH). The prostate contours in post-implant CT images were expanded/contracted uniformly for margins of ±1.00mm, ±2.00mm, ±3.00mm, ±4.00mm and ±5.00mm (±0.01mm). The values for V100 and D90 were extracted from Dose Volume Histograms for each contour and compared. Results: The mean value of V100 and D90 was obtained as 92.3±8.4% and 108.4±12.3% respectively (Rx=145Gy). V100 was reduced by −3.2±1.5%, −7.2±3.0%, −12.8±4.0%, −19.0±4.8%, − 25.5±5.4% for expanded contours of prostate with margins of +1mm, +2mm, +3mm, +4mm, and +5mm, respectively, while it was increased by 1.6±1.2%, 2.4±2.4%, 2.7±3.2%, 2.9±4.2%, 2.9±5.1% for the contracted contours. D90 was reduced by −6.9±3.5%, −14.5±6.1%, −23.8±7.1%, − 33.6±8.5%, −40.6±8.7% and increased by 4.1±2.6%, 6.1±5.0%, 7.2±5.7%, 8.1±7.3% and 8.1±7.3% for the same set of contours. Conclusion: Systematic expansion errors of more than 1mm may likely render a plan sub-optimal. Conversely contraction errors may Result in labeling a plan likely as optimal. The use of MRI images to contour the prostate should results in better delineation of prostate organ which increases the predictive value of post-op plans. Since observers tend to overestimate the prostate volume on CT, compared with MRI, the impact of the

  16. SU-E-J-166: Sensitivity of Clinically Relevant Dosimetric Parameters to Contouring Uncertainty During Post Implant Dosimetry of Prostate Permanent Seed Implants

    Purpose: There is a strong evidence relating post-implant dosimetry for permanent seed prostate brachytherpy to local control rates. The delineation of the prostate on CT images, however, represents a challenge as it is difficult to confidently identify the prostate borders from soft tissue surrounding it. This study aims at quantifying the sensitivity of clinically relevant dosimetric parameters to prostate contouring uncertainty. Methods: The post-implant CT images and plans for a cohort of 43 patients, who have received I–125 permanent prostate seed implant in our centre, were exported to MIM Symphony LDR brachytherapy treatment planning system (MIM Software Inc., Cleveland, OH). The prostate contours in post-implant CT images were expanded/contracted uniformly for margins of ±1.00mm, ±2.00mm, ±3.00mm, ±4.00mm and ±5.00mm (±0.01mm). The values for V100 and D90 were extracted from Dose Volume Histograms for each contour and compared. Results: The mean value of V100 and D90 was obtained as 92.3±8.4% and 108.4±12.3% respectively (Rx=145Gy). V100 was reduced by −3.2±1.5%, −7.2±3.0%, −12.8±4.0%, −19.0±4.8%, − 25.5±5.4% for expanded contours of prostate with margins of +1mm, +2mm, +3mm, +4mm, and +5mm, respectively, while it was increased by 1.6±1.2%, 2.4±2.4%, 2.7±3.2%, 2.9±4.2%, 2.9±5.1% for the contracted contours. D90 was reduced by −6.9±3.5%, −14.5±6.1%, −23.8±7.1%, − 33.6±8.5%, −40.6±8.7% and increased by 4.1±2.6%, 6.1±5.0%, 7.2±5.7%, 8.1±7.3% and 8.1±7.3% for the same set of contours. Conclusion: Systematic expansion errors of more than 1mm may likely render a plan sub-optimal. Conversely contraction errors may Result in labeling a plan likely as optimal. The use of MRI images to contour the prostate should results in better delineation of prostate organ which increases the predictive value of post-op plans. Since observers tend to overestimate the prostate volume on CT, compared with MRI, the impact of the

  17. Preparation and characterization of 125I-labelled proinsulin for radioimmunoassay (Preprint No. CT-62)

    Bovine proinsulin is iodinated with 125I. The labelled proinsulin was purified over sephadex. The preparation was characterized for stability and immunoreactivity. A radioimmunoassay was standardized using this labelled preparation. (author)

  18. Radioiodination of ibuprofen with 125I and its biological behavior in mice

    A procedure for radioiodination of Ibuprofen with iodine-125 is carried out via an electrophilic substitution reaction. The reaction parameters were studied Ibuprofen concentration, pH of the reaction mixture, reaction time temperature, and different oxidizing agents to optimize the conditions for the labeling of Ibuprofen to abstain a high radiochemical yield of 125I-Ibuprofen (125I-Ib up). Using 3.7 MBq of of Na 125I, 100μg of ibuprofen as substrate and 100μg of iodogen as oxidizing agent in ethanol at 60 OC for 10 min, a maximum radiochemical yield of 125I-Ib up (78%) was obtained. The labeled compound was separated and purified from inactive Ibuprofen by means of high-pressure liquid chromatography (HPLC). The biological distribution in normal and inflamed mice indicates the suitability of radioiodinated Ibuprofen for imaging of inflammation only induced with turpentine oil. (Author)

  19. In vitro cell-mediated immunity assay using 125I-iododeoxyuridine

    We investigated an in vitro cell-mediated immunity assay using incorporation of 125I-iododeoxyuridine as an indicator of lymphocyte responsiveness to mitogen stimulation. The system permits the use of whole-blood cultures in rats and dogs

  20. Report of a minor 125I exposure in a research laboratory

    In routine thyroid scanning of personnel whose work involved the use of 125I in biological research, it was discovered that an individual who had been iodinating proteins periodically for over 6 months showed a high thyroid count rate. It was decided to monitor the individual's thyroid weekly and to curtail his work in the laboratory until the cause of the thyroid uptake could be determined. Initially the 125I concentration in his thyroid decreased as expected but a subsequent scan on the 21st day showed an 125I concentration even greater than the initial level despite his absence from the laboratory. However on monitoring his office space, it was discovered that a felt pen was grossly contaminated and that the individual habitually put the pen in his mouth during moments of cogitation. It was concluded that a contaminated glove had transferred some 125I to the pen during the course of the experiment. (U.K.)

  1. Surface redistribution of 125I-insulin in cultured human lymphocytes

    1981-01-01

    The cultured human lymphocyte (IM-9) binds 125I-insulin by a receptor- mediated process; the receptor, in turn, is regulated by the ligand. In the present study we have examined quantitatively the morphologic events involved in 125I-insulin interaction with the surface of the lymphocyte. At 2 min of incubation of 15 degrees or 37 degrees C, the ligand localizes preferentially at the villous surface of the cell, whereas with longer periods of incubation, the ligand distributes indistinguishabl...

  2. Intracellular modification of 125I-labeled epidermal growth factor by normal human foreskin fibroblasts

    Intracellular processing of 125I-labeled epidermal growth factor (EGF) in normal human foreskin fibroblasts was examined after incubation with saturating concentrations of [125I]EGF. This report describes the column chromatographic separation of multiple processed forms of EGF generated by human foreskin fibroblasts and their structural characterization. More than 95% of the cell-bound [125I]EGF was converted into multiple forms, which were separated into four distinct peaks of radioactivity using columns of Bio-Gel P-150 equilibrated with 0.2% sodium dodecyl sulfate. These were designated peaks 1-4. Cellular generation of these four peaks was dependent on culture conditions. Differences in absolute and relative amounts of peaks 1-4 were observed as a function of time of incubation at 37 C. In addition, chromatographic profiles of cell-associated 125I varied in relation to cell density. The radioactivity in peak 1 comigrated with 125I-labeled native EGF on nondenaturing polyacrylamide gels (pH 9.5), whereas peaks 2 and 3 exhibited more rapid electrophoretic mobilities. Electrophoretic mobilities of the radioactivity in peaks 2 and 3 were indistinguishable from those of chemically prepared derivatives of [125I]EGF which were lacking either one or six amino acid residues from the carboxyterminus, respectively. The EGF receptor bound the radioactive material in peak 2 with an affinity equal to or greater than that of EGF; however, the radioactivity in peak 3 was bound to a much lesser extent. The radiolabel in both peaks 2 and 3 was greater than 95% precipitable by antiserum to native EGF. The labeled material in peak 4 was composed of [125I]monoiodotyrosine, 125I-, and an unidentified peptide. None of the radiolabeled compounds in peak 4 interacted with the EGF receptor or with antiserum to native EGF

  3. Relative biological effectiveness of 125I seeds for low-dose-rate irradiation of PANC-1

    Objective: To investigate the relative biological effectiveness(RBE) of National Model 6711 125I seeds and the response patterns of PANC-1 exposed to 125I seeds irradiation. Methods: PANC-1 cells in exponential growth were irradiated at initial dose rate of 2.59 cGy/h in vitro and exposed to 1, 2, 4, 6, 8 and 10 Gy. Meanwhile, the other part of cells were exposed to the same doses by 60Co at dose rate of 2.21 Gy/min. After irradiation, the cells were stained by trypan blue to measure the cellular mortality rate and to compare the changes along with plating times of 12, 24, 48 and 72 h after 4 Gy. The colonies were counted to obtain the plating efficiencies by colony-forming assay and the cell surviving faction was calculated to plot cell survival curves, and RBE of 125I seeds relative to 60Co was determined. Results: The cell death rate for continuous low- dose-rate (LDR) irradiation by 125I seeds was greater than 60Co at the same doses above or equal to 4 Gy. After 4 Gy irradiation, the cellular mortality rates were increased with times. The difference was significant between 125I seeds and 60Co. The survival fractions of 125I were lower than those of 60Co, and the RBE of 125I relative to 60Co was determined to be 1.45. Conclusion: The cell-killing effects for continuous low-dose-rate (LDR) irradiation by 125I seeds are greater than acute high-dose-rate of 60Co. (authors)

  4. Microchemical synthesis of the serotonin receptor ligand, 125I-LSD

    The synthesis and properties of 2-[125I]-lysergic acid diethylamide, the first 125I-labeled serotonin receptor ligand, are described. A novel microsynthesis apparatus was developed for this synthesis. The apparatus employs a micromanipulator and glass micro tools to handle microliter to nanoliter volumes on a microscope stage. This apparatus should be generally useful for the synthesis of radioligands and other compounds when limited amounts of material must be handled in small volumes

  5. Inhibition effects of 125I-triplex forming oligonucleotide to hepatoma cells

    Objective: Triplex forming oligonucleotide (TFO) has been reported as a new antigene strategy. The purpose of this study was to observe the inhibition effects of 125I-TFO on hepatoma cells and to investigate the possibility of using 125I-TFO as an antigene radiotherapy technique for hepatocellular carcinoma (HCC) related to HBV. Methods: TFO complementary to the initiator of S gene of HBV was synthesized and labeled with 125I. HepG2.2.15 cells, in which HBV genome was integrated, were incubated with 125I-TFO, TFO and 125I respectively. After incubation, hepatitis B e antigen (HBeAg) and hepatitis B surface antigen (HBsAg) of each group were assayed with ELISA and the survival rate of cells in each group was determined with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-trazolium bromide (MTT) reduction assay. Results: 125I-TFO showed a high stability with a radiolabeling rate of >93%. The radiochemical purity of labeled compound was 90.8%, 81.1% and 73.2% respectively after 12, 48 and 72 h at 37 degree C. The peak inhibition effect of 125I-TFO on synthesizing HBsAg and HBeAg by HepG2.2.15 cells were found at 48 h after transfection, with significantly the highest inhibition rate of 45.2% for HBsAg and 74.5% for HBeAg expression among the three groups(P125I-TFO may inhibit the antigen expression of HBV and the growth of hepatocarcinoma cells, thus it may provide a new approach to develop gene-based radiotherapeutic pharmaceuticals for anti-HBV and HCC. (authors)

  6. Tissue distribution and excretion of 125I-lidamycin in mice and rats

    You-Ping Liu; Quan-Sheng Li; Yu-Rong Huang; Chang-Xiao Liu

    2005-01-01

    AIM: To investigate the tissue distribution, urinary and fecal excretions of 125I-lidamycin (125I-C-1027) in mice and its biliary excretion in rats.METHODS: The total radioactivity assay (RA method) and the radioactivity assay after precipitation with 200 mL/L trichloroacetic acid (TCA-RA method) were used to dete-rmine the tissue distribution, and the urinary and fecal excretions of 125I-C-1027 in mice and its biliary excretion in rats.RESULTS: Tissue concentrations reached the peak at the fifth minute after administration of 125I-C-1027 to mice. The highest concentration was in kidney, and the lowest in brain at all test-time points. The organs of the concentrations of 125I-C-1027 from high to low were kidney, lung, liver, stomach, spleen, uterus, ovary, intestine, muscle, heart, testis, fat, and brain in mice. The accumulative excretionamounts of 0-24 h, and 0-96 h after administration of125I-C-1027 were 68.36 and 71.64% in urine, and 2.60 and 3.21% in feces of mice, respectively, and the accumulative excretion amount of 0-24 h was 3.57% in bile in rats.CONCLUSION: Our results reflect the characteristics of the tissue distribution, urinary and fecal excretions of 125IC-1027 in mice and the biliary excretion of 125I-C-1027and its metabolites in rats, and indicate that 125I-C-1027and its metabolites are mainly distributed in kidney, and excreted in urine.

  7. (E)-[125I]-5-AOIBV: a SPECT radioligand for the vesicular acetylcholine transporter

    The premise that, over the course of Alzheimer's disease (AD), changes in the levels of the vesicular acetylcholine transporter (VAChT) occur in parallel with changes to other cholinergic marker proteins provides the basis for the applicability of benzovesamicol derivatives as radioligands for AD studies by single photon emission computed tomography or positron emission tomography. We report the synthesis of enantiopure benzovesamicol derivatives: (R,R) or (S,S)-(E)-2-hydroxy-5-(3-iodoprop-2-en-1-oxy)-3- (4-phenylpiperidino)tetralin [(R,R)-AOIBV: Kd=0.45 nM or (S,S)-5-AOIBV: Kd=4.3 nM] and their corresponding tributyltin precursors for radioiodination. (R,R or S,S)-5-AOIBV was labeled with iodine-125 from their corresponding n-tributyltin precursors. Both compounds were obtained with radiochemical and optical purity greater than 97% and in radiochemical yields ranging 34-36%. To determine if these compounds could provide an advantage when compared to [125I]-iodo benzovesamicol (IBVM), IBVM was also labeled and used as the reference compound in all ex vivo experiments. Ex vivo biodistribution experiments in rats revealed that [125I]-(R,R)-5-AOIBV displayed the most suitable pharmacological profile as the radioactivity distribution corresponded well with the known VAChT brain density. Moreover, pre-injection of vesamicol prevented the uptake of [125I]-(R,R)-5-AOIBV in striatum, cortex and hippocampus, demonstrating selectivity for the VAChT. However, even if time activity curves of [125I]-(R,R)-5-AOIBV confirmed that this compound could be used to visualize the VAChT in vivo, at each point of the kinetic study, [125I]-(R,R)-5-AOIBV showed a lower specific binding compared to [125I]-IBVM. These results made [125I]-( R,R)-5-AOIBV inferior to [125I]-IBVM for the VAChT exploration in vivo

  8. Heparin blocks /sup 125/I-calmodulin internalization by isolated rat renal brush border membrane vesicles

    Meezan, E.; Elgavish, A.; Roden, L.; Wallace, R.W.

    1986-03-05

    /sup 125/I-Calmodulin is internalized by isolated rat renal brush border membrane vesicles (BBV) in a time, temperature and calcium dependent manner. Internalization of /sup 125/I-calmodulin into the osmotically sensitive space of BBV was distinguished from binding of the ligand to the outer BBV surface by examining the interaction of ligand and BBV at different medium osmolarities (300-1100 mosm), uptake was inversely proportional to medium osmolarity. Internalized /sup 125/I-calmodulin was intact and Western blots of solubilized BBV with /sup 125/I-calmodulin demonstrated the presence of several calmodulin-binding proteins of 143, 118, 50, 47.5, 46.5 and 35 kilodaltons which could represent potential intravesicular binding sites for the ligand. Heparin and the related glycosaminoglycan heparin sulfate both showed a dose-dependent inhibition (0.5-50 ..mu..g/ml) of /sup 125/I-calmodulin uptake by BBV, but other sulfated and nonsulfated glycosaminoglycans including chondroitin sulfates, keratan sulfate and hyaluronic acid showed little or no inhibitory effect. Desulfation of heparin virtually abolished the inhibition of uptake while depolymerization reduced it. Heparin did not block the binding of /sup 125/I-calmodulin to BBV proteins as assessed by Western blotting technique suggesting its effect was on internalization of the ligand rather than on its association with internal membrane proteins.

  9. Study of dose deposition of 125I brachytherapy seeds in a solid water phantom

    Currently, many kinds of radioactive sources are used in brachytherapy for cancer treatment. The 125I seed used in this work is the model Onco Seed 6711, produced by Oncura, which is ranked among the best options for treating prostate cancer. This source emits gamma photons with average energy of 28 keV and has a half-life of 59.4 days. After the implants, the natural movement of the organ can cause the seeds undergo slight displacements relative to the position originally planned, which can cause changes in dose distribution in the tumor volume. This work seeks to compare the dose distribution in a solid water phantom of two symmetrical, but different arrangements of four seeds. For this study, the phantom was machined to accommodate the seeds and TLD-100 LiF rod type dosimeters. The study, using TLD dosimeters, was conducted up to 4 cm of the settings. In addition, an Ebt Gafchromic radiochromic film was positioned over the two configurations during a period of time enough for 1 Gy deposition on it, to observe possible changes in the shape of the isodose curves. The TLD results showed a difference up to 35.8% of the dose deposited in the center of the configurations and different doses were deposited at distances corresponding to 1 and 2 cm radius from the symmetrical seeds arrangements. After 3 cm radius, the dose discrepancy is no longer significant. Another important point is that despite the configurations are symmetric, different dose values were deposited at symmetrical points. The isodose qualitative curves shown by the films showed a difference in the shape of that curves. Thus, the different positions of the seeds proved decisive in dose deposition and this fact should be taken into consideration in planning treatment

  10. Use of brachytherapy with permanent implants of iodine-125 in localized prostate cancer; La curietherapie par implants permanents d'I-125 dans le cancer localise de la prostate

    Bladou, F.; Serment, G. [Hopital Salvador, Service d' Urologie, 13 - Marseille (France); Salem, N.; Simonian, M. [Hopital Salvador, Dept. de Radiotherapie, 13 - Marseille (France); Rosello, R.; Ternier, F. [Institut Paoli-Calmettes, Dept. de Radiologie, 13 - Marseille (France)

    2002-07-01

    Approximately 15,000 cases of early stage prostate cancer T1 and T2 are diagnosed every year in France by testing for PSA and performing prostatic biopsies. The treatment of these localized forms is based in most cases on radical prostatectomy or nn external beam radiotherapy. Although the ontological results obtained by these two therapeutic methods are satisfactory and equivalent in the long term, the side effects can be important. For a number of years, trans-perineal brachytherapy using permanent implants of iodine -125 or palladium-103 has proved itself as an alternative therapy with equivalent medium to long-term results. The low urinary, digestive and sexual side effects of prostate brachytherapy are important reasons for the enthusiasm among patients and the medical community for this therapy and the growing number of applications and centres which practice it. In September 1998 we started the prostate brachytherapy programmes- in Marseilles with close collaboration between the department of urology of the Hopital Salvator, and the departments of radiotherapy, medical imaging and medical physics of the Institut Paoli-Calmettes. To date, around 250 patients with localized adenocarcinoma of the prostate have benefited from this alternative therapy in our centre. Preliminary results, with a 3 year-follow-up, are comparable to results published in the literature by pioneer teams. (authors)

  11. Plasmid DNA breakage by decay of DNA associated isotopes 123I and 125I

    The biological consequences of decay of DNA-associated 125I have been extensively investigated using a variety of systems. It is well established that decay of the isotope in close proximity to DNA produces a DSB with an efficiency close to 1. Much less information is available for another iodine isotope - 123I. It is a 'weaker' Auger emitter than 125I, and has much shorter half-life; 13.2 hours compared to 60 days for 125I. Cell culture studies indicate that decay of 123I is more than two times less efficient in killing V79 cells than decay of 125I, and produces from 0.45 to 0.74 DSB per decay in the cell nucleus. The Monte Carlo simulation of 123I decay and DSB induction has generated a value of 0.4 DSB per decay of incorporated isotope. We have adapted the plasmid DNA assay to compare strand breakage by decay of DNA-associated 125I and 125I, exploiting DNA minor groove binding ligand Hoechst 33258 labelled with either of these isotopes. Application of the plasmid assay to this study highlighted a range of important factors, which were taken into account to ensure a valid outcome. These factors involve the statistical implications of the nature of the breakage events (such as multiple breaks arising from a single decay event), two different sources of damage, namely internal (from DNA-associated decay events) and external (from decays occurring anywhere in solution), and consideration of the fraction of DNA-bound ligand. In our experiments, we incubated pBR322 plasmid with [125I]-iodoHoechst 33258 or with mixture of ligands labelled with 123I and 125I. The latter approach allows measurement of the ratio of probabilities of DSB formation per decay for the two isotopes, with much higher precision than determination of the individual breakage probabilities for each isotope. We obtained for the probability (per decay) of induction of DSB by the 125I-labeled ligand a value of 0.82 ± 0.05. Inclusion of DMSO as a radical scavenger, reduces this value to 0.65 ± 0

  12. DNA strand breakage by 125I-decay in oligoDNA

    Full text: A double-stranded oligodeoxynucleotide containing 125I-dC in a defined location, with 5'- or 3'-32P-end-labelling of either strand, was used to investigate DNA strand breakage resulting from 125I decay. Samples of the 32P-end-labelled and 125I-dC containing oligoDNA were incubated in 20 mM phosphate buffer (PB), or PB + 2 M dimethylsulphoxide (DMSO) at 4 deg during 18-20 days. The 32P-end-labelled DNA fragments produced by 125I decays were separated on denaturing polyacrylamide gels, and the 3P activity in each fragment was determined by scintillation counting after elution from the gel. The fragment size distribution was then converted to a distribution of single stranded break probabilities at each nucleotide position. The results indicate that each 125I decay event produces at least one break in the 125I-dC containing strand, and causes breakage of the opposite strand in 75-80% of events. Thus, the double stranded break is produced by 125I decay with probability ∼0.8. Most of single stranded breaks (around 90%) occurred within 5-6 nucleotides of the 125I-dC, however DNA breaks were detected up to 18-20 nucleotides from the decay site. The average numbers of single stranded breaks per decay are 3.7 (PB) and 3.3 (PB+DMSO) in 125I-dC containing strand, and 1.5 (PB) and 1.3 (PB+DMSO) in the opposite strand. Deconvolution of strand break probabilities as a function of separation from the 125I, in terms of both distance (to target deoxyribosyl carbon atoms, in B-DNA) and nucleotide number, show that the latter is an important parameter for the shorter-range damage. This could indicate a role for attenuation/dissipation of damage through the stacked bases. In summary, the results represent a much more extensive set of data than available from earlier experiments on DNA breakage from l25I-decay, and may provide new mechanistic insights

  13. Cetuximab affects the capacity of DNA repair in colorectal cancer cells after 125I seeds irradiation

    Objective: To investigate the effect of C225 on DNA repair and molecular pathways in CL187 colorectal cancer cells after irradiated by 125I radioactive seeds. Methods: In the experiment involved were four groups:control group, 100 nmol/L C225 treatment group,125I radioactive seeds continuous low-dose rate irradiation group and C225 combined with 125I radioactive seeds continuous low dose rate irradiation group. Cells were collected at 48 h after 4 Gy irradiation, and γH2AX foci/cell and γH2AX foci positive cells were counted with immunofluorescence. At the same time, DNA repair proteins were detected by Western blot. Cells were analyzed immediately after 4 Gy irradiation,and changes in EGFR downstream signaling molecules were detected by Western blot. Results: Compared with 125I seeds irradiated cells,cells treated with C225 and 125I seeds irradiation showed more γH2AX foci per cell (t=8.0, P=0.05), and more γH2AX foci positive cells (t=6.8, P<0.05) and less expression of Ku70 (t=6.6, P<0.05) and DNA-PKcs (t=5.6, P<0.05). Combined with 125I-CLDR irradiation, C225 reduced cellular EGFR level (t=4.9, P<0.05) and inhibited the activation of Akt (t=5.5, P<0.05). Conclusions: In the condition of 125I seeds irradiation, C225 reduced the expression of Ku70 and DNA-PKcs, inhibited the activation of Akt and attenuated the DNA damage repair capacity in CL187 colorectal cancer cells. (authors)

  14. Autoradiographic localization of putative nicotinic receptors in the rat brain using 125I-neuronal bungarotoxin

    Neuronal bungarotoxin (NBT), a snake venom neurotoxin, selectively blocks nicotinic receptors in many peripheral and central neuronal preparations. alpha-Bungarotoxin (alpha BT), on the other hand, a second toxin isolated from the venom of the same snake, is an ineffective nicotinic antagonist in most vertebrate neuronal preparations studied thus far. To examine central nicotinic receptors recognized by NBT, we have characterized the binding of 125I-labeled NBT (125I-NBT) to rat brain membranes and have mapped the distribution of 125I-NBT binding in brain sections using quantitative light microscopic autoradiography. The binding of 125I-NBT was found to be saturable, of high affinity, and heterogeneously distributed in the brain. Pharmacological studies suggested that more than one population of sites is labeled by 125I-NBT. For example, one component of 125I-NBT binding was also recognized by alpha BT, while a second component, not recognized by alpha BT, was recognized by the nicotinic agonist nicotine. The highest densities of these alpha BT-insensitive, nicotine-sensitive sites were found in the fasciculus retroflexus, the lateral geniculate nucleus, the medial terminal nucleus of the accessory optic tract, and the olivary pretectal nucleus. alpha BT-sensitive NBT binding sites were found in highest density in the lateral geniculate nucleus, the subthalamic nucleus, the dorsal tegmental nucleus, and the medial mammillary nucleus (lateral part). The number of brain regions with a high density of 125I-NBT binding sites, blocked either by alpha BT or by nicotine, is low when compared with results obtained using other approaches to studying the central distribution of nicotinic receptors, such as labeling with 3H-nicotine or labeling with cDNA probes to mRNAs coding for putative receptor subunits

  15. Preparation of a 125I labelled [1,3H]imidazole: 2-n-butyl-4(5)-125I-iodo-5(4)-hydroxymethylene imidazole

    A method for the introduction of 125I in a substituted imidazole has been devised. 2-n-Butyl-4(5)-hydroxymethylene imidazole undergoes rapid and selective electrophilic substitution on the ring when treated with a halogenating agent such as, i.a., N-chlorosuccinimide. This reaction has been adapted to the preparation of 2-n-butyl-4(5)-125I-iodo-5(4)-hydroxymethylene imidazole by treatment of 2-n-butyl-4(5)-hydroxymethylene imidazole by chloramine-T in the presence of sodium iodide. The radiolabelled product purified and isolated by HPLC is obtained at a high specific activity (2200Ci/mmol) with good chemical and radiochemical yields (∼70%). (author)

  16. Autoradiographic comparison of [{sup 125}I]epidepride and [{sup 125}I]NCQ 298 binding to human brain extrastriated dopamine receptors

    Hall, Haakan; Halldin, Christer; Jerning, Eva; Oesterlund, Marie; Farde, Lars; Sedvall, Goeran

    1997-07-01

    Extrastriatal D{sub 2}-dopamine receptors can be visualized in the monkey and human brain using the benzamides [{sup 11}C]- and [{sup 76}Br]FLB 457 in PET and [{sup 123}I]epidepride in SPECT but not with the salicylamide analogues [{sup 76}Br]FLB 463 and [{sup 123}I]NCQ 298. To clarify the background for the differences in binding seen in vivo, we have compared the in vitro binding of [{sup 125}I]epidepride and [{sup 125}I]NCQ 298, using human whole hemisphere autoradiography. The images obtained with any radioligand showed detailed distribution with very dense binding in the putamen and the caudate nucleus and with the same detailed extrastriatal distribution. Thus, the divergent results obtained in vivo cannot be explained by different binding properties of the extrastriatal receptors.

  17. Targeted radiotherapy of multicell neuroblastoma spheroids with high specific activity [125I]meta-iodobenzylguanidine

    Purpose: Iodine-125 induces cell death by a mechanism similar to that of high linear energy transfer (high-LET) radiation. This study investigates the cytotoxicity of high-specific-activity [125I]meta-iodobenzylguanidine (125I-mIBG) in human SK-N-MC neuroblastoma cells grown as three-dimensional multicellular spheroids. Materials and Methods: Spheroids were incubated with high-specific-activity 125I-mIBG (6 mCi/μg, 1000 times that of the conventional specific activity used for autoradiography). Cytotoxicity was assessed by fluorescence viability markers and confocal microscopy for intact spheroids, fluorescence-activated cell sorting and clonogenic assay, and clonogenic assays for dispersed whole spheroids. Distribution of radioactive mIBG was determined by quantitative light-microscope autoradiography of spheroid cryostat sections. Dose estimation was based on temporal knowledge of the retained radioactivity inside spheroids, and of the radiolabel's emission characteristics. Findings were compared with those of spheroids treated under the same conditions with 131I-mIBG, cold mIBG, and free iodine-125. Results: 125I-mIBG exerted significant cell killing. Complete spheroids were eradicated when they were treated with 500 μCi of 125I-mIBG, while those treated with 500 μCi or 1000 μCi of 131I-mIBG were not. The observed difference in cytotoxicity between treatments with 125I- and 131I-mIBG could not be accounted for by the absorbed dose of spheroid alone. The peripheral, proliferating cell layer of the spheroids remained viable at the moderate radioactivity of 100 μCi for both isotopes. Cytotoxicity induced by 125I-mIBG was quantitatively comparable by the peripheral rim thickness to that of 131I-mIBG at the dose of 100 μCi. The peripheral rim thickness decreased most significantly in the first 17 hours after initial treatment. There was no statistical decrease in the rim thickness identified afterwards for the second, third, and fourth days of incubation

  18. Accumulation and metabolism of [125I] HIPDM in the rat pancreas

    Our previous studies have shown a high accumulaiton of [125I] N,N,N'- trimethyl-N'- (2-hydroxy-3-methyl-5-iodobenzyl)- 1,3-propanediamine (HIPDM) in the human pancreas. In this study, the pancreatic accumulation and metabolism of [125I]HIPDM were studied in rats to determine the factors influencing its uptake by this organ. In biodistribution studies, [125I]HIPDM showed a high uptake by the pancreas similar to that by the brain and lungs, both organs with a low tissue pH. TLC analysis of pancreatic homogenate after the injection of [125I]HIPDM showed that it was metabolically stable in this organ. Moreover, in the pancreatic homogenate, the bulk of the radioactivity was recovered from the microsomal fraction, and the radioactivity bound to microsomal particles showed release that was dependent on the Ca2+ or Mg2+ concentration in the incubation medium. These results suggest that the initial pancreatic uptake of [125I]HIPDM may be a function of blood flow and governed by the pH gradient hypothesis, while subsequent retention may occur secondary to ionic binding within the pancreas. (author)

  19. Monte Carlo dosimetry for 125I and 60Co in eye plaque therapy

    Monte Carlo calculations of radiation dosimetry using morse code are performed for 125I and 60Co point sources in a cylindrical head phantom that simulates the geometry of eye plaque therapy for choroidal melanoma. We obtain the dose variation in the eye at submillimeter intervals over distances as close as 1 mm and up to 2.5 cm from the source. The calculations for 125I are performed for the phantom media of water, protein, and a homogenized protein--water mixture simulating the composition of the eye. Relative dose functions for 125I for these phantom media are fitted to second-degree polynomials. Agreement is found with published results. The relative dose function for 60Co at eye position in the water head phantom is fitted to a third-degree polynomial and compared with that for 60Co at the center of a large water sphere. A boundary effect due to the head phantom--air interface on the dose distribution for 60Co is demonstrated. The dose falloff with distance is faster for the eye geometry compared with the bulk geometry. We also show that the relative dose distributions within the tumor are comparable for 125I and 60Co by comparing their relative dose functions. This result is consistent with the success of clinical trials of large melanoma treatments with 125I plaques

  20. Labeling and biodistribution of therapeutic radiopharmaceutical for brain cancer 125I-Nimotuzumab in normal mice

    Nimotuzumab is a monoclonal antibody which known giving contribution in anti proliferation, pro apoptosis and antiangionik effect on the therapy of brain cancer (glioma). The labeling of monoclonal antibody nimotuzumab with 125I which radiate auger electrons has been done with idogen method. The best result of radiochemical purity (97%) was shown in fraction 6 with the mol ratio of nimotuzumab towards potassium iodide and iodogen was 1 : 2 : 1200. Radiochemical purity was examined by paper chromatography with whatman paper no. 1 as the stationary phase and ethano!-butanol-ammonium hydroxide with a ratio of 3 : 2 : 1 as the mobile phase. Rf Values for 125I-nimotuzumab is 0.0, while Rf value of 125I .is 0.9. The biodistribution result on normal mice for 72 hours showed that 125I-nimotuzumab not only has a long half-life time but also has high accumulation in liver (1.97 + 1.18%), kidney (0.82 + 0.28%) and muscle (0.61+ 0.98%). The highest accumulation in brain on normal mice (0.128 + 0.06 %) occurred 24 hours after injection. Based on the therapeutic effects and organ accumulation on normal mice, 125I-nimotuzumab could be potentially used for brain cancer therapy. (author)

  1. /sup 125/I-spiperone: a novel ligand for D/sub 2/ dopamine receptors

    Gundlach, A.L.; Largent, B.L.; Synder, S.H.

    1984-11-05

    /sup 125/I-Spiperone binds with high affinity K/sub D/ 0.3 nM) to a single specific site (B/sub max/ 34 pmole/g wet weight) in homogenates of rat corpus striatum. Specific binding is about 40-60 percent of total binding and is displaced stereo-specifically by butaclamol and clopenthixol. Neuroleptic drugs of various classes are potent inhibitors of /sup 125/I-spiperone binding (/sub i/'s 1-10 nM). Selective dopamine antagonists such as sulpiride (K/sub i/ 50 nM) and dopamine agonists such as apomorphine (K/sub i/ 200 nM) are also potent inhibitors. The drugs specificity of /sup 125/I-spiperone binding correlates well with that of /sup 3/H-spiperone binding, providing good evidence that /sup 125/I-spiperone labels D/sub 2/ dopamine receptors in striatal membranes. /sup 125/I-Spiperone, with its high specific activity (2200 Ci/mmol) may prove to be a useful ligand in studies examining D/sub 2/ dopamine receptors in soluble preparations and by autoradiography. Furthermore iodinated spiperone may be useful in radioreceptor assays of neuroleptic drug levels and, in a /sup 123/I-labeled form for imaging of dopamine receptors, in vivo, using single photon tomography. 18 references, 4 figures, 1 table.

  2. 125I-iomazenil-benzodiazepine receptor binding during psychological stress in rats

    We investigated the changes in 125I-iomazenil (125I-IMZ) benzodiazepine receptor (BZR) binding with psychological stress in a rat model. Six male Wistar rats were placed under psychological stress for 1 hour by using a communication box. No physical stress was not received. 1.85 MBq of 125I-IMZ was injected into the lateral tail vein and the rat was killed 3 hours later. Twenty-micormeter-thick sections of the brain were collected and % injected dose per body weight (% ID/BW) of eleven regions (frontal, parietal, temporal, occipital cortices, caudate putamen, accumubens nuclei, globus pallidus, amygdala, thalamus, hippocampus and hypothalamus) were calculated by autoradiography. The %ID/BW of rats which were placed under psychological stress was compared with that of 6 control rats. The %ID/BW of rats which were placed under psychological stress diffusely tended to show a reduction in 125I-IMZ-BZR binding. A significant decrease in BZR binding was observed in the hippocampus of the rats which were placed under psychological stress. 125I-IMZ-BZR binding tended to decrease throughout the brain. (author)

  3. Synthesis of 125 I - Salicyl Hydroxamic Acid for Urinary Bladder Imaging

    Salicylhydroxamic acid is a salicylate derivative. Radiolabeling of Salicyl hydroxamic acid ( SHA ) with iodine-125 may have considerable interest for imaging of urinary bladder. This study is aimed to optimize the radiolabeling yield of Salicyl hydroxamic with radio iodine (125-123) using chloramine - T (CAT) as an oxidizing agent with respect to factors that affect the reaction conditions such as SHA amount, CAT amount, reaction time and ph of the reaction mixture. In - vitro stability of the radiolabeled complex was checked and it was found to be stable for up to 24 h. 125 I-SHA was injected via intravenous administration routes into normal male Sprague – Dawley rats. Bio - distribution studies have revealed that 125I-SHA was excreted in urine with extent that it could give a clear image for urinary bladder especially if the bladder it tightly closed. The amount of 125 I - Salicyl hydroxamic excreted was increased in case of giving potassium bicarbonate to rat before injection of 125 I-SHA. The result of biodistribution study of 125 I - SHA in experimental animal suggest ed the possibility of using 123 I-SHA to image the urinary bladder

  4. Study on apoptosis of prostate cancer cell induced by 125I seed irradiation

    Objective: To explore the mechanism of apoptosis induced by 125I seed irradiation on PC3 cells. Methods: Human prostate cancer cell line PC3 was treated by irradiation of 125I (2.77 cGy/h) with various dose. Agarose gel electrophoresis of DNA and flows cytometry were used to detect the apoptosis of PC3 cells and indirect immunofluorescence assay was used to detect the expression of Bcl-2. The activity of Caspase-3 was measured by Caspase Colorimetric Assay Kits. Results: Apoptosis of PC3 cells could be efficiently induced by 125I seed irradiation. The apoptotic peaks were found by flow cytometry and DNA ladder appeared on 1.8% agarose gel. The activity of Caspase-3 on PC3 cells treated by 125I seed irradiation was not changed significantly. Bcl-2 gene expression was down-regulated with the sample concentration increased. Conclusion: 125I irradiation can induce the apoptosis of PC3 cells and the mechanism of apoptosis is related with down regulation of Bcl-2 gene expression and is not related with Caspase-3 activity. (authors)

  5. Studies of the distribution of intrathecally injected 125I-tetanus antitoxin-F(ab')2

    Overall F(ab')2 and antitetanus-f(ab')2 - fragments were labelled with 125I and injected i.th. into normal juvenile cats and adult rats. One group of rats was normal; in the other, unilateral local tetanus had been induced by injection of tetanus toxin into a M. gastrocnemius. The animals were sacrificed 24 h after the i.th. injection, and tissue samples were taken for histoautoradiography. 125I-antitetanus-F(ab')2 permeated into the extracellular space of the spinal cord, roots, and ganglia but not into the neuronal intracellular space. 125I-overall-F(ab') showed identical permeation behaviour. 125I-antitetanus-F(ab')2 reacted with tetanus toxin issuing from the motoneurons after i.th. injection, forming an immunocomplex around the motorneurons. The immunocomplex was not formed around pseudo-unipolar ganglian cells in the spinal ganglia even though some of the ganglian cells contained tetanus toxin, and 125I-antitetanus-F(ab')2 was present in the extracellular space. As an explanation, it was suggested that tetanus toxin does not permeate into the extracellular space through the membrane of the pseudo-unipolar ganglian cells so that immune reactions will not occur. These findings help to explain the widely divergent results of tetanus therapy by means of i.th. injection of tetanus antitoxin. Recommendations for future therapy measures are derived from the findings. (orig./MG)

  6. Radioimmunoassay for etorphine in horses with a 125I analog of etorphine

    To improve the sensitivity and specificity of screening for etorphine in horses, an 125I-labeled etorphine analog was synthesized and an antibody to etorphine was raised in rabbits. A radioimmunoassay (RIA) for etorphine was developed, using these reagents. Bound and free 125I-labeled etorphine was separated by a double-antibody method that reduced interference from materials associated with equine urine. The 125I-labeled etorphine binding was rarely greater than 250 pg of background etorphine equivalents/ml in raw urine and was 100 pg/ml in hydrolyzed urine. The 125I-RIA was capable of detecting etorphine equivalents in urine above these background values. Etorphine equivalents were detected in equine urine samples for about 7 days after 4 mares were dosed with 0.22 microgram of etorphine/kg of body weight, IV. The stability of etorphine in urine from these mares was evaluated. Urine from these dosed mares was held in constant -20 C storage, and aliquots were repeatedly frozen and thawed. When analyzed for etorphine equivalents using an 125I-RIA, etorphine and its metabolites in urine samples were stable for less than or equal to 38 days if continuously frozen and also were resistant to repeated freezing and thawing

  7. Inulin-125I-tyramine, an improved residualizing label for studies on sites of catabolism of circulating proteins

    Residualizing labels for protein, such as dilactitol-125I-tyramine (125I-DLT) and cellobiitol-125I-tyramine, have been used to identify the tissue and cellular sites of catabolism of long-lived plasma proteins, such as albumin, immunoglobulins, and lipoproteins. The radioactive degradation products formed from labeled proteins are relatively large, hydrophilic, resistant to lysosomal hydrolases, and accumulate in lysosomes in the cells involved in degradation of the carrier protein. However, the gradual loss of the catabolites from cells (t1/2 approximately 2 days) has limited the usefulness of residualizing labels in studies on longer lived proteins. We describe here a higher molecular weight (Mr approximately 5000), more efficient residualizing glycoconjugate label, inulin-125I-tyramine (125I-InTn). Attachment of 125I-InTn had no effect on the plasma half-life or tissue sites of catabolism of asialofetuin, fetuin, or rat serum albumin in the rat. The half-life for hepatic retention of degradation products from 125I-InTn-labeled asialofetuin was 5 days, compared to 2.3 days for 125I-DLT-labeled asialofetuin. The whole body half-lives for radioactivity from 125I-InTn-, 125I-DLT-, and 125I-labeled rat serum albumin were 7.5, 4.3, and 2.2 days, respectively. The tissue distribution of degradation products from 125I-InTn-labeled proteins agreed with results of previous studies using 125I-DLT, except that a greater fraction of total degradation products was recovered in tissues. Kinetic analyses indicated that the average half-life for retention of 125I-InTn degradation products in tissues is approximately 5 days and suggested that in vivo there are both slow and rapid routes for release of degradation products from cells

  8. Polyclonal 111In-IgG, 125I-LDL and 125I-endothelin-1 accumulation in experimental arterial wall injury

    To test iodine-125 labelled low-density lipoprotein (125I-LDL), polyclonal indium-111 labelled immunoglobulin G(111In-IgG) and iodine-125 labelled endothelin-1 uptake in metabolically active atheromatous plaques after arterial wall injury, we performed balloon de-endothelialization of carotid arteries or abdominal aortas in 24 New Zealand male rabbits which were fed with a normal diet (n=14) or a hypercholesterolaemic diet (n=10) after surgery. Six weeks later the animals were injected with 200 μCi of 125I-LDL and/or with 100 μCi of 111In-IgG or with 9 μCi of 125I-endothelin-1. Forty-eight hours later the animals were sacrificed. Carotid arteries and aortas were removed, counted and fixed for autoradiography and light microscopic examination. Contralateral carotid arteries and thoracic aortas served as controls. Significant 111In-IgG uptake was observed in the injured arteries at autoradiography, with localization mainly in the healing edges, and at well counting. The percentage of the injected dose per gram (%D.inj/g) was 0.0188±0.06 versus 0.0059±0.003 in controls (P111In-IgG uptake between arteries with injury alone and those with active atheroma formation at the site of the injury. Significant 125I-LDL uptake was observed only when lipid deposition was present at light microscopy (%D.inj/g of 0.0024±0.0005 vs 0.0010±0.0003 in controls, P125I-endothelin-1 accumulation was observed in four of five injured aortas both at autoradiography, with diffuse localization, and at well couting (%D.inj/g of 0.0012±0.0004 in the abdominal aortas vs 0.0008±0.0003 in the thoracic aortas). Polyclonal IgG may accumulate in injured arteries without active atheroma formation. Inflammatory reaction at the site of the injury may cause 111In-IgG uptake independently of atheromatous plaque formation. LDL accumulation takes place only with active atheroma formation at the site of the injury. Use of labelled peptides such as endothelin-1 may provide further insight into the

  9. Nanodosimetry of 125I – Auger electrons – Experiment and modeling

    The experiment with 125I-Auger electrons, interacting with gaseous nitrogen with size equivalent to segment of DNA in mass per unit area scale, are described. The discrete ionization cluster-size distributions have been obtained. The shapes of which are definitely determined by the size of the interaction volumes. The volume sizes studied in the present work are comparable with a segment of DNA and of nucleosome. The experiments have been carried out with the set up, called Jet Counter, and are the first cluster-size distributions as yet measured for an Auger-electron emitter like 125I. The experimental results have been compared with those obtained by Monte Carlo simulation. The results for 125I have been compared with calculated cluster size distribution for 131I.

  10. Radiolabelling and assay of Chinese agkistrodon acutus venom with carrier-free Na 125I

    Chinese agkistrodon acutus venom (CAAV) was radiolabelled with carrier-free Na125I by the method of Iodogen. The specific activity and radiochemical purity for radiolabelled products were 4236.5 x 1010 Bq/mmol and 98%, respectively. Each CAAV molecule carried 0.52 125I atom. Physical and chemical characterization of radiolabelled CAAV was similar to unradiolabelled CAAV. Binding analysis showed that 125I-CAAV was bound to platelet in a saturable manner. Binding sites per platelet were 13255 +-6292/platelet. The dissociation constant (Kd) was 3.2 +- 0.69 x 10-10 mol/L. These results are similar to binding sites of other snake venom on platelet. The investigation showed that radiolabelled CAAV made by our laboratory was useful for radioligand binding assay